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Abstract 
Bioinorganic chemistry has fostered the interdiscipHnary prosperous research area of 
medicinal inorganic chemistry involving metal ions and biology of living systems. Metal-
based chemotherapeutics have attracted considerable attention after the serendipitous 
discovery of cisplatin - an archetypical inorganic drug used for treating solid malignancies. 
There is however, a growing demand for more efficacious metal-based pharmaceutical 
remedies which are safer, more potent, exhibit fewer side effects and reduced toxicity; not 
only from the point of view of cancer therapeutics but also for other itenary diseases viz; 
viral HIV, neurodegenerative diseases, alzheimer and diabetes etc. 
It has been well established for many years that, for testing drugs pure stereoisomers have 
to be studied since only one optical isomer exhibits in general the desired therapeutic 
effects, due to its interaction with targeted chiral biomolecules or chiral biological sites. 
The structure-function relationship in nature is so powerful that when a functional disorder 
manifests in the form of disease, it can be handled in many cases only by using a molecule 
of specific chiral structure. The chiral metal complexes thus, play a profound role in their 
interactions with DNA as they have the potential to demonstrate both enantioselectivity 
and stereoselectivity with their chiral target such as DNA. Furthermore, since DNA is the 
primary cellular receptor, many metal complexes exert their antitumor effects through 
binding to DNA, thereby interfere in the complicated mechanism of uncontrolled 
proliferation and contribute to the elimination of neoplastic cells by inhibiting replication, 
and by inducing differentiation or by triggering apoptotic processes. 
Among the various features governing the binding modes with DNA (covalently or non-
covalently by intercalation, groove binding or external electrostatic binding), the most 
significant is the "molecular shape" of the interacting metal complex in addition to ligand 
modifications in geometry, size, hydrophobicity, planarity, charge and hydrogen bonding 
interaction which leads to subtle or to spectacular changes in the binding modes, location, 
affinity and to a different cleavage effect. For example, various ancillary ligands such as 
chiral diam(m)ine and amino acids were used to modulate the interaction between the 
complex and DNA and to accentuate any enantiomeric differences. Variation of the 
am(m)ine ligands of these complexes is now knovm to influence the type of cancers 
effectively treated by each compounds with oxaliplatin proving active against colon 
cancer. 
A particular type of absorption spectroscopy alone cannot possibly deduce the mode of 
binding accurately with DNA, therefore various others spectroscopic methods viz; 
fluorescence, circular dichroism, NMR dynamics with nucleotides, hydrodynamic 
measurements such as viscosity and DNA cleavage activity assays were performed to 
validate the modes and extent of metal complex- DNA interaction. 
In view of this rationale, we have synthesized and characterized a variety of complexes 
derived from, well - designed ligand motifs with first row transition metal ions viz. Co(II), 
Cu(II) and 2'n(II) and Sn(IV) ion {SnCU and (CH3)2SnCl2} employing de novo synthetic 
strategy. The interaction studies of these complexes with CT DNA have been studied by 
various biophysical methods. 
New potential metal-based antitumor chemotherapeutic heterobimetallic complexes 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] derived from salicylaldimine monometallic complexes 
[Cu(Sb)2] ;and [Zn(Sb)2] were synthesised and thoroughly characterized by spectroscopic 
(IR, ' H , '-'C and '^ ^Sn NMR, EPR, UV-vis, FAB-MS) and analytical methods. In the 
complexes, the geometry of copper and zinc metal ions were square planar and tetrahedral 
while tin ions were present in hexacoordinate environment. The comparative interaction of 
free Schiff base ligand (Sb), monometallic complexes and their heterobimetallic 
counterpart with CT DNA in Tris buffer were studied by electronic absorption titration, 
fluorescence titration and viscosity measurements. The intrinsic binding constant Kb of 
ligand and the complexes were determined which follows the order: [Zn(Sb)2Sn2] > 
[Cu(Sb)2Sn2] > [Zn(Sb)2] > [Cu(Sb)2] > Sb which is in conformity with our hypothesis that 
heterobimetallic complexes are more prominent DNA binders than the monometallic in 
comparison to the free ligand. Further, interaction studies of heterobimetallic complexes 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] with supercoiled pBR322 DNA were carried out 
employing gel electrophoresis, noticeably both heterobimetallic are efficient cleavage 
agents and specific groove binders (complex [Cu(Sb)2Sn2] binds to both major and minor 
groove while complex [Zn(Sb)2Sn2] is a specific minor groove binder ). In addition, the 
complexes show high inhibition activity against topoisomereses I and II. However, 
complex [Zn(Sb)2Sn2] exhibits significant inhibitory effects on the Topo I activity at a very 
low concentration ~2.5 ^M. 
To evaluate the biological preference of chiral drugs for molecular target DNA, new 
potential metal-based chemotherapeutic agents of late 3d- transition metals {Co(II), Cu 
(II) and Zn(II)} derived from L-, D-, and DL-tryptophan, respectively and followed by 
reaction with 1,2-diaminobenzene were synthesized and thoroughly characterized. The 
complexes are stable towards air and moisture and soluble in DMSO and DMF. Analytical 
data of complexes is consistent with their proposed molecular formulae. Due to the 
presence of chiral auxiliary "L-tryptophan, D-tryptophan", complexes exhibited optical 
rotation [ctlu values which indicate that all the complexes are optically active except the 
complexes which were derived from racemic DL-tryptophan (an optically inactive 
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component). In complexes the coordination geometry of central Co(II) ion is pseudo-
octahedral whilst Cu(II) and Zn(II) complexes were found to possess square-planar and 
tetrahedral geometry, respectively. Comparative DNA binding studies were carried out 
with the complexes to evaluate the effect of conformations on DNA binding . The resuhs 
reveal that the extent of DNA binding of L-form of Cu(II) complex [Cu(trp)(dabz)]Cl was 
higher in comparison to rest of the complexes . This was further confirmed by nuclease 
activity of L-form of Cu(II) complex [Cu(trp)(dabz)]Cl with supercoiled pBR322 DNA . 
The observed cleavage reaction involves various oxygen species and superoxide radicals 
by oxidative cleavage mechanism. The L-form of Cu(II) complex [Cu(trp)(dabz)]Cl 
exhibited significant antitumor activity against MCF-7 cell line (human breast carcinoma) 
Indeed, L-form of Cu (II) complex [Cu(trp)(dabz)]Cl is one of the most effective chiral 
cancer chemotherapeutic agent designed in terms of its selective antitumor activity. 
A new series of potential antitumor chiral metal-based complexes of Co(II), Cu(II) and 
Zn(II) were designed and synthesized to examine the effect of chirality on the binding 
propensity of DNA. Syntheses of mononuclear complexes [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl were achieved by mixing stoichiometric amounts 
of L-tryptophan and D-tryptophan with corresponding metal chlorides followed by 
reaction with (lR,2R)-(-)-l,2-diaminocyclohexane. The composition of the complexes 
were confmned by elemental analysis, infrared, nuclear magnetic resonance spectroscopy, 
EPR, mass spectrometry and optical rotation. The complexes are stable towards air and 
moisture and soluble in DMSO and DMF. Molar conductance values of complexes in 
DMSO (1 X 10"^  M) at 25 °C suggest their 1:1 electrolyte nature. Due to the presence of 
chiral auxiliaries "L-tryptophan, D-tryptophan" and (lR,2R)-(-)-l,2-diaminocyclohexane 
ligand (1,2-DACH), the complexes [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
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[Zn(trp)(dach)]Cl exhibited optical rotation [af^v) values which indicate that all the 
complexes are optically active. In complexes, the coordination geometry of Co(II) complex 
is pseudo-octahedral whilst Cu(II) and Zn(II) complexes were found to possess square-
planar and tetrahedral geometry, respectively. Comparative DNA binding studies were 
carried out by electronic absorption titrations, fluorescence and circular dichoric studies in 
free complexes and in the presence of DNA supported that both the enantiomers bind to 
DNA by noncovalent mode of binding viz, preferably electrostatic interaction via 
phosphate backbone of the helix, however, L-form is more potent and exhibits enhanced 
binding propensity for DNA as compared to D-fbrm analogs. The L-form of 
[Cu(trp)(dach)]Cl exhibits a remarkable DNA cleavage activity with pBR322 DNA in 
presence of different activators viz. H2O2, ascorbic acid, 3-mercaptopropionic acid and 
glutathione suggesting the involvement of active oxygen species for the DNA scission. In 
vitro anticancer activity of L-form of complexes were screened against 14 different human 
carcinoma cell lines of different histological origin and results reveal that complex 
[Cu(trp)(dach)]Cl is potent selective antitumor agent against MIAPACA2 (Pancreatic 
cancer cell line ) with GI50 value of 21 compared to 47 and >80 for complex 
[Co(trp)(dach)(H20)2]Cl and [Zn(trp)(dach)]Cl, respectively in the same cell line. 
Understanding the reason for chiral preference can underlay the protocol for efficacious 
drug design. This concept rationalizes the pre- requirement of enantionselectivity of drug 
entities by interacting with inherently chiral DNA structure at the molecular level. 
Comparison of Cu(II) drug entities with Sn(IV) complexes - a notably important class of 
metallated antitumor agents can throw insight to their potential to act as effective 
chemotherapeutic lead drug regime. New chiral complexes (S)- and (R)- of LI, L2, metal 
complexes [CU2LI2]. [Sn2Ll2], [CU2L22] and [Sn2L22] were designed and synthesized with 
an aim to develop new potent chiral chemotherapeutic antitumor entities where Ll= 2-(2-
hydroxy-l-phenylethylaminomethyl)phenol and L2 = 2-(benzylamino)-2-phenylethanol. 
The synthesis involves the in situ reduction (by NaBH4) of Schiff base of salicylaldehyde / 
benzaldehyde and (S)-/(R)-2-phenylgIycinol to yield the ligand LI and L2. The 
complexation of LI and L2 with CUCI2.2H2O and (CH3)2SnCl2 were carried to obtain 
stable complexes, soluble in DMSO and DMF. Molar conductance values of metal 
complexes reveal their non electrolytic nature. In vitro DNA binding studies of both 
enantiomers (S)- and (R)- of ligands (LI and L2) and complexes were carried out 
employing UV-vis titrations, fluorescence and circular dichoric studies to outline the effect 
of chirality on DNA binding propensity. These findings demonstrate that S-enantiomer of 
Cu(II) complex [CU2LI2] binds more avidly and readily to DNA in comparison to its R-
enantiomeric form and Sn(IV) complexes. DNA cleavage studies employing gel 
electrophoresis of all complexes with pBR322 plasmid DNA were carried out, complex 
[CU2LI2] (S-enantiomer) exhibits effective DNA cleavage in the absence of external 
agents. The in vitro antitumor activity of complexes including ligands LI and L2 has been 
examined on a panel of 19 human tumor cell lines of different histological origins by SRB 
assay. [CU2L22] (S-enantiomer) and surprisingly, [CU2LI2] (R-enantiomer) exhibited 
remarkably excellent cytotoxity activitiy (GI50 values <10) against T24 (Urinary Bladder), 
DU145 (Prostate), U373MG (Astrocytoma) and HCT15, SW620 (Colon) cancer cell lines, 
respectively clearly underlining the influence of enantiomeric discrimination in in vitro 
cytotoxicit)' experiments .On the other hand, ligands LI, L2 and rest of the complexes 
displayed poor cytotoxicity , (GI50 values < 40) only against Hela (Epithelial 
Carcinoma) and A2780 (Ovary) human cancer cell lines, respectively. Since the 
differences in cytotoxicity do not correlate with simple measurements of DNA binding 
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which reveal greater propensity of S-enantiomer for DNA while cytotoxicity 
experiments demonstrate good activity in case of R-enantiomer only, therefore it is 
concluded that strong DNA binding of the complexes is not always necessarily the 
criteria for significant in vitro cytotoxicity . 
Another novel series of chiral potential metal-based chemotherapeutic complexes was 
designed and synthesized to ascertain structure-activity relationship of these complexes 
towards cellular target DNA. The synthesis involves the in situ reduction (by NaBH4) of 
Schiff base of salicylaldehyde / benzaldehyde and (S)- and (R)-2-amino-l-propanol to 
yield the ligand L3 and L4. Subsequently, the complexation of L3 and L4 was carried out 
with Cu(CH3COO)2. in methanol. The crystal structure of Cu(II) [Cu^\iii-
Ll)2(OAc)2].2H20 complex was obtained with R-enantiomer while the S-enantiomer was 
not suitable for single crystal diffraction studies. The asymmetric part of the unit cell of R-
enantiomer of [Cu 2(^-Ll)2(OAc)2].2H20 consists of two crystallographically independent 
and chemically identical [Cu^2(|i-Ll)2(OAc)2].2H20 units la and lb, respectively and four 
symmetrically H-bonded lattice water molecules. The asymmetric part represents a [CU2] 
complex bridged by phenolate oxygen (Oph) atoms. Two tridentate deprotonated 
[OphNamOiaH] ligands bind the Cu" ion in a facial mode. In the square-pyramidal 
coordination environment, depending on the axial or equatorial positions, the Cu-0 bond 
distances in Cu-^-Oph unit vary within a wide range of 1.936-1.900 for la and 1.927-1.981 
A for lb, respectively. Combination of two short and two long bonds clearly indicate the 
presence of an asymmetric CU2O2 diamond motif. The complexes exhibit square pyramidal 
geometry around both the Cu(II) centers as ascertained by X-ray data in case of R-
enantiomer, EPR studies at different temperatures (solid and liquid) and by UV-vis 
spectroscopic studies. The complexes were stable toward air and moisture , soluble in H2O 
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and other common solvents. Molar conductance values of complexes reveal their non 
electrolytic nature. In vitro DNA binding studies of both enantiomers (R)- and (S)-of 
complexes were carried out to evaluate their enantioselective influence. The (R)- and (S)-
enantiomers of [Cu"2(n-L3)2(OAc)2].2H20 and [Cu"2(l>OAc)2(L4.H20)2] exhibits a 
remarkable degree of enantioselectivity in their interaction with DNA ascertained by UV-
vis, fluorescence, circular dichroism and viscosity and the results reveal that both the 
complexes [Cu"2(^-L3)2(OAc)2].2H20 and [Cu"2(^-OAc)2(L4.H20)2] bind to DNA by 
coordinate covalent and groove binding, respectively. (R)-enantiomers bind more strongly 
in comparison to (S)-enantiomeric analogues. Interaction between complexes and pBR322 
DNA was evaluated by agarose gel electrophoresis assay, both the (R)-enantiomeric 
complexes exhibit effective DNA cleavage and proceed via oxidative pathway. 
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Abstract 
Bioinorganic chemistry has fostered the interdisciphnary prosperous research area of 
medicinal inorganic chemistry involving metal ions and biology of living systems. Metal-
based chemotherapeutics have attracted considerable attention after the serendipitous 
discovery of cisplatin - an archetypical inorganic drug used for treating solid malignancies. 
There is however, a growing demand for more efficacious metal-based pharmaceutical 
remedies which are safer, more potent, exhibit fewer side effects and reduced toxicity; not 
only from the point of view of cancer therapeutics but also for other itenary diseases viz; 
viral HIV, neurodegenerative diseases, alzheimer and diabetes etc. 
It has been well established for many years that, for testing drugs pure stereoisomers have 
to be studied since only one optical isomer exhibits in general the desired therapeutic 
effects, due to its interaction with targeted chiral biomolecules or chiral biological sites. 
The structure-function relationship in nature is so powerful that when a functional disorder 
manifests in the form of disease, it can be handled in many cases only by using a molecule 
of specific chiral structure. The chiral metal complexes thus, play a profound role in their 
interactions with DNA as they have the potential to demonstrate both enantioselectivity 
and stereoselectivity with their chiral target such as DNA. Furthermore, since DNA is the 
primary cellular receptor, many metal complexes exert their antitumor effects through 
binding to DNA, thereby interfere in the complicated mechanism of uncontrolled 
proliferation and contribute to the elimination of neoplastic cells by inhibiting replication, 
and by inducing differentiation or by triggering apoptotic processes. 
Among the various features governing the binding modes with DNA (covalently or non-
covalently by intercalation, groove binding or external electrostatic binding), the most 
significant is the "molecular shape" of the interacting metal complex in addition to ligand 
modifications in geometry, size, hydrophobicity, planarity, charge and hydrogen bonding 
interaction which leads to subtle or to spectacular changes in the binding modes, location, 
affinity and to a different cleavage effect. For example, various ancillary ligands such as 
chiral diam(m)ine and amino acids were used to modulate the interaction between the 
complex and DNA and to accentuate any enantiomeric differences. Variation of the 
am(m)ine ligands of these complexes is now known to influence the type of cancers 
effectively treated by each compounds with oxaliplatin proving active against colon 
cancer. 
A particular type of absorption spectroscopy alone carmot possibly deduce the mode of 
binding accurately with DNA, therefore various others spectroscopic methods viz; 
fluorescence, circular dichroism, NMR dynamics with nucleotides, hydrodynamic 
measurements such as viscosity and DNA cleavage activity assays were performed to 
validate the modes and extent of metal complex- DNA interaction. 
In view of this rationale, we have synthesized and characterized a variety of complexes 
derived from well - designed ligand motifs with first row transition metal ions viz. Co(II), 
Cu(II) and Zn(II) and Sn(IV) ion {SnCU and (CH3)2SnCl2} employing de novo synthetic 
strategy. The interaction studies of these complexes with CT DNA have been studied by 
various biophysical methods. 
New potential metal-based antitumor chemotherapeutic heterobimetallic complexes 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] derived from salicylaldimine monometallic complexes 
[Cu(Sb)2] and [Zn(Sb)2] were synthesised and thoroughly characterized by spectroscopic 
(IR, 'H , '^C and ''^Sn NMR, EPR, UV-vis, FAB-MS) and analytical methods. In the 
complexes, the geometry of copper and zinc metal ions were square planar and tetrahedral 
while tin ions were present in hexacoordinate environment. The comparative interaction of 
free Schiff base Hgand (Sb), monometalHc complexes and their heterobimetallic 
counterpart with CT DNA in Tris buffer were studied by electronic absorption titration, 
fluorescence titration and viscosity measurements. The intrinsic binding constant Kb of 
ligand and the complexes were determined which follows the order: [Zn(Sb)2Sn2] > 
[Cu(Sb)2Sn2] > [Zn(Sb)2] > [Cu(Sb)2] > Sb which is in conformity with our hypothesis that 
heterobimelallic complexes are more prominent DNA binders than the monometallic in 
comparison to the free ligand. Further, interaction studies of heterobimetallic complexes 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] with supercoiled pBR322 DNA were carried out 
employing gel electrophoresis, noticeably both heterobimetallic are efficient cleavage 
agents and specific groove binders (complex [Cu(Sb)2Sn2] binds to both major and minor 
groove while complex [Zn(Sb)2Sn2] is a specific minor groove binder ). In addition, the 
complexes show high inhibition activity against topoisomereses I and II. However, 
complex [Zn(Sb)2Sn2] exhibits significant inhibitory effects on the Topo I activity at a very 
low concentration -2.5 ^M. 
To evaluate the biological preference of chiral drugs for molecular target DNA, new 
potential metal-based chemotherapeutic agents of late 3d- transition metals {Co(II), Cu 
(II) and Zn(II)} derived from L-, D-, and DL-tryptophan, respectively and followed by 
reaction v/ith 1,2-diaminobenzene were synthesized and thoroughly characterized. The 
complexes are stable towards air and moisture and soluble in DMSO and DMF. Analytical 
data of complexes is consistent with their proposed molecular formulae. Due to the 
presence of chiral auxiliary "L-tryptophan, D-tryptophan", complexes exhibited optical 
rotation [a]u values which indicate that all the complexes are optically active except the 
complexes which were derived from racemic DL-tryptophan (an optically inactive 
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component). In complexes the coordination geometry of central Co(II) ion is pseudo-
octahedral whilst Cu(II) and Zn(II) complexes were found to possess square-planar and 
tetrahedral geometry, respectively. Comparative DNA binding studies were carried out 
with the complexes to evaluate the effect of conformations on DNA binding . The results 
reveal that the extent of DNA binding of L-form of Cu(II) complex [Cu(trp)(dabz)]Cl was 
higher in comparison to rest of the complexes . This was further confirmed by nuclease 
activity of L-form of Cu(II) complex [Cu(trp)(dabz)]Cl with supercoiled pBR322 DNA . 
The obser\'ed cleavage reaction involves various oxygen species and superoxide radicals 
by oxidative cleavage mechanism. The L-form of Cu(II) complex [Cu(trp)(dabz)]Cl 
exhibited significant antitumor activity against MCF-7 cell line (human breast carcinoma) 
Indeed, L-form of Cu (II) complex [Cu(trp)(dabz)]Cl is one of the most effective chiral 
cancer chemotherapeutic agent designed in terms of its selective antitumor activity. 
A new series of potential antitumor chiral metal-based complexes of Co(II), Cu(II) and 
Zn(II) were designed and synthesized to examine the effect of chirality on the binding 
propensity of DNA. Syntheses of mononuclear complexes [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl were achieved by mixing stoichiometric amounts 
of L-tryptophan and D-tryptophan with corresponding metal chlorides followed by 
reaction vath (lR,2R)-(-)-l,2-diaminocyclohexane. The composition of the complexes 
were confirmed by elemental analysis, infrared, nuclear magnetic resonance spectroscopy, 
EPR, mass spectrometry and optical rotation. The complexes are stable towards air and 
moisture imd soluble in DMSO and DMF. Molar conductance values of complexes in 
DMSO (1 X 10"^  M) at 25 °C suggest their 1:1 electrolyte nature. Due to the presence of 
chiral auxiliaries "L-tryptophan, D-tryptophan" and (lR,2R)-(-)-l,2-diaminocyclohexane 
ligand (1,2-DACH), the complexes [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
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[Zn(trp)(dach)]CI exhibited optical rotation [a] D values which indicate that ail the 
complexes are optically active. In complexes, the coordination geometry of Co(II) complex 
is pseudo-octahedral whilst Cu(II) and Zn(II) complexes were found to possess square-
planar and tetrahedral geometry, respectively. Comparative DNA binding studies were 
carried out by electronic absorption titrations, fluorescence and circular dichoric studies in 
free complexes and in the presence of DNA supported that both the enantiomers bind to 
DNA by noncovalent mode of binding viz, preferably electrostatic interaction via 
phosphate backbone of the helix, however, L-form is more potent and exhibits enhanced 
binding propensity for DNA as compared to D-form analogs. The L-form of 
[Cu(trp)(dach)]Cl exhibits a remarkable DNA cleavage activity with pBR322 DNA in 
presence of different activators viz. H2O2, ascorbic acid, 3-mercaptopropionic acid and 
glutathione suggesting the involvement of active oxygen species for the DNA scission. In 
vitro anticancer activity of L-form of complexes were screened against 14 different human 
carcinoma cell lines of different histological origin and results reveal that complex 
[Cu(trp)(dach)]Cl is potent selective antitumor agent against MIAPACA2 (Pancreatic 
cancer cell line ) with GI50 value of 21 compared to 47 and >80 for complex 
[Co(trp)(d.ach)(H20)2]Cl and [Zn(trp)(dach)]Cl, respectively in the same cell line. 
Understanding the reason for chiral preference can underlay the protocol for efficacious 
drug design. This concept rationalizes the pre- requirement of enantionselectivity of drug 
entities by interacting with inherently chiral DNA structure at the molecular level. 
Comparison of Cu(II) drug entities with Sn(IV) complexes - a notably important class of 
metallated antitumor agents can throw insight to their potential to act as effective 
chemotherapeutic lead drug regime. New chiral complexes (S)- and (R)- of LI, L2, metal 
complexes [CU2LI2], [SniLh], [CU2L22] and [Sn2L22] were designed and synthesized with 
an aim to develop new potent chiral chemotherapeutic antitumor entities where Ll= 2-(2-
hydroxy-l-phenylethylaminomethyl)phenol and L2 = 2-(benzylamino)-2-phenylethanol. 
The synthesis involves the in situ reduction (by NaBH4) of Schiff base of salicylaldehyde / 
benzaldehyde and (S)-/(R)-2-phenylglycinol to yield the ligand LI and L2. The 
complexation of LI and L2 with CUCI2.2H2O and (CH3)2SnCl2 were carried to obtain 
stable complexes, soluble in DMSO and DMF. Molar conductance values of metal 
complexes reveal their non electrolytic nature. In vitro DNA binding studies of both 
enantiomers (S)- and (R)- of ligands (LI and L2) and complexes were carried out 
employing LTV -vis titrations, fluorescence and circular dichoric studies to outline the effect 
of chirality on DNA binding propensity. These findings demonstrate that S-enantiomer of 
Cu(II) complex [CU2LI2] binds more avidly and readily to DNA in comparison to its R-
enantiomeric form and Sn(IV) complexes. DNA cleavage studies employing gel 
electrophoresis of all complexes with pBR322 plasmid DNA were carried out, complex 
[CU2LI2] (S-enantiomer) exhibits effective DNA cleavage in the absence of external 
agents. The in vitro antitumor activity of complexes including ligands LI and L2 has been 
examined on a panel of 19 human tumor cell lines of different histological origins by SRB 
assay. [CU2L22] (S-enantiomer) and surprisingly, [CU2LI2] (R-enantiomer) exhibited 
remarkably excellent cytotoxity activitiy (GI50 values <10) against T24 (Urinary Bladder), 
DU145 (Prostate), U373MG (Astrocytoma) and HCT15, SW620 (Colon) cancer cell lines, 
respectively clearly underlining the influence of enantiomeric discrimination in in vitro 
cytotoxicity^ experiments .On the other hand, ligands LI, L2 and rest of the complexes 
displayed poor cytotoxicity , (GI50 values < 40) only against Hela (Epithelial 
Carcinoma) and A2780 (Ovary) human cancer cell lines, respectively. Since the 
differences in cytotoxicity do not correlate with simple measurements of DNA binding 
VI 
which reveal greater propensity of S-enantiomer for DNA while cytotoxicity 
experiments demonstrate good activity in case of R-enantiomer only, therefore it is 
concluded that strong DNA binding of the complexes is not always necessarily the 
criteria for significant in vitro cytotoxicity. 
Another novel series of chiral potential metal-based chemotherapeutic complexes was 
designed and synthesized to ascertain structure-activity relationship of these complexes 
towards cellular target DNA. The synthesis involves the in situ reduction (by NaBH4) of 
Schiff base of salicylaldehyde / benzaldehyde and (S)- and (R)-2-amino-l-propanol to 
yield the ligand L3 and L4. Subsequently, the complexation of L3 and L4 was carried out 
with Cu(CH3COO)2. in methanol. The crystal structure of Cu(II) [Cu'V^-
Ll)2(OAc)2].2H20 complex was obtained with R-enantiomer while the S-enantiomer was 
not suitable for single crystal diffraction studies. The asymmetric part of the unit cell of R-
enantiomer of [Cu"2(^-Ll)2(OAc)2].2H20 consists of two crystallographically independent 
and chemically identical [CU"2(H-L 1)2(0Ac)2].2H20 units la and lb, respectively and four 
symmetrically H-bonded lattice water molecules. The asymmetric part represents a [CU2] 
complex bridged by phenolate oxygen (Opj,) atoms. Two tridentate deprotonated 
[OphNamOiaH] Hgands bind the Cu ion in a facial mode. In the square-pyramidal 
coordination environment, depending on the axial or equatorial positions, the Cu-0 bond 
distances in Cu-^-Oph unit vary within a wide range of 1.936-1.900 for la and 1.927-1.981 
A for lb, respectively. Combination of two short and two long bonds clearly indicate the 
presence of an asymmetric CU2O2 diamond motif. The complexes exhibit square pyramidal 
geometry around both the Cu(II) centers as ascertained by X-ray data in case of R-
enantiomer, EPR studies at different temperatures (solid and liquid) and by UV-vis 
spectroscopic studies. The complexes were stable toward air and moisture , soluble in H2O 
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and other common solvents. Molar conductance values of complexes reveal their non 
electrolytic nature. In vitro DNA binding studies of both enantiomers (R)- and (S)-of 
complexes were carried out to evaluate their enantioselective influence. The (R)- and (S)-
enantiomers of [Cu"2(|i-L3)2(OAc)2].2H20 and [CU"2(H-OAC)2(L4.H20)2] exhibits a 
remarkable degree of enantioselectivity in their interaction with DNA ascertained by UV-
vis, fluorescence, circular dichroism and viscosity and the results reveal that both the 
complexes [Cu"2(^-L3)2(OAc)2].2H20 and [Cu"2(n-OAc)2(L4.H20)2] bind to DNA by 
coordinate covalent and groove binding, respectively. (R)-enantiomers bind more strongly 
in comparison to (S)-enantiomeric analogues. Interaction between complexes and pBR322 
DNA was evaluated by agarose gel electrophoresis assay, both the (R)-enantiomeric 
complexes exhibit effective DNA cleavage and proceed via oxidative pathway. 
vni 
Abbreviations 
AMP 
CD 
CMP 
CTDNA 
DABZ 
DACH 
DMF 
DMSO 
EDTA 
EPR 
ESI 
EthBr 
EtOH 
FAB 
GMP 
IL 
LMCT 
LNT 
MeOH 
NMR 
SRB 
TCNE 
TGA 
TMP 
Tris 
UV 
adenosine monophosphate 
circular dichroism 
cytidine monophosphate 
calf-thymus DNA 
diaminobenzene 
diaminocyclohexane 
dimethylformamide 
dimethylsulfoxide 
ethylenediaminetetraacetic acid 
electron parmagentic resonance 
electrospray lonisation 
ethidium bromide 
ethanol 
fast-atom bombardment 
guanosine monophosphate 
intra ligand 
ligand to metal charge transfer 
Liquid nitrogen temperature 
methanol 
nuclear magnetic resonance 
sulphorhodamine B 
tetracyanoethylene 
thermogravimetric analysis 
thymidine monophosphate 
tris(hydroxymethyl)aminomethane 
ultra-violet 
Introduction 
Medicinal inorganic chemistry [1-5], a recent offshoot of bioinorganic chemistry is at the 
interface between medicine and inorganic chemistry, and includes metal-based drugs, metal-
containing diagnostic aids, and the medkinal recruitment of endogenous metal ions. 
Considerable interest in this field emerged after the serendipitous discovery of the antitumor 
activity of cisplatin [6], gadolinium complexes in magnetic resonance imaging (MRI) [7], 
and the rise of nuclear medicine, for both therapy and diagnosis [8] (Figure 1). 
The use of metal complexes as therapeutic agents can be traced back to 3500 BC [9]. Copper 
and iron have been used since antiquity in metal-based therapies. A curious connection 
between the discovery of a new precious element and its quick application into the 
medicinal armamentarium has been witnessed [10]. 
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Figure 1. (a) Cisplatin, (b) A dual-function Gcf^ -texaphyrin derivative for cancer 
Irnaging and therapy, (c) ^^Cu-bis(thiosemicarbazone) complex localization under 
conditions of hypoxia. 
Recent medicinal inorganic chemistry spurs considerable interest for the design of 
therapeutic and diagnostic agents for the treatment of cancers. Cisplatin (cis-
diamminedichloroplatinum(ll), [cis-(NH3)2PtCl2]), an antitumor compound is considered as 
the archetypical inorganic drug [11], as it contains not one atom of carbon. Nonetheless, 
most metal-based pharmaceuticals are constructed with carbon-based ligands. 
Transition metals, due to the unique properties, such as redox transfer, electron shuttling, 
thermodynamic and kinetic stability and versatile coordination geometries arising from 
various oxidation states that go beyond sp, sp and sp hybridization of carbon [12] could be 
complementary to organic compounds [13]. Metal complexes are more appealing for design 
of new lead therapeutic drugs as metal plays an important role in the chaperoning and or 
delivery of drugs away from the sites where they exert most toxicity and toward their sites 
of action. Additionally, the formation of a metal complex will alter the solubility and 
lipophilicity of the drug, resulting in changes in pharmacokinetics, biodistribution and 
biotransformation [1]. The platinum based cisplatin and the second generation alternative 
carboplatin are still the most widely used chemotherapeutic agents for treating solid 
malignancies. Both compounds appear to act by forming adducts with DNA, thereby 
interfering with transcription and DNA replication to trigger apoptosis of the cell. However, 
platinum-based anticancer agents are non-specific resulting in significant toxicity (severe 
side effects and activity to act in a restricted spectrum of tumors) as well as inherent or 
acquired resistance; these effects limit their successful clinical use. Therefore, alternative 
strategies based on non-platinum metals and ligand scaffold bearing functionalities are being 
developed with improved pharmacological properties and a broader range of antitumor 
activity, particularly, based on increased understanding of the biochemical differences 
between normal and cancerous tissues. 
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Cancer is a class of disease in which a group of cells display uncontrolled growth (division 
beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and 
sometimes metastasis (spread to other locations in the body via lymph or blood). Most 
cancerous cells divide uncontrollably to form lumps or masses of tissue called tumors but 
some like leukemia (where cancer prohibits normal blood function by abnormal cell division 
in the blood stream) do not. Systems that irreversibly bind to DNA such as cisplatin and its 
analogues have become some of the most important first-line treatment for solid tumors [16-
20]. On the other hand, complexes that bind to DNA reversibly have possible application as 
tools for probing the structure and function of DNA [21-23]. 
Metal ions exist as electron deficient cations (Lewis acid) in the biological system and hence 
are attracted to electron rich (Lewis bases) biological molecules such as protein and DNA. 
Since pharmacological target of the antitumor drugs is cellular DNA and N7 atom of the 
imidazole rings of guanine and N3 atom of adenine residues located in the major groove of 
the double helix, the most accessible and reactive nucleophilic sites for binding to DNA, 
therefore, search for the DNA binding non-platinum metal complexes has gained increased 
momentum. A novel DNA binding metal complex with good anticancer activity and clinical 
efficacy must ftilfiU the following key criteria [16]. 
i) good intrinsic properties, including saline solubility and enough stability to arrive intact at 
the cellular target ii)efficient DNA binding properties iii) efficient transport in blood and 
through membranes (iv) the ability to differentiate between cancerous and normal cells vi) 
activity against tumors that are, have become resistant to cisplatin and its second generation 
derivatives. 
A large percentage of chemotherapeutic anticancer drugs are compounds that interact with 
DNA directly or prevent the proper relaxation of DNA. The next generation of oncology 
therapeutics will more likely focus on 'targeted' small molecule therapies, DNA- targeting 
drugs as evidenced by marketing of belotecan [24] which have proven its utility as 
chemotherapeutic anticancer drug and such drugs will continue to be a staple of anticancer 
regimes. 
DNA, an inherently chiral molecule has a polymorphic structure with polyanionic nucleotide 
chains and sugar phosphate back bone [25]. The asymmetric D-ribose and D-2 deoxyribose 
units contain several stereogenic centers, whose configuration is important in overall DNA 
structure. 
Figure 2. Different conformational variations of DNA structure. 
It is well Icnown that DNA does not exist in a single three-dimensional structure, but can 
adopt different conformations which are defined both locally and macroscopically by 
different stmctural parameters (Figure 2). Double stranded DNA commonly adopts a right-
handed helical conformation that of B- and the A-form, however, they differ in the 
conformation of the sugar (C2'-endo for B-DNA and C3'-endo for A-DNA, and in helical 
parameters). It was discovered that certain sequences of DNA have the propensity to 
undergo conformational transitions to left-handed helical form termed as Z-DNA [26,27]. 
In addition to DNA, most objects found in nature are not identical with their mirror images 
and therefore cire said to possess 'chirality' (originated from the Greek word "cheir meaning 
hand") or handedness. Handedness or chiraUty is displayed by nature on many levels, 
ordinarily, proteins and DNA wind in right handed helixes; left-handed versions are rare and 
true mirror image versions do not appear in nature. Right and left-handed amino acid 
molecule exists at different energy levels as a result of the asymmetric weak nuclear force, 
those in organisms are almost always left-handed. The elementary particle known as the 
neutrino exists only as a left handed object [29]. Because of the chirality of its key 
molecules, human chemistry is highly sensitive to enantiomeric differences. 
Understanding the reason for chiral preference shown by nature has also practical 
applications. Single enantiomeric drugs constitute more than 30 % of the total therapeutic 
drugs used in recent years. The growing use of enantiomeric drugs is closely- related to 
structure-fimction relationship. The structure-ftmction relationship in nature is so powerftil 
that when a lunctional disorder manifests in the form of disease, it can be handled in many 
cases only by using a molecule of specific chiral structure. Consequently, the appropriate 
designing of enantiomeric tumor inhibiting motifs or compoimds is well-understood. 
The chiralit)' of the metal complex and the various structural interactions of these rigid 
enantiomers with the asymmetric DNA helix dictate the binding modes (steroselective 
intercalation [30], groove binding [31], direct coordination [32] (Figure 3), and therefore is 
responsible for site specific binding [33]. The origin of stereoselectivity can be attributed to 
a combination of different contributions: the intercalation, which is usually the driving force 
of the interaction between the complex and DNA double helix, and other specific 
interactions such as electrostatic interaction, hydrogen bonding or Van der Waals contacts of 
the small molecules with DNA residues either in the major or the minor groove. Even 
though chiral molecules may lack hydrogen-bonding donors or acceptors, the simple 
coordination complexes undergo their discrete site-specific reactions solely on the basis of 
matching of shapes and symmetries; also termed as "shape selectivity" [34], 
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Figure 3. External binding (leji), intercalation (middle), groove (right) binding. 
Among the chiral metal complexes first synthesized by Werner were enantiomers of 
tris(phenanthroline)iron(lI) [35,36]. In 1950's Dwyer [37] looked for differential biological 
activity between isomers of these simple metal complexes and perhaps not surprisingly, 
differential effects on biological activity were detected. Some examples of chiral structure 
are given in (Figure 4). 
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Figure 4. Depiction of enantiomeric pairs of metal complexes. 
Chirality in metal complexes can arise by the asymmetry of ligands or in an inherently 
achiral coordination mode (such as square planar complexes) or by coordination chirality 
such as A or A isomers of octahedral complexes of bidentate or terdentate ligands. 
Although converting a molecule from one enantiomer to the other seems like only a small 
change in the structure, it can provide a paramount impact on the way the molecule interacts 
with its surroundings, and especially other chiral compounds. Many of the molecules that 
are important in nature are chiral, these include proteins (and their constituent amino acids), 
which control most processes within biological systems, and the nucleic acids DNA and 
RNA which are responsible for holding the information necessary for proteins to be 
synthesized. 
The precise mechanism of cisplatin is not yet completely understood, but it is known to 
target DNA, forming a critical lesion by cross-linking two adjacent guanine or one adenine 
and one guanine on the same strand, through metallation to the N7 nitrogen [15]. Cisplatin, 
due to undesirable side effects, inherent and acquired resistance has been modulated by 
inducing a novel feature of chirality. Chirality has a well known relevance in this field and 
has played am important role in the quest for new and more effective platinum and non 
platinum drags. 
The effect of chiral primary monoamines such as 1 -phenylethylamine used as ligand instead 
of ammonia in cisplatin derivatives was demonstrated which revealed little differences in 
two enantiomeric species. Therefore, chiral diamines mostly ethylenediamine analogous 
[38], were used as ligands and their efficacy as antitumor drugs was shown to be dependent 
on stereochemistry. Another good example of the power of chirality in the development of 
new drugs concerns the use of (R,R)- and (S,S)- enantiomer of trans-1,2-
diaminocyclohexane (1,2-DACH), which give rise to enantiomeric complexes with platinum 
and exchangeable ligands such as chloride or oxalate (Figure 5). The complexes containing 
meso cis-l,2-DACH were less effective than that of the trans-form, and the two enantiomers 
of the latter have different toxicity and activity [39]. When a secondary amine is used as a 
ligand, the nitrogen atom can in some cases also become a stereogenic centre thus, the 
chirality at nitrogen atom can affect the biological property [38]. 
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Figure 5. Structure of platinum complexes used as antitumor agents with different amines 
and imines. 
3- aminohexahydroazepine abbreviated as ahaz is a unique chiral 1,2-diamine having C-
and N-substituent which are connected to form a seven-membered monoazaheterocycle. 
The two enantiomers of [Pt(ahaz)Cl2] (Figure 6) were investigated to establish whether they 
demonstrated any enantioselectivity in their DNA binding and cytotoxic action and it was 
found that S-enantiomer binds more readily to DNA than the R-enantiomer. But 
surprisingly, it was the R-enantiomer which was more potent cytotoxic than S-enantiomer 
on human bladder cancer cells [40]. 
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Figure 6. Schemetic representation of the enantiomer of [Pt(ahaz)Cl2j 
The stereochemical properties of copper complexes of aliaz have been studied extensively 
[41-43]. The X-ray crystal structure of a copper(II) complex S-ahaz, [CuBr(S-ahaz)2]C104, 
revealed that ligand ahaz functions as a bidentate ligand and possess square pyramidal 
geometry [41]. 
Tailored multifunctional ligands for metal based medicinal drugs offer many exciting 
possibilities including targeting specific tissues, membrane receptors, or endogenous 
molecules and can play an integral role in modulating the potential toxicity of a 
metallodrugs [44]. Recent advances in ligand design have resulted in potent antitumor 
compounds that are active in cisplatin resistant cell lines, and also include additional 
features to allow for an increased understanding of the mechanism of action of drug. 
Recently Qing Yang et al. investigated several novel heterocyclic fused napthalimides 
having chiral amino side chains (Figure 7); effects of chirality of amino side chains on DNA 
binding ability, photo damage activity as well as antitumor cytotoxicity were evaluated [45]. 
Their side chain chiral configuration determined DNA binding activities in the order; S-
enantiomer > R-enantiomer. And their DNA photodamaging activities were in good 
agreement with their DNA binding constants. S-enantiomer, cleaved supercoiled plasmid 
pBR322 DNA from Form I to Form 11 completely at 50 ^M. Furthermore, S-enantiomer 
demonstrated effective antitumor cytotoxicity against human lung cancer cells and murine 
leukemia cells while R-enantiomer by comparison exhibited different cytotoxicity. 
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Figure 7. Heterocyclic-fused naphthalimide chiral amino side chains. 
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Amino acids, which are naturally occurring chiral compounds, have been extensively used 
as chiral auxilliaries to create / induce a quatemary stereogenic carbon center. The relevance 
of amino acids lies in their biological importance, not only as they form the building block 
of peptides and proteins but also cellular tissues in fluid in living organism which contain a 
reservoir of free amino acids. They take part in important metabolic reactions, including the 
biosynthesis of polypeptides and proteins and the syntliesis of nucleotides. High biological 
importance, chirality and amphiphility combined with a low molecular weight and relative 
simplicity of molecular structures make amino acids the most suitable candidates for drugs 
scaffold representing typical features of natural bioactive substances [46-49]. 
Metal complexes of amino acids are involved in exchange and transport mechanism of trace 
metal ions in human body. Such systems provide models of protein-DNA and peptide 
derived antitumor agent-DNA interaction. Polar or charged amino acid side-chain groups, 
such as hydroxyl, amide, guanidium and oa-ammonium groups, are involved in hydrogen 
bonds with strongly electronegative atoms^ and the peptide groups. Various side groups of 
amino acid are found to have a potential to recognize the specific base sequence through 
hydrogen bond formation with the nucleic bases in DNA [50-51]. The physiologically 
interesting mixed ligand complexes of amino acids are the most studied class of this field. 
Two copper complexes (Figure 8) of the type [CU(L')(L^)] (where L ' = tryptophanate or 
phenylalaninate, L = cysteinethiolate) were prepared, characterized and their 
spectrophotiDmetric and voltammetric behaviour was investigated [52]. 
TO,C-CH-NH, O HO,C-CH-K<f ^ < ^ 
Figure 8. Structure of[Cu(V)(L^)] 
11 
Since metal ions coordinate these amino acids through the amino and carboxylato groups in 
a fixed geometry which can be favorable for intermolecular interactions and affect their 
conformation, electron density etc. a wide variety of possibilities regarding structures and 
function of metal-amino acid complexes can be expected [53]. Amino acid complexes of 
Cu(II) and Zn(Il) are known to be important for metal ion transport in blood. A ternary 
Cu(II) complex, Cu(his)(thr) (his = histidine, thr = threonine) was isolated from human 
blood serum by Sarkar et al. [54] and tracer studies indicated that ternary Cu(II)-amino acid 
complexes composed of his and asparagine (asn), glutamine (gin) are preferentially formed 
in blood plasma [55]. 
Mixed ligand ternary metal complexes of amino acids and nucleic acid constituents play an 
important role in biochemical processes, for example genetics and molecular biology [56] as 
nucleic acids and proteins recognize each other by very specific and selective interactions 
through amino acid side chain and nucleic acid constituents [57]. Mixed ligand ternary 
complexes of nucleic acid bases and nucleotides such as thymine, cytidine, 2- thiouracil and 
amino acids viz. L-alanine, L-phenylalanine and L-tryptophan (Figure 9) were synthesized 
and characterized by various spectroscopic techniques [58,59]. 
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Figure 9. Structure of few ternary complexes of thymine and cytidine ^ M = Cu(II), Ni(II) 
and Co(II). 
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The condensation of primary amines with carbonyl compounds was first reported by Schiff 
and since then condensation products are referred to as Schiff bases [60]. Several Schiff base 
complexes were found to inhibit tumor growth [61]. A few structurally characterized amino 
acid derived Schiff bases and their metal complexes were reported [62-65]. Amino acid 
Schiff base complexes of first row transition metals such as Co(II), Ni(II), Cu(II) etc. were 
reported to exhibit fungicidal, bactericidal, antiviral and antitubercular activity [66]. 
For the given ligand with flexible conformation, the conversion from one 
structure to another is possible by changing pH, anion, solvent etc. and hence the physical 
and chemical properties are greatly influenced [67,68]. In this respect, Vittal et al. have 
studied the structures of metal complexes containing reduced Schiff base ligands formed 
between an^ iino acids and salicylaldehyde [69] (Figure 10). 
H H.R 
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Figure 10. Schematic diagrams of ligand (left) and the dicopper complexes (right) where R 
= Hor Me, L = anion or water. 
Four copper (II) complexes containing the reduced Schiff base ligands, namely, N-(2-
hydroxybenzyl)-glycinamide (Hsglym) and N-(2-hydroxybenzyl)-L-alaninamide (Hsalam) 
have been synthesized and characterized (Figure 10). 
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Transition metal complexes containing Schiff base ligands or their reduced products are 
often used as artificial nucleases and some such complexes have proven to be efficient DNA 
binding and cleaving agents [70]. Recently, three new reduced amino-acid Schiff base 
complexes [Co(HL)2(H20)2].4H20, [Cu(HL)2(H20)2].2H20 and [Cd(HL)2(H20)3].3H20 
{H2L = N-(4-hydroxy-benzyl)-L-glycine, a biolgically relevant reduced amino acid Schiff 
base} were synthesized and characterized by physicochemical and spectroscopic methods 
[71] (Figure 11). In these complexes, the two bidentate monoanionic Schiff base ligands 
coordinate the metal centre through the secondary amine N atom and the carboxylate O 
atom. 
The binding of complexes with CT DNA has been investigated by UV-vis 
spectrophot(3metry and fluorescence quenching methods. In addition, DNA cleavage 
experiments were also evaluated by gel electrophoresis. The results reveal that complexes 
bind to DNA by an intercalative mode. The DNA cleavage shows oxidative DNA cleavage 
activity in presence of H202/sodium ascorbate and the reactive oxygen species responsible 
for the DNA cleavage was most likely singlet oxygen. 
Figure 11. The ORTEP drawing of mononuclear unit of [Co(HL)2(H20)2j (a), 
[Cu(HL)2(H20)2] (b) and [Cd(HL)2(H20)3](c). 
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First report of a structurally characterized mononuclear chiral Mn(lV) complex derived from 
S-2-[2-hydroxy-1 -phenylethylimino)methyl]phenoI] {(S)-2-phenylglycinol and 
salicylaldehyde (Scheme 1) appeared in research article by Zachrias and Das et al. [72] and 
its catalytic activity for the oxidation of olefin using iodosobenzene as an oxidant was 
described. In an another attempt, they prepared dichloro-bridged dinuclear copper(II) 
complex with the same ligand [73] (Figure 12). However, DNA binding profile of these 
complexes or their derivatives is still scarce in literature. 
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MeOH 
R.T. 
Scheme 1. Synthesis of S-2-[2-hydroxy-l-phenylethylimino)methyl]phenol]. 
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Figure 12. The ORTEP drawing of mononuclear chiral Mn(IV) and dichloro-bridged 
dinuclear copper (II) derivedfr-om derived from S-2-[2-hydroxy-l-
phenylethylimino)methyl]phenol]. 
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Tin is found in a wide variety in inorganic and organometallic compounds, which are 
characterized by the presence of one covalent carbon-tin bond. Tin has an electronic shell 
configuration 5s^p .^ Principally it is able to lose two 5p electrons and form simple Sn(II) 
ions or acquire the electronic configuration of xenon by sharing all the four electrons with 
other atoms,. It seems that although tin may exist either in Sn(II) or in Sn(IV) oxidation 
states, almost all organotin have tetravalent structure because Sn(II) compounds are readily 
oxidized to Sn(IV). Depending on the number of organic moieties ,organotins are classified 
as mono, di, and tetraorganotin (RSnXs, R2Snx2, RaSnX, I^Sn), where X is an anionic 
species (halide, oxide, hydroxide, carboxylate, or thiolate). Tin and organotin compounds 
containing electronegative atoms such as halogen atoms show Lewis acid character and the 
tin atom increases its coordination number from four or five, six or seven upon addition of 
neutral orgi-mic donor ligands [74,75]. Pettinari and his group have published several 
contributions on interaction of 4-acy 1-5-pyrazolones, a typical class of enolizable beta-
diketone ligands with tin [76]. Pettinari et al. synthesized stable six- coordinate organotin 
derivative of the general formula Q2-SnRX where (Q = l-phenyl-3-methyl-4-benzoyl-5-
pyrazolone). Later, they expanded their research on pyrazolones by using alkane (ethane, 
butane, pentane and hexane) spacers [77]. 
In 2006, Pettinari et al. presented results on the structure and in vitro antitumor profile of 
new 4-acylpyrazolon-5-ato-dihalotin complex (Q2SnX2) using as ligands [78]. The 
antitumor profile of the compounds was moderate but one of the compound, (Q^" ^ S n C b 
exhibited a definite antiproliferative effect, consistently observed in all human melanoma 
experimental models tested. The SK-MEL cell line was the most sensitive and activity was 
correlated to the nature of the R-substituent attached to the pyrazole group decreasing in the 
order: pyridyl > phenyl» methyl. 
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The chemical, biological and pharmaceutical properties of tin(IV) and dior^notin(IV) 
complexes have been studied extensively [79-82]. There is however, promising and recent 
success in using different organotin derivatives, which have shown acceptable in vitro 
cytotoxicity and antiproliferative in vivo activity as new lead chemotherapeutic agents 
[66,83]. In the search for effective alternatives, Organotin(rV) dithiocarboxylates received 
utmost attention on account of their potential apoptotic inducing character [84]. Since 1980, 
United States national cancer institute (NCI) has tested over one thousand tin compounds, 
and 170 of these were found to be active [85]. 
The binding ability of organotin compound towards DNA depends on the coordination 
number, nature of the groups bonded to the central tin atom [86]. The phosphate group of 
DNA sugar back bone usually acts as an anchoring site. Nitrogen of DNA base binding is 
extremely effective, stabilizing the tin centre as an octahedral stable species. However, 
researches indicate that there is negligible interaction of tin complexes with nucleotide 
bases, but rather strong and irreversible binding to the vicinal phosphate groups of 
phosphoribose residues (Scheme 2) [87]. The presence of cyclic groups (aromatic or 
heterocyclic) in the tin-containing molecules was found to be important for anticancer 
activity aj; well [88-94]. The structure-antitumor relationship of diorganotin(IV) derivatives 
are well documented in literature [86]. 
Diorganotin complexes of Schiff base have been studied extensively because organotins 
possess good biocidal and significant cytotoxic activity in some human tumor cell lines 
[95,96]. irhe stmcture of these complexes has been verified by X-ray crystallography 
(Scheme 3). 
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Scheme 3. Synthetic route ofSchiffbase bearing tin(IV) metal complexes. 
Mala Nath et al. have synthesized and characterized organtin(IV)-amino acid Schiff base 
complexes of the general formula BuaSnL (L= dianion of tridentate Schiff base derived from 
the condensation of 2-hydroxy-l-naphthaldehyde or acetyl acetone with glycine) [97] 
(Figure 13). An attempt was made to prove the structure of resulting complexes on the basis 
of elemental analysis, conductance measurement and electronic IR, multinuclear magnetic 
^ILT 13/-. „ _ J 117 119c 
resonance ( H, C and Sn) and Sn Mossbauer spectral studies 
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Figure 13. Structures ofBu2SnL with different Schiffbase ligands. 
The cytotoxicity of compounds were screened in vitro against seven tumor cell lines, viz. 
MCF-7, EVSA-T, WiDr, IGROV, Ml9 MEL, A498 and H226. The activities were found to 
be better than cisplatin and carboplatin (Table 1). 
Table 1, ID50 values (in ng ml') of selected diorganotin derivatives of Schiffbase derived 
from amino-acids, and of some reference compounds. 
Complex 
Bu^n-I(l) 
Bu^r»L-2(I) 
BujSnL-6(II) 
Pb,SnL-l(I) 
PhjSnL-2(I) 
Carboplatin' 
Ci^Jadn' 
ID^(ng 
MCF-7 
75 
20 
60 
170 
600 
10500 
1400 
ml"') agsiinst*: 
EVSA-T 
35 
17 
120 
70 
150 
4500 
920 
WiDr 
480 
114 
420 
490 
1750 
3500 
1550 
IGROV 
75 
27 
130 
120 
480 
2400 
230 
MI9MEL 
90 
71 
70 
530 
620 
5500 
780 
A498 
170 
62 
130 
230 
690 
18 000 
1200 
H226 
190 
160 
200 
350 
1100 
25 000 
3160 
The DNA binding and cleaving activity of tin(IV) and organotin(IV) are scarce in literature. 
However, numerous reports in literature are available for cytotoxicity of tin(IV) and 
organotin(IV) complexes. One such example of DNA binding and cleaving activity of 
organotin(IV) was provided by M. Gielen et al. [98] in which the reactions with DNA of 
two antitumor active organotin(lV) compounds, the dimer of bis[(di-n-butyl3,6-
dioxaheptanoato)tin] and tri-n-butyltin3,6,9-trioxodecanoate (Figure 14) were analyzed by 
circular dichroism, DNA melting experiments and gel mobility shift assays. It was found 
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that both complexes modify only slightly the B-type spectrum of CT DNA as witnessed by 
circular dichroism spectroscopy (CD). 
/ 
0 ''^ ''2 I 
bis[(di-n-butyl3,6-dioxaheptanoato)tin] 
SnBu, \^^^^^0' 
tri-n-butyltin3,6,9-trioxodecanoate 
Figure 14. Structure ofbis[(di-n-butyl 3,6-dioxaheptanoato)tin] andtri-n-butyltin3,6,9-
trioxodecanoate. 
Addition of organotin(IV) compound affects only slightly the CD spectrum of DNA. A 
modest decrease of the negative band at 240 nm and an even smaller decrease of the positive 
band at 270 nm was observed for both compounds at the higher ratio. In any case, CD 
results were diagnostic of the occurrence of some orgajiotin-DNA interaction although the 
observed effects on DNA conformation were relatively small (Figure 15). 
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Figure 15. CD spectra in the UV of CT DNA following addition of his[(di-n-butyl3,6-
dioxaheptanoato)tin] for a final metal-to-bp ratio of 0.5. Spectra were recorded before 
mixing (a) and after 24 hour incubation (b). DNA concentration: 30 fig/ml; buffer: NaCl 
ImM, NaCl0410 mM, pH7.4. 
In an another attempt, gel electrophoresis experiments were carried out with pBR322 
plasmid DNA which was incubated for 12 hours with increasing amounts of organotin(IV) 
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compounds at 25 °C (Figure 16). Apparently there was negligible effect of organotin(IV) 
compounds on DNA gel mobility even after using a varied range of stoichiometries. Even 
at the highest ratios (r = 1) both compounds did not modify appreciably the electrophoretic 
mobility of both plasmid DNA forms, that is, they did not alter the position of the fast-
migrating band, associated to the open circular form(OC), with respect to the dominant 
slow-migrating band associated to linear DNA (LC). 
1 2 3 4 5 6 
23.1 Kb 
9.4Kb 
6.6 Kb 
Figure 16. Gel electrophoresis ofpBR322 DNA samples incubated with compound bis[(di-
n-butyl3,6-dloxaheptanoato)tin] or tri-n-butyltin3,6,9-trioxodecanoate at different 
stoichiometries. Lanel: molecular mass marker (DNA digested with Hind III (GIBCO BRL, 
USA)); lanel: plasmid pBR322; lane3: bis[(di-n-butyl3,6-dioxaheptanoato)tin]-treated-
pHV14 at r = 1 stoichiometry; lane4: bis[(di-n-butyl3,6-dioxaheptanoato)tin]-treated-
pHV14 at r = 0.1 stoichiometry; laneS: tri-n-butyltin3,6,9-trioxodecanoate -treated-pHV14 
at r = 1.0 stoichiometry; lane6: tri-n-butyltin3,6,9-trioxodecanoate-treated-pHV14 at r = 
0.1 stoichiometry. OC, open circular DNA; LC, linear DNA. 
Since no significant effects on gel mobility of plasmid DNA samples were detected. Overall 
results wen; suggestive of the interaction of organotin(IV) compounds with DNA via 
external phosphate groups. 
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Z. Guo et al. have synthesized [99] highly water soluble 3:2 complex of Cu(II) and 2,4,6-
tris(di-2-pyridylamine)-l,3,5-triazine (TDAT) and structurally characterized by means of X-
ray crystallography (Figure 17) and different spectroscopic methods. 
Figure 17. ORTEP plot (30%) for the cationic core of TDAT- Cu(II) complex. The carbon 
atom labelings and hydrogen atoms are omitted for clarity. 
Upon addition of CT DNA to TDAT-Cu(n) complex, a moderate 'hyperchromicity' was 
observed in the UV-spectra (Figure 18a), which imply some interaction other than 
intercalation. The intrinsic binding constant (Kb) was calculated to be 7.8 x 10 M". 
Judging by the changing tendency of the UV spectra and the binding constant, the 
intercalative binding mode was ruled out. 
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FigurelS. (a) UV-vis absorption spectra for TDAT-Cu(II) complex in absence and presence 
ofCTDNA, (b) CD spectra ofCTDNA in absence and presence ofTDAT-Cu(II) complex 
and (c)Fluorescence emission spectra ofEB-CTDNA system in absence and presence of 
TDAT-Cu(II) complex. 
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The circular dichroism studies reveal on the addition of TDAT-Cu(Il) complex to the 
solution of CT DNA , an increase in intensity for both positive and negative ellipticity bands 
was induced implying that the stacking mode and orientation of base pairs in DNA were 
disturbed (Figure 18b). Intercalative binding mode is ruled out because this binding mode 
would cause ai characteristic decrease in both positive and negative bands [100]. 
A concentration dependent DNA cleavage activity by TDAT-Cu(II) complex was performed 
employing gel electrophoresis. Change in the electrophoretic mobility of plasmid DNA on 
agarose gel is commonly taken as evidence for direct DNA-metal interactions. Alteration of 
the DNA structure cause retardation in the migration of supercoiled DNA and a slight 
increase in the mobility of open circular DNA to a point where both forms comigrate. 
Impairment of DNA function results in the inhibition of replication and transcription 
processes and, eventually, if the DNA lesions are not rapidly and properly repaired, it results 
in cell death. Metal- DNA interaction cause alterations in the structure of DNA, where upon 
the mobility of supercoiled DNA decreases and the migration of open-circular DNA slightly 
increases at the comigration junction of both forms [2]. 
When a circular plasmid DNA is subjected to agarose gel electrophoresis, the fastest 
migration will be observed for supercoiled form (Form I). If one strand is cleaved, the 
supercoils v.'ill relax to produce a slower moving open circular form (Form II). If both 
strands are cleaved, a linear form (Form III) will be generated that migrates in between [99]. 
With the increase of concentration of TDAT-Cu(II) complex plasmid DNA was converted 
from Form I to Form II and then to Form III (Figure 19). 
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Lane 
Form II - • -
Form lll-ii-
Form I -•"i-
Figure 19. The cleavage pattern of the agarose gel electrophoresis and the corresponding 
cleavage extent (%) for pBR322 plasmid DMA (100 ng) by TDAT-Cu(ll) complex at 310 K 
after 30 min of incubation. Lane 1, DNA control; Lane 2, DNA + 0.4 mM H2O2; Lanes 3-6 
represent the DNA cleavage status at 2,4,6 and 8 fiM of TDAT-Cu(II) complex in the 
presence of 100 fold excess ofH202, respectively. 
Minor groove binding agent DAPI and major groove binding agent mettiyl green were used 
to determine the potential interacting site of TDAT-Cu(II) complex. The pattern 
demonstrated that neither DAPI nor methyl green were the preferred reacting sites [101] for 
TDAT-Cu(II) complex. Therefore, it was concluded that, TDAT-Cu(II) complex interacts 
with the exterior phosphate of DNA via electrostatic attraction (Figure 20). 
Lane 1 2 3 
Form II -i 
Form III-* 
Form I -» 
Figure 20. Agarose gel electrophoresis patterns for the cleavage of pBR322 plasmid DNA 
(100 ng) by TDAT-Cu(lI) complex (4 fiM) in the presence of DNA minor binding agent 
DAPI and major binding agent methyl green (5 mM Tris-HCl/40 mMNaCl buffer, pH 7.40) 
at 310 K after incubation for 30 min. Lane 1, DNA control; lane 2, DAPI (10 fiM); lane 3, 
methyl green (10 juM). 
The design of heterobimetallic trinuclear architecture utilizes a unique building block 
strategy which involve combination of both the active metal centres exhibiting differential 
behaviour towards the cellular target site on DNA [102-107]. Such complexes have been 
prepared considering the intrinsic DNA-interaction characteristic of the two separate active 
metallic centres [108,109]. For example, heterodinuclear bifiinctional molecules containing 
copper and platinum active metal centres were designed as combination agents [110], due to 
their preferential reactivity at site of interaction namely, the nitrogen atom N7 of guanine in 
the major groove for the pahinum component while the minor groove is preferred for copper 
unit [111] (Figure 21). The minimum separating distance required to achive such 
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concomitant minor and major interaction was determined from crystal strucutre of DNA-
cispaltin adduct [112] 
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Figure 21. Strategy adopted for the synthesis of heterodinuclear minor / major groove 
interacting complexes. 
Heterobimetallic complexes exhibit cleavage activities and were able to perform direct 
double strand cuts in contrast to monometallic Cu(3-clip-Phen) alone which was capable of 
carrying out successive single strand cuts (Figure 22). 
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 
Figure 22. Comparison of the oxidative cleavage of 0X174 plasmid DNA performed by 13, 
14, and Cu(3-Clip-Phen) in the presence of 5 mMMPA. Lane 1: control DNA. Lane 2:250 
nM13 without MPA. Lane 3:100 nM 13. Lane 4:150 nM13. Lane 5: 250 nM13. Lam 6: 
250 nM 14 without MPA. Lane 7:100 nM 14. Lane 8:150 nM 
Here 13= CuPt[N*l*-(6-[3-Clip-Phen]-hexyl}-ethane-l,2-diamine]Cl4and, 14= 
CuPt[N*l *-{l 0-[3-Clip-Phen]-decyl}-ethane-l, 2-diamine] CI 4. 
The DNA binding of compounds such as BBR 3464 (Figure 23) is covalent, but a 
significant noncovalent component arises from the presence of the central platinum 
CI \ /NHj HjN^  /NHjfCH j^N^ ^NHj 
y \ 
4+ 
BBR 3464 (1.0.1/tit) 
Figure 23. Structure of BBR 3464. 
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(tetramine) unit which interacts with DNA only through electrostatic and hydrogen-bonding 
effects [113]. The highly charged compound induce B —•A and B —•Z conformational 
changes in canonical sequences of DNA. Noncovalent concept is extended in this complex 
by use of dangling amines which increase the charge and charge dispersion along these 
linear cations, surprisingly results in significantly enhanced cellular accumulation, with a 
higher charge (8+) has about 5 times greater cellular uptake than the parent BBR 3464 (4+) 
[114]. As a consequence of this accumulation, enhanced cytotoxity is observed across a 
panel of ovarian tumor cell lines despite the reversible nature of DNA binding. 
With the objective of lowering the systemic toxicity of. metal-based drugs, successful 
modular synthesis of heterotrinuclear complexes has been carried out that combines the 
class of compounds with paltinum (II) centre, resembling cisplatin and two ruthenium (III) 
centres that resemble NAMI by bridging dinitrogen ligands [115]. Such design has been 
done to achieve both efficacy and selectivity of the drugs and studies pertaining to these 
complexes have demonstrated that these complexes are potent against both neoplastic 
tumors and metastatic cancer. 
Hoti et al. have studied the effect of tri-phenyl tin benzimidazole thiol- copper chloride 
(TPT-CuCb)- a novel class of heterobimetallic compounds [116]. The effect of TPT-CuCla 
on the regulation of apoptosis in HeLa cells, MCF-7 human cervial cancer cell in vitro and 
in vivo on Wistar rat model was evaluated which demonstrated significant anti proliferative 
activity against tumor development with minimal cytotoxicity toward normal physiological 
function of experimental rats. Treating confluent HeLa cells with the TPT and 
chemotherapeutic drugs cisplatin alone, separately for different time intervals resulted in a 
significant differences in cell viability by MTT assay showing that TPT is a stronger inducer 
of apoptosis than cisplatin. TPT can efficiently kill tumor cells at a very low doses (2 
|xg/mL) thus minimizing the toxic side effect in contrast to high dosage of cisplatin (16 
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^g/mL) [117].Combining TPT with CuCl2 yields more efficacious drug regime due to their 
preferential selectivty at the DNA helix (TPT prefers vicinal phosphate oxygen atoms of 
phosphate sugar backbone, while CuCla component coordinates to N7 atom of guanine). 
Understanding the concept of combining the metal centres with preferential selectivity 
towards DNA with a new critical feature of chirality was examined in trinuclear aminoacid 
derived complexes Cu-Sn2/Cu-Zr2 by our group [118]. Introduction of L-aminoacid 
additionally enahances / modulates the pharmacological behaviour of the metal complexes 
by adopting specific conformation and target selective binding affinity with DNA. The 
interaction with DNA was carried out in Tris buffer by electronic absorption titration, 
luminiscence titration, cyclic voltammetry, circular dichroism and viscometric 
measurements. 
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Figure 24. Chemical structures ofheteronuclear Sn(IV)/Zr(IV) modulated Cu(II)/Zn(II) 
trinuclear complexes. 
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The emission quenching of these complexes by [Fe(CN)6] depressed greatly when bound to 
DNA. Observed changes in the circular dichoric spectra of DNA in presence of Cu-Sni/Cu-
Zr2 support the strong binding of complexes with DNA. The relative specific viscosity of 
DNA bound to Cu-Sn2/Cu-Zr2 decreased, indicating that the complexes bind to DNA via 
covalent binding. To evaluate the mechanistic pathway of DNA inhibition, counting 
experiments and MTT assay was employed to assess the induction of apoptosis by Cu-Sn2. 
Western blot analysis of whole cell lysates and mitochondrial fractions with Bcl-2 and p-53 
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family proti^ins and caspase-3 colorimetry assay was also carried out on a human 
neuroblastoma cell line SY5Y. Cu-Sni complex exhibited selective antitumor activity and 
further studies pertaining to this complex are currently underway. 
More recently, copper-based heteronuclear complexes were explored for displaying some 
intriguing nuclease properties [119]. The combination of a site-specific group and a scission 
moiety could enhance the regional selectivity and cleavage efficacy of such an artificial 
nuclease model. A number of natural nucleases require multinuclear metal centers to achieve 
a synergisitic effect in the process of substrate recognition and scission [120]. Guo et al. 
have demonstrated that synergestic effect between multicopper(II) centres in previous DNA 
cleavage studies [99,121-123]. Two monometallic copper(II) complexes 1, 2 and 
heteronucle<ir complexes 3, 4 were synthesized using bifunctional ligands [124] (Figure 24). 
The DNA bindng ability of these complexes follows an order ofl < 2 < 3 < 4 a s revealed by 
results of spectroscopic and agarose gel electrophoretic studies. The introduction of Pt(II) 
centre to ttie Cu(II) complexes induce a significant enhancement in DNA binding and 
cleaving ability, underlining the importance of heterobimetallic complexes in contrast to 
monometallic complexes in drug design regimes. 
^ 
Cu 
c/ \ . C\ CI 
complex 2 complex 1 
Figure 25. Chemical structures of complexes 1-4. 
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complex 3 complex 4 
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Present Work 
New potential metal-based antitumor chemotherapeutic heterobimetallic complexes 
[Cu(Sb)2Sn2]/ [Zn(Sb)2Sn2] derived from salicylaldimine complexes [Cu(Sb)2] and 
[Zn(Sb)2] were prepared by employing de novo synthetic strategy and they were 
thoroughly characterized by spectroscopic (IR, ' H , '^C and "^SnNMR, EPR, UV-vis, FAB-
MS) and analytical methods. In the complexes, the geometry of copper and zinc metal ions 
were square planar and tetrahedral while tin ions were present in hexacoordinate 
environment. The comparative interaction of free Schiff base ligand Sb, monometallic 
complexes, and their heterobimetallic with CT DNA in Tris buffer were studied by 
electronic absorption titration, fluorescence studies and viscosity measurements. DNA 
cleavage activity employing agarose gel electrophoresis was also carried out examine the 
scission activity of the complexes. These studies demonstrate both the heterobimetallic 
complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] were efficient cleavage agents of pBR322 
plasmid DNA and specific groove binders (complex [Cu(Sb)2Sn2] binds to both major and 
minor groove while complex [Zn(Sb)2Sn2] is specifically minor groove binder only). In 
addition, the complexes were evaluated for inhibition activity against topoisomereses I and 
11. However, complex [Zn(Sb)2Sn2] exhibits significant inhibitory effects on the Topo I 
activity at a very low concentration -2.5 ^M. This work embodies the design of metal-based 
topoisomerase inhibitors, also specific DNA groove binders, and since such inhibitions are 
related to DNA binding therefore, they can act as potent antitumor drugs. 
Understanding the binding modes viz; covalent or non-covalent plays a pronounced 
influence on the efficacy of a drug or chemical entity as a potential drug; among the factors 
governing the binding modes, the most significant and fascinating criteria for drug design is 
the molecular shape-chiral preference or enantioselectivity. Those complexes that fit best 
against the DNA helical structure display the highest binding affinity. Upon binding to 
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DNA, these conformations give rise to the preferential binding of one conformation over 
another, which is termed as enantioselectivity. In an attempt to unravel details of 
conformational differences; we have undertaken the comparative DNA binding studies of 
enantiomeric forms L-, D- and their racemic analog DL-(tryptophan) of late 3d transition 
metal complexes {Co(II), Cu(II) and Zn(II)} with 1,2-diaminobenzene. Comparative DNA 
binding studies were carried out with the complexes to evaluate their extent of binding in 
different conformations of chirality. The interaction studies of complexes with CT DNA 
indicate that Cu complex derived from L-tryptophan [Cu(trp)(dabz)]Cl binds to DNA with a 
strongest affinity. This was further confirmed by nuclease activity of [Cu(trp)(dabz)]Cl with 
supercoiled pBR322 DNA and it was observed that cleavage reaction involves various 
oxygen species and superoxide radicals by oxidative cleavage mechanism. The complex 
[Cu(trp)(dabz)]Cl (L-form) exhibited significant antitumor activity against MCF-7 cell line. 
The structuial analogs of the above complexes derived from non-planar ligand (lR,2R)-(-)-
1,2-diaminocyclohexane) and L-, D-tryptophan of the composition [Co(trp)(dach)(H20)2]CI, 
[Cu(trp)(dach)]Cl, [Zn(trp)(dach)]Cl were synthesized and thoroughly characterized. Two 
different enantiomers bind to DNA by a similar non-covalent electrostatic mode; however, 
the extent of interaction is different as visualized by optical measurement methods which 
outline the effect of chirality. Electronic absorption titrations, fluorescence and circular 
dichoric studies in free complexes and in the presence of DNA supported that both the 
enantiomers bind to DNA by noncovalent mode of binding viz, electrostatic interaction via 
phosphate backbone of the helix, nevertheless, L-form is more potent and exhibits enhanced 
binding propensity for DNA as compared to D-form cinalog. This could be understood well 
by the hypothesis put forth in two-pole complementary principle that the B-form of DNA is 
best suited conformation for L-form. The L-form of complex [Cu(trp)(dach)]Cl is potent 
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selective ariititumor agent against MIAPACA2 (Pancreatic cancer cell line) as evaluated by 
anticancer SRB assay. 
New chiral complexes (S)- and (R)- of Cu(II) and Sn(IV) were designed and synthesized 
with an aim to develop new chiral chemotherapeutic antitumor agents. The synthesis 
involves the in situ reduction by NaBH4 of Schiff base of salicylaldehyde / benzaldehyde 
and (S)-/(R)-2-phenylglycinol to yield the reduced Schiff base ligand. The complexation of 
ligands with CUCI2.2H2O and (CH3)2SnCl2 were carried to obtain stable complexes 
[CU2LI2], [SnzLb ], [CU2L22] and [Sn2L22] soluble in DMSO and DMF. Molar 
conductance values of complexes reveal their non electrolytic nature. In vitro DNA binding 
and cleavage studies of both enantiomers (S)- and (R)- of complexes were carried out to 
evaluate their enantioselective influence. DNA binding findings demonstrate that S-
enantiomer of Cu(II) complex [CU2LI2] binds more avidly and readily to DNA in 
comparison to its R- enantiomeric form and Sn(IV) complex. Cleavage studies employing 
gel electrophoresis of with pBR322 plasmid DNA were carried out, noticeably, S-
enantiomer of complex [CU2LI2] exhibited effective DNA cleavage in absence of any 
external reducing agents. The in vitro antitumor activity of all complexes including ligands 
LI and L2 has been examined on a panel of 19 human tumor cell lines of different 
histological origins by SRB assay. S-enantiomer of complex [CU2L22] and surprisingly, R-
enantiomer of complex [CU2LI2] exhibited remarkably good cytotoxity activitiy against 
T24 (Urinary Bladder), DU145 (Prostate), U373MG (Astrocytoma) and HCT15, SW620 
(Colon), respectively clearly underlining the influence of enantiomeric discrimination in in 
vitro cytotoxicity experiments . The ligands LI, L2 and rest of the complexes displayed 
poor cytotoxicity activity. 
Another set of chiral complexes(R)- and (S)- of Cu(II) were synthesized which involves the 
in situ reduction (by NaBH4) of Schiff base of salicylaldehyde / benzaldehyde and (S)- /(R)-
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2-amino-l-p:ropanoI, to yield the ligand, with the aim to evaluate the effect of aliphatic chain 
((S)-/-(R)-2-amino-l-propanol) on DNA binding and cleaving studies in place of their 
aromatic counterpart (S)-/(R)-2-phenylglycinol. The complexes were thoroughly 
characterized by various physicochemical and spectroscopic studies. A very exciting crystal 
structure of Cu(II) complex exhibiting diamond morphology has been obtained in case R-
enantiomer of [Cu"2(^-L3)2(OAc)2].2H20. The asymmetric part of the unit cell of R-
enantiomer of [Cu"2(li-L3)2(OAc)2].2H20 consists of two crystallographically independent 
and chemically identical [CU"2(M--L3)2(OAC)2] units la and lb, respectively and four 
symmetrically H-bonded lattice water molecules. Comparative DNA binding studies of (R)-
and (S)- of both Cu(II) complexes by various techniques viz. absorption titration, 
fluorescence spectral studies, circular dichroism and viscosity measurements to evaluate 
their enantioselective influence. 
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1, Materials 
Salicylaldehyde (Alfa Aesar), 5-Aminosalicylic acid (Fluka), 1,2-Diaminobenzene, (1R,2R)-
(-)-l,2-Diaminocyclohexane), (S)-/(R)-2-Phenylglycinol (Sigma), (S)/(R)-2-Amino-l-
propanol (Aldrich), L-Tryptophan, DL-Tryptophan (Fluka), D-Tryptophan (Loba Chemei), 
NaBH4, C0CI2.6H2O, CUCI2.2H2O, Zn(CH3COO)2.2H20, Cu(CH3COO)2.H20 (E. Merck), 
ZnCb anhydrous (Rankem), SnCl4.5H20 (Lancaster), (CH3)2SnCl2 (Sigma) were used as 
received. Tris(hydroxymethyl)aminomethane or Tris Buffer, Calf thymus DNA (CT DNA), 
Adenosine 5'-monophosphate disodium salt salt (5'-AMP), Cytidine 5'-monophosphate 
disodium salt hydrate (5'-CMP), Guanosine 5'-monophosphate disodium salt (5'-GMP) and 
Thymidine 5'-monophosphate (5'-TMP), were purchased from Fluka and were stored at -20 
°C. 6X loading dye (Fermental Life Science), Agarose, Ascorbic acid. Sodium azide (NaNs), 
DMSO, Superoxide dismutase (SOD), Methyl green, DAPI, Mercaptopropionic acid (MPA) 
(Sigma-Aldrich) and Super coiled plasmid DNA pBR322 (Genei) were utilized as received. 
All reagents and solvents were of the best commercial grade and were used without further 
purification. 
2. Characterization techniques 
Carbon, hydrogen and nitrogen contents were determined using Carlo Erba Analyzer Model 
1106. The visualization of spots on TLC plates was effected by exposure to iodine or 
spraying with 10% H2SO4 and charring and single spots of the products were observed 
which were; different from those of the starting materials. 
2.1 Infrared spectroscopy 
Infra-red spectra of the ligands and complexes were recorded as KBr pellets on Interspec 
2020 FTIR spectrometer. The formation of the ligands and complexes behavior has been 
ascertained by scanning their infrared spectra in 4000-200 cm''. 
2.2 Ultraviolet and visible spectroscopy 
The electronic spectral studies of metal complexes provide useful information about the 
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stereochemi stry, oxidation state of the metal ion and in suitable circumstances, the nature of 
metal-ligand bond. Electronic spectra were recorded on UV-1700 PharmaSpec UV- vis 
spectrophotometer (Shimadzu). Data were reported in A,max/nm. 
2.3 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number I = 1/2, 
example of which include 'H , '^C, ^^P, "^Sn and '^F. 
For a nucleus with I = 1/2, there are two values for the nuclear spin angular momentum 
quantum number mi = ±1/2 which are degenerate in the absence of a magnetic field. 
However, in the presence of the magnetic field, this degeneracy is destroyed such that the 
positive value of mi corresponds to the lower energy state and negative value to higher 
energy state separated by AE. 
In an NMR experiment, one applies strong homogeneous magnetic field causing the nuclei 
to presses. Radiation of energy comparable to AE is then imposed with radio frequency 
transmitter equal to precision or Larmor frequency and the two are said to be in resonance. 
The energy can be transferred from the source to the sample. The NMR signal is obtained 
when a nucleus is excited from low energy to high energy state. 
The 'H , '-'C NMR and "^Sn spectra were obtained on a Bruker DRX-400 & 500 
spectrometer at 400 and 500 MHz, respectively operating at room temperature. Chemical 
shifts were reported on the 5 scale in parts per million (ppm). 
2.4 Electron paramagnetic resonance spectroscopy 
Electron paramagnetic resonance (EPR) spectra of the Co(II) and Cu(II) complexes were 
obtained on a Varian E 112 EPR spectrometer using tetracyanoethylene (TCNE) as field 
marker. The spectra were recorded for solid and solutions of the complexes in appropriate 
solvents at room temperature (RT) as well as at liquid nitrogen temperature (LNT). 
35 
2.5 Mass spectroscopy 
Mass spectrometry is one of the most accurate microanalytical technique which requires 
only a few nanomoles of the sample to obtain characteristic information regarding the 
molecular mass and to detect within a molecule the places at which it prefers to fragment 
from which the presence of recognizable group within the molecule can be deduced. Mass 
spectrometry is complementary to FT IR, NMR, UV-vis and EPR spectral techniques for 
structural identification of compounds. 
FAB mass spectra is relatively routine technique for mass spectrometric analysis of 
inorganic and organometallic compounds whether charged or neutral but involves 
complication by redox, fragmentation and clustering processes in the study of metal 
complexes. 
FAB mass spectra were recorded on Joel SX-102, while Electrospray mass spectra were 
recorded on Micromass Quattro II triple quadrupol mass spectrometer. 
2.6 Thermogravimetric analysis (TGA) 
TGA was performed with a universal V3.8 B TA SDT Q600 Build 51 Thermal Analyzer 
under nitrogen atmosphere using alumina powder as reference material. The final 
thermolysis product of metal complex as metal oxides was studied. 
2.7 X-ray diffraction analysis 
To obtain Jiurther evidence about the structure of the metal complexes, X-ray diffraction 
studies were performed. Powder X-ray diffraction (XRDP) patterns were recorded with 
Rigaku Miniflux.., 
2.8 Crystallographic data collection and structure analysis 
The crystal was mounted on a glass fibre and all measurements were performed on 
BRUKER SMART APEX CCD diffractometer with graphite monochromator using Mo-Ka 
(k = 0.71069A) radiation [125]. Cell constants and the orientation matrix for data collection 
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were obtained from a least-square refinement [126] using the setting angles of 21 carefully 
centered reflections in the range of 2.51< 20 <25.99°. Hydrogen atoms were refined 
isotropically. 
2.9.1 Conductance measurements 
The conductivity measurement is one of the simplest and easily available techniques used to 
study the nature of the complexes. It gives direct information regarding whether a given 
compound is ionic or covalent. For this purpose, the measurement of molar conductance 
(Am), which is related to the conductance value in the following maimer is made. 
cell constant x conductance 
Am = 
concentration of solute expressed in mol cm -3 
•1 
Conventionally, solutions of 1x10' M strength are used for the conductance measurements. 
Molar conductances were measured at room temperature on a Digsun Electronic 
conductivity Bridge. 
2.9.2 Polariimetry 
Optical isomerism manifests itself by the rotation that certain molecules impart to the plane 
of polarized light when in gaseous, liquid or mohen state or in solution. This rotation is 
observed and measured by a rather simple instrument, known as polarimeter. The specific 
rotation [a] of a dissolved substance is given by the expression 
a 
[a] 
I x c 
where a is the observed rotation in degrees 
1 is the path length of the sample in decimeters 
c is the concentration in grams per milliliter 
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The dependence on wavelength and temperature is indicated by subscripts and superscripts 
respectively. Thus [a]D^^  means the specific rotation at 25 ''C measured at the wavelength of 
the sodium D line. 
Optical rotations of chiral ligands and complexes were determined on a Polarimeter Rudolf 
Autopol III. 
3. DNA binding studies 
All the experiments involving interaction of the complexes with CT DNA were conducted in 
buffer containing Tris(hydroxymethyl)aminomethane or Tris Buffer (0.01 M) adjusted to pH 
7.2 with hydrochloric acid. The CT DNA was dissolved in Tris HCl buffer and was dialyzed 
against the same buffer overnight. Solutions of CT DNA gave ratios of UV absorbance at 
260 and 280 nm above 1:1.8, indicating that the DNA was sufficiently free of protein [127]. 
DNA concentration per nucleotide was determined by absorption spectroscopy using the 
molar absoiption coefficient 6600 dm mof cm" at 260 nm [128]. The stock solution was 
stored at 4 "C. 
3.1 Absorption spectral studies 
The intrinsic binding constant Kb of the complex to CT DNA was determined from equation 
(1), through a plot of [DNA]/ Sg-Sf vs [DNA], where [DNA] represents the concentration of 
DNA, and Ea, Sf, and Eb the apparent extinction coefficient (Aobs /[M]), the extinction 
coefficient for free metal complex (M), and the extinction coefficient for the free metal 
complex (M) in the fully bound form, respectively. In plots of [DNA]/Ea-Ef vs. [DNA], Kb is 
given by the ratio of slope to intercept [129]. These absorption spectral studies were 
performed on Shimadzu UV-1700 PharmaSpec UV-vis spectrophotometers. 
[DNA]/|Sa-Ef] = [DNA]/|Eb-£fi +1/Kb|£b-Ef| (1) 
Absorption spectral titration experiments were performed by maintaining a constant 
concentration of the complex and varying the nucleic acid/nucleotide concentration. This 
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was achieved by diluting an appropriate amount of the metal complex solutions and CT 
DNA/5'-GMP, 5'-TMP stock solutions while maintaining the total volume constant. This 
results in a series of solutions with varying concentrations of CT DNA/5'-GMP/5'-TMP but 
a constant concentration of the complex. The absorbance (A) was recorded after successive 
additions of CT DNA/5'-GMP/5'-TMP. While measuring the absorption spectra an equal 
amount of CT DNA/5'-GMP/5'-TMP was added to both the compound solution and the 
reference solution to eliminate the absorbance of the CT DNA/5'-GMP/5'-TMP itself. 
3.2 Fluorescence spectral studies 
The emission spectrum is obtained by setting the excitation monochromator at the maximum 
excitation wavelength and scanning with emission monochromator. Often an excitation 
spectrum is first made in order to confirm the identity of the substance and to select the 
optimum excitation wavelength. Further experiments were carried out to gain support for the 
mode of binding of complexes with CT DNA. Non-fluorescent or weakly fluorescent 
compounds can often be reacted with strong fluorophores enabling them to be determined 
quantitatively. On this basis molecular fluorophore EthBr was used which emits 
fluorescence in presence of CT DNA due to its strong intercalation. Quenching of the 
fluorescence of EthBr bound to DNA were measured with increasing amount of metal 
complexes 'AS a second molecule and Stem-Volmer quenching constant K was obtained from 
the following equation 2 [130]. 
I o / I = l + K r (2) 
where r is the ratio of total concentration of complex to that of DNA and lo and I are the 
fluorescence intensifies of EthBr in the absence and presence of complex. 
Binding constant K of the metal complexes was also determined from Scatchard equations 3 
and 4 by employing emission titrafion [131,132]. 
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CF = C T ( I / I O - P ) ( 1 - P ) (3) 
r/CF = K(n-r) (4) 
Where Cp is the free probe concentration, CT is the total concentration of the probe added^ I 
and lo are fluorescence intensities in presence and absence of CT DNA, respectively and P is 
the ratio of the observed fluorescence quantum yield of the bound probe to that of the free 
probe. The value P was obtained as the intercept by extrapolating from a plot of I/Io vs 1/ 
[DNA], r denotes ratio of CB (=CT-CF) to the DNA concentration i.e., the bound probe 
concentration to the DNA concentration, K is the binding constant and Cp, is the free metal 
complex concentration and "n" is the binding site number. Emission intensity measurements 
were carried out using Hitachi F-2500 spectrofluorometer at room temperature. 
3.3 Circular dichoric spectral studies 
Circular dichroic spectra of CT DNA were obtained by using JASCO J-716 
spectropolarimeter equipped with a peltier temperature control device. All experiments were 
done using a quartz cell of 1 or 0.3 cm path length. Each CD spectrum was collected after 
averaging over at least 3 accumulations using a scan speed of 100 nm min"' and a 1 second 
response time. Machine plus cuvette base lines, and CD contribution by the CT DNA and 
Tris buffer were subtracted and the resultant spectrum zeroed 50 nm outside the absorption 
bands. 
3.4 Viscometry studies 
The hydrodynamic changes are the consequence of the change in length of the molecule, the 
diminished bending between layers and the diminished length-specific mass. Viscosity 
measurements were carried out using Ostwald's viscometer at 29 ± 0.01 "C. Flow time was 
measured v/ith a digital stopwatch. Each sample was measured three times and an average 
flow time was calculated. Data were presented as (TJ/TIO) versus binding ratio ([M]/[DNA]), 
[133,134] v/here r\ is viscosity of DNA in the presence of complex and TIO is the viscosity of 
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DNA alone. Viscosity values were calculated from the observed flow time of DNA 
containing solution (t >100s) corrected for the flow time of buffer alone (to), q = t- to. 
3.5 Gel electrophoresis 
The cleavage experiments of supercoiled pBR322 DNA (300 ng) in (5mM Tris-HCl, 50 mM 
NaCl), buffer at pH 7.2 was carried out using agarose gel electrophoresis. The samples w e^re 
incubated for 1 hour at 37 "C. A loading buffer containing 25% bromophenol blue, 0.25% 
xylene cyanol, 30% glycerol was added and electrophoresis was carried out at 60 V for 
Ihour in Tris-HCl buffer using 1% agarose gel containing 1.0 |ig/mL ethidium bromide. The 
DNA cleavage with added reductant was monitored as in case of cleavage experiment 
without added reductant using agarose gel electrophoresis. The reaction were also monitored 
upon addition of various radical inhibitors such as sodium azide (NaNs), DMSO, superoxide 
dismutase (SOD), distamycin, methyl green, mercaptopropionic acid (MPA). The samples 
were incubated for 45 minutes at 37 °C. The gel was visualized by photographing the 
fluorescence of intercalated ethidium bromide under a UV illuminator. The cleavage 
efficiency was measured by determining the ability of the complex to convert the 
supercoiled DNA (SC) to nicked circular form (NC) and linear form( LC). 
4. Topoisomerase inhibition assay 
4.1 Topoisomerase I inhibition assay 
DNA topoisomerase I, Human (Topo I) was purchased from CALBIOCHEM and no further 
purification was performed. One unit of the enzyme was defined as completely relax 1 i^g of 
negatively supercoiled pBR322 DNA in 30 minutes at 37 °C under the standard assay 
conditions. The reaction mixture (30 ^L) contained 35 mM Tris-HCl (pH 8.0), 72 mM KCl, 
5mM MgCb, 5mM DTT, 2mM spermidine, 0.1 mg/mL BSA, 0.25 ^g pBR322 DNA, 2 Unit 
Topo I and metal complexes. These reaction mixtures were incubated at 37 "C for 30 
minutes, and the reaction was terminated by addition of 4 ^L of 5X stock solution consisting 
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of 0.25% bromophenol blue, 4.5 % SDS and 45% glycerol. The samples were 
electrophoresed through 1% agarose in TBE at 30 V for 8 hours. Then the gel was 
photographed under UV light. The concentration of the inhibitor that prevented 50% of the 
supercoiled DNA from being converted into relaxed DNA (IC50 values) was calculated by 
the midpoint concentration for drug-induced DNA unwinding. 
4.2. Topoisomerase II inhibition assay 
DNA topoisomerase Ila (Topo II) was purchased from Sigma. And no further purification 
was perfonned. One unit of the enzyme was defined as completely relax 0.3 |ig of 
negatively supercoiled pBR322 DNA in 15 minutes at 37 °C under the standard assay 
conditions. The reaction mixture (30 [iL) contained 10 mM Tris-HCl (pH 7.9), 50 mMNaCl, 
50 mM KCl, 5.0 mM MgCla, 0.1 mM NazHaedta, 15 i^g/mL BSA, 1.0 mM ATP, 0.25 l^g 
pBR322 DNA, 5 Unit Topo II, and metal complexes. The reaction mixtures were incubated 
at 30 °C for 15 minutes. Reactions were stopped, processed, and subjected to gel 
electrophoresis as above. 
5. Antitumor activity 
The cell lines used for in vitro antitumor screening activity were, MIAPaCa-2 (Pancreatic), 
MCF-7, ZR-75-1 (Breast), SiHa (Uterine Cervix), Colo205, HCT15, SW620 (Colon), HOP-
62, A549 (Lung), DWD (Oral), K562 (Leukemia), DU145, PC-3 (Prostate), A498 (Renal 
Cell), A2780 (Ovary), T24 (Urinary Bladder), U373MG (Astrocytoma), HT29 (colon 
adenocarcinoma grade II cell line) and Hela (Epithlial Carcinoma). G-adriamycin, standard 
anticancer drug was taken as control. These human malignant cell lines were procured and 
grown in FLPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FES) and 
antibiotics to study growth pattern of these cells. The proliferation of the cells upon 
treatment with chemotherapy entities was determined using the Sulphorhodamine-B (SRB) 
semi automated assay [135,136]. The dose response parameters such as growth inhibition 
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50% (GIso), total growth inhibition (TGI) and lethal concentration 50% (LC50) were 
calculated. GI50 is the concentration of drug required to decrease the cell growth to 50%, 
compared with that of the untreated cell number. TGI is the concentration of drug required 
to decrease the cell growth to 100%, compared with that of the untreated cell number, during 
drug incubation. LC50 is the concentration of drug required to decrease the cell growth by 
50% of the initial cell number prior to the drug incubation. Cells were seeded in 96 well 
plates at an appropriate cell density to give optical density in the linear range (from 0.5 to 
1.8) and were incubated at 37 "C in COT incubator for 24 hour. Stock solutions of the 
complexes v/ere prepared as 100 mg/mL in DMSO and four dilutions i.e. 10 i^L, 20 nL, 40 
I^ L, 80 i^L, in triplicates were tested, each well receiving 90 i^L of cell suspension and 10 i^L 
of the drug solution. Appropriate positive control (adriamycin) and vehicle controls were 
also run. The plates with cells were incubated in CO2 incubator with 5% CO2 for 24 hours 
followed by drug addition. The plates were incubated further for 48 hours. Termination of 
experiment was done by gently layering the cells with 50 |iL of chilled 30% TCA (in case of 
adherent cells) and 50% TCA (in case of suspension cell lines) for cell fixation and kept at 4 
°C for 1 hour. Plates were stained with 50 i^L of 0.4% SRB for 20 minutes. The bound SRB 
was eluted by adding 100 |iL 10 mM Tris (pH 10.5) to each of the wells. The absorbance 
was read at 540 nm with 690 nm as reference wave length. All experiments were repeated 3 
times. 
CHAPTER III 
Synthesis of heterobimetallic topoisomerase I and II inhibitor 
complexes: Their in vitro DNA binding, interaction studies 
with 5' GMP and 5'-TMP and cleavage activity. 
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Synthesis 
Synthesis of 5-{[(lE)-(2-Hydroxyphenyl)methylene]amino}-2-hydroxybenzoic acid (Sb) 
The ligand Ibb was synthesized according to the procedure reported earlier [137] which is 
described below (scheme 1). 
To an ethariolic (10 mL) solution of 5-aminosalicylic acid (0.50g, 3.26 mmol) was added 
salicylaldehyde (0.44 g, 3.60 mmol) in ethanol. The mixture was heated on reflux for 2 
hours to ensure completion of reaction which yielded yellow colored solid product, washed 
with ethanol (15 mL) and diethyl ether (30 mL). The yellow solid was then dried to afford 
ligand L. 
Yield 75%. m.p. 258-260 °C. IR (KBr, cm'') 1610 v (C=N). ' H N M R (DMS0-d6, ppm): 
13.07 (br, s, IH, -OH); 8.98 (s, IH, C(H)=N); 7.84 (s, 2H, Ar); 7.67-7.64 (m, 2H/Ar); 7.39 
j(dd, IH, Ar); 7.06-6.94 (ov, m, 3H, Ar). "C NMR (DMS0-d6 ppm): 172.2 (C=0); 162.2 
(C=N); 160.8 (CO); 160.7 (CO); 139.7 (Ar C); 133.4 (Ar C); 133.0 (Ar C); 129.1 (Ar C); 
123.1 (ArC); 119.8(ArC); 119.5 (ArC); 118.6 (ArC); 117.0(ArC); 114.1 (ArC). 
Synthesis of monometallic complexes [Cu(Sb)2] and [Zn(Sb)2] 
To a solution of Cu(CH3COO)2 (0.20 g, 1.10 mmol)/ Zn(CH3COO)2 (0.20 g, 1.09 imnol) in 
methanol (25 mL), ligand L (0.59 g, 2.29 mmol) in ethanol (25 mL) was added slowly and 
the reaction mixture was heated on reflux for 3 hours. Yellow green product was collected 
and washed with cold ethanol (15 mL) and diethyl ether (30 mL). The pale yellow solid was 
then dried to afford complexes. 
[Cu(Sb)2]: Yield 95%. m.p. 291-292 °C (decomposition). IR (KBr, cm'') 1608 v (C=N). 
Anal. (%) Calc. for C28H20N2O8CU: C, 58.38; H, 3.51; N, 4.86. Found: C, 57.74; H, 3.32; N, 
4.75. 
[Zn(Sb)2];; Yield 95%. m.p. 332-334 °C (decomposition). IR (KBr, cm'') 1608 v (C=N). 
Anal. (%) Calc. for C28H2oN208Zn: C, 58.19; H, 3.50; N, 4.85. Found: C, 58.14; H, 3.62; N, 
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4.87. H^ NMR (DMSO-dg, ppm): 13.36 (br, s, 2H, -OH); 8.91 (s, 2H, C(H)=N); 7.79 (d, 2H, 
AT); 7.59 (d, 2H, Ar); 7.44 (dd, 2H, Ar); 7.33 (t, 2H, Ar); 6.95-6.80 (ov, m, 6H, Ar). ^^ C 
NMR(DMS0-d6, ppm): 173.6 (C=0); 161.5 (C=N); 161.1 (CO); 160.8 (CO); 139.1 (Ar C); 
133.3 (Ar C); 133.0 (Ar C); 127.6 (Ar C); 123.7 (Ar C); 120.0 (Ar C); 119.6 (Ar C); 118.1 
(ArC);117.6(ArC);117.1(ArC). 
Synthesis of heterobimetallic complexes 
[Cu(Sb)2Sn2| 
To a solution of complex [Cu(Sb)2] (0.576 g, 1 mmol) was added NaOH (0.08 g, 2 mmol) 
in ethanol (15 mL) with stirring for 10 minutes until the solution became clear. This was 
followed by addition of SnCl4.5H20 (0.702 g, 2 mmol) in methanol (20 mL) and the 
reaction mixture was heated on reflux for a period of 2 hours, then it was isolated by 
filtration, washed with diethyl ether and ethanol in portion and dried in vacuum. 
Yield 60%. m.p. 300 °C. Anal. (%) Calc. for C28H24N20i2Cl4CuSn2: C, 32.87; H, 2.36; N, 
2.74. Found: C, 32.91; H, 2.37; N, 2.76. IR (KBr, cm'') 3300-3400 v (H2O); 1608 v (C=N); 
1690 (sym COO); 1335 (antisym COO); 787 (Ar); 538 v (Cu-0); 433 v (Cu-N); 650 v (Sn-
O); 270 V (Sn-Cl). Molar Conductance, AM (1 x 10'^  M, DMSO): 12.0 Q"'cm^ mof' (non-
electrolyte). UV-vis (1 X 10'^  M, DMSO): 262 nm; 592 nm. 
[Zn(Sb)2Sn2] 
This complex was synthesized with monometallic complex [Zn(Sb)2] (0.578 g, 1 mmol) 
according to the method outlined above. 
Yield 62%. m.p. 300 °C (decompose). Anal. (%) Calc. for C28H24N2O12CI4 ZnSn2.C2H50H: 
C, 33.65; H, 2.83; N, 2.62. Found: C, 33.69; H, 2.86; N, 2.64. IR (KBr, cm"') 3300-3400 v 
(H2O); 1608 V (C=N); 1592 (sym.COO); 1336 {antisym COO); 787 (Ar); 522 (Zn-0); 462 
(Zn-N); 652 v (Sn-0), 268 v (Sn-Cl). Molar Conductance, AM (1 x 10'^  M, DMSO): 15.0 
Q"'cm^mol"' (non-electrolyte). UV-vis (1 x 10'^  M, DMSO): 318 nm; 390 nm. 
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' H N M R (DMSO-de, ppm): 8.75 (s, 2H, C(H)=N); 8.03 (s, 2H, Ar); 7.83 (d, 2H, Ar); 7.77 
(dd, 4H, Ar); 6.99-6.84 (m, 6H, Ar); 3.7-4.0 (br, s, 8H, H2O); 2.15 (s, IH, -OH); 1.15 (s, 5H, 
-C2H5). '^ C NMR (DMS0-d6, ppm): 171.62 (C=0); 160.8 (C=N); 160.4 (CO); 160.2 (CO); 
139 (AT C); 132.4 (Ar C); 131.9 (Ar C); 128.59 (Ar C); 124.1 (Ar C); 122.4 (Ar C); 122.1 
(ArC); 119.3 (Ar C); 118.7(ArC); 116.3 (Ar C); 112.9(ArC); 18.02 (-CH2); 14.8 (-CH3). 
'•^Sn NMR (DMSO-de, ppm): -622.33. 
Results and discussion 
All the complexes are stable towards air and moisture and soluble in DMSO and DMF. In all 
complexes the coordination geometry of central metal ions {Cu(ll) and Zn(II)} was square 
planar and tetrahedral, respectively while the Sn(IV) atom was present in hexacoordinated 
environment (Scheme 4), which was proposed on the basis of '^'Sn NMR and other 
spectroscopic studies. 
IR spectral studies 
The IR spectrum of free ligand Sb displayed a strong characteristic band at 1610 cm"' due to 
1) (C=N) which shifted slightly to 1608 cm"' in the monometallic complexes [Cu(Sb)2] and 
[Zn(Sb)2] implying the coordination of nitrogen atom of the ligand to the metal center. In 
heterobimetallic complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2], v (OH) stretching band shifted, 
indicating thie coordination of the second metal ion Sn(lV) through the oxygen atom of both 
the phenolic groups by the elimination of NaCl/HCl [138]. The bands around 1590 cm"' and 
1335 cm"' observed in the free monometallic complexes [Cu(Sb)2] and [Zn(Sb)2] attributed 
to antisymmetric and symmetric -C=0. stretching vibrations were shifted to lower 
frequencies, suggesting the terminal coordination mode of carboxylate group of 
monometallic complexes to the Sn(IV) through deprotonation. 
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Figure 26. Cy/indrical bonded three dimensional model of complexes [Cu(Sb)2Sn2] is?/;*^  
/Z«(Sb)2Sn2/ Cc/o/- scheme: Cu(II) dark gray; Zn(II) dark gray; Sn(IV) Ught green; CI dark 
green; H white; N dark blue; 0 red; C gray. Other H atoms are omitted for clarity. 
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The Av (VasCCOi)" Vs(C02)) value was used to determine the nature of binding of carboxylate 
to metal centre. In general, the difference in Av between asymmetric (Vas(C02)) and 
symmetric (Vs(C02) ) absorption frequency below 200 cm"^  suggests the bidentate 
carboxylate moiety while greater than 200 cm'' implies the unidentate carboxylate moiety 
[139]. In heterobimetallic complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2], the Av values were 
255 and 258 cm"' indicative of unidentate carboxylate ligation. The coordination of the 
water molecules to Sn(IV) ions was fiirther supported by the appearance of non-ligand band 
in the region 840-851 cm' attributed to rocking mode of water [140]. Other medium 
intensity bands at 749-755 cm' were attributed to the characteristic signatures of aromatic 
ring vibration. The heterobimetallic complex formation of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] 
were also revealed by the presence of medium intensity (Cu/Zn-N), (Cu/Zn-0) and (Sn-Cl) 
bands around (433, 462), (538, 522) and -270 cm'', respectively in the far IR region 
[141,142]. 
NMR spectral studies 
The ' H NMR spectrum of complex [Zn(Sb)2Sn2] displays several interesting features in 
comparison to the free ligand Sb and complex [Zn(Sb)2] as depicted in Figure 27. In ' H 
NMR spectnim of complex [Zn(Sb)2Sn2], signals due to free carboxylic (-COOH) and 
phenolic (-0H) groups at 12.0-10.0 and 13.36 ppm, respectively were absent indicating the 
coordination of monometallic complex to Sn(IV) atom via deprotonation [139]. Coupled 
with these observations, the characteristic signals appeared at 8.75, 8.03-6.94 and 4.0-3.7 
corresponding to CH=N, aromatic proton [143] and coordinated H2O groups, respectively. 
The complex [Zn(Sb)2Sn2] exhibits '^ C NMR spectrum displaying various resonances due to 
0 -C=0 , CH=N, C-O-Sn and C-O-Zn carbons at 171.6, 160.8, 160.4 and 160.2 ppm, 
respectively. In addition, aromatic carbon signals were observed at 112.9-139 ppm (Figure 
28). 
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Figure 27. HNMR spectrum of the heterobimetallic complex [Zn(Sb) 28112]. 
119c Sn NMR spectroscopy has been found to be a useful technique for structure elucidation 
and the nature of coordination of tin atom in complexes. The "^Sn chemical shift, d ("^Sn) 
is sensitive to the chemical environments of the tin atom. '^^ Sn NMR spectrum of the 
complex [Zn(Sb)2Sn2] displayed one sharp signal at -622.33, due to the presence of two tin 
centers (Figure 29) in the same environment [144]. These chemical shift values are 
consistent with those reported for complexes with hexacoordinated geometry of tin metal 
atom [78]. 
Mass spectral analysis 
The FAB mass spectrum of complex [Cu(Sb)2Sn2] showed a prominent peak at m/z 954 
which corresponds to the fragment [C2«H24N20i2Cl4CuSn2-Cl2+2H ]^. The appearance of 
other peciks at m/z 885, 631 and 579 (50%) were ascribed to the species 
[C28H24N2O i2Cl4CuSn2-Cl4+4Hf, [C28H24N2O i2Cl4CuSn2-Sn2Cl4.2H20+7H]^ and 
[C28H24N20i2Cl4CuSn2-Sn2Cl4.4H2O+7H]^ , respectively. The spectrum of [Zn(Sb)2Sn2] 
revealed molecular ion peak at m/z 1073 (20%) due to [C28H24N20i2Cl4ZnSn2.C2H50H 
+2H]'^ . The appearance of peaks at m/z 989, 938, 919 and 613 (50%), respectively were 
ascribed to the species [C28H24N20i2Cl4ZnSn2-C2H50H-Cl]'^ , 
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Figure 29. "^Sn NMR spectrum of the heterobimetallic complex [Zn(Sb)2Sn2j. 
[C28H24N20i2Cl4ZnSn2-C2H50H-Cl2-H20+3H]^ [C28H24N20i2Cl4ZnSn2-C2H50H-Cl2-
2H20+4H]^ and [C2gH24N20i2Cl4ZnSn2-C2H50H-Cl4-2H20-Sn2+H]^ These spectral 
features confirm the formation of heterobimetallic complexes. 
EPR studies 
The X-band EPR spectrum of complex [Cu(Sb)2Sn2] at LNT consists of a very broad axial 
symmetrical signal with g\\ at 2.18, gj at 2.073 and gov at 2.10 computed from the formula 
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gm ^ g\\'+2g±l'i .These parameters are consistent with the square planar geometry of the 
central metal ion viz, Cu(II) (Figure 30) and are quite similar to the values reported for 
other related square planar Cu(Il) systems .The trend g|| > gi > 2 further confirm that the 
ground state of the Cu(II) is predominantly dx .y orbital [145]. 
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Figure 30. EPR spectrum of the heterobimetallic complex [Cu(Sb)2Sn2]. 
Thermal Studies 
Thermogravimeteric analysis of heterobimetallic complex [Zn(Sb)2Sn2] was carried out to 
study the pyrolysis pattern in temperature range 25-800 C. The thermogram of 
[Zn(Sb)2Sn2] was shown in Figure 31, exhibited weight loss in three steps over the 
temperature range 75-90, 210-400 and 415-650 "C. These were in close agreement with the 
proposed structure .The weight loss in the temperature range 75-90 °C confirmed the 
removal of C2H5OH (4.2 %) while at 210-400 °C (12.48 %) the noticeable weight loss 
indicated the removal of both the coordinated water molecule and the chloride ions [146]. 
At 510 °C, the compound exhibited approximately 41 % of the weight loss corresponding to 
the decomposition of aryl group and its substituents [147]. Finally, the TGA curve showed a 
plateau above 710 °C corresponding to the formation of Sn-oxide and Zn-oxide as the final 
products. 
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Figure 31. TGA curve showing the degradation ofheterohimetallic complex [Zn(Sb)2Sn2] 
Electronic Spectra 
The absorption spectra of the complexes were recorded in DMSO, except ligand Sb which 
was soluble in ethanol. The electronic spectrum of Sb exliibits two bands at 210 nm and 335 
nm, which has been assigned to (TI-TI*) and (n-Ti*). The complex [Cu(Sb)2] reveals three 
broad bands at 255 nm, 300 nm and 550 nm, which were assigned to (TI-JI*), (n-7t*) 
and d-d transition, respectively while complex [Zn(Sb)2] revealed two bands at 240 nm and 
334 nm due to intraligand and LMCT transitions, respectively. The heterobimetallic 
complex [Cu(Sb)2Sn2] revealed two bands at 262 nm and 592 nm which were assigned 
to (;r-7t*) and d-d transition. These results are consistent with the square planar environment 
around Cu(II) ion [148]. Similarly, the absorption spectrum of complex [Zn(Sb)2Sn2], 
revealed bands at 318 nm and 390 nm due to intraligand and LMCT transitions, 
respectively. 
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Interaction stuidies with CT DNA 
Absorption titrations 
The UV-vis spectra of ligand Sb, monometallic complexes [Cu(Sb)2] , [Zn(Sb)2] and their 
heterobimetallic complexes [Cu(Sb)2Sn2], [Zn(Sb)2Sn2] depicted in Figure 32 at room 
temperature in DMSO exhibited strong bands in the UV region at 210-340 rnn attributed to 
n-K* or intraligand transitions. Changes in the JI-TC* transition of Sb, [Cu(Sb)2] , [Zn(Sb)2] 
[Cu(Sb)2Sn2] iind [Zn(Sb)2Sn2] in 5% DMSO/ 5mM Tris HCl/ 50mM NaCl buffer at pH 7.2 
were determined as a function of added CT DNA concentration (0-1 x 10"^  M). The 
"hyperchromic effect" is typical of cationic complexes involving ligand with extended 
hydrophobic regions or surfaces usually bind to DNA noncovalently [149]. Electrostatic 
interaction, intercalation and groove binding are three major non covalent binding modes for 
the small molecules interacting with DNA [150]. The cationic core of heterobimetallic 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] could exert a stronger electrostatic attraction to the anionic 
phosphate backbone of DNA due to the presence of Sn(IV) which has preferential selectivity 
for phosphate in addition to the presence of second metal ion Cu(II) / Zn(II) which prefers 
coordinate covalent binding to N7/ N3 of the nucleobases. These complexes show dual 
mode of action at the molecular target site and exhibit novelty due to preferential selectivity 
and recognition toward nucleobases inside the cells [151]. To quantify the extent of DNA 
binding the intrinsic binding constant Kb of ligand and the complexes were determined 
(Table 2) which follows the order: [Zn(Sb)2Sn2] > [Cu(Sb)2Sn2] >[Zn(Sb)2] > [Cu(Sb)2] > 
Sb and is in conformity with our hypothesis that heterobimetallic complexes are more 
i 
prominent DNA binders than the monometallic complexes and the free ligand. It is well 
established in literature that Zn(II) complexes effectively function to recognize thymine base 
and Zn(II) complexes in contrast to Cu(II) break the hydrogen bonds of A-T base pairs of 
DNA helix to selectively bind thymine; altering the local structure of the AT- region of 
53 
DNA [151]. These observations were also validated by interaction with 5'-GMP and 5'-TMP 
by UV-vis and (in case of [Zn(Sb)2Sn2]) by 'H and ^'P NMR spectroscopy. 
Table 2. The binding constant (Kb) values of all complexes including ligand with the DNA 
(mean standard deviation of± 0.06) 
Complex Kb(M"') Monitored at (nm) % Hyperchromism Red Shift (nm) 
Sb 
[Cu(Sb)2] 
[Zn(Sb)2] 
[Cu(Sb)2Sn2] 
[Zn(Sb)2Sn2] 
0.76x10^ 
2.20x10^ 
5.50x10^ 
1.67 X 10^  
4.00 X 10^  
210 
334 
334 
257 
265 
23 
51 
57 
20 
55 
00 
02 
02 
03 
02 
Interaction vnth 5'-GMP and 5'-TMP 
In the heterobimetallic complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2], a sharp increase in 
absorbance intensity "hyperchromic effect" was obsei-ved in the UV region which was 
followed by concomitant decrease in intensity "hypochromic effect" (Figure 33,34). 
Table 3. The binding constant Kb values of complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] with 
5'-GMP and 5'-TMP (mean standard deviation of± 0.06) 
Complex 
[Cu(Sb)2Sn2] 
[Cu(Sb)2Sn2] 
[Cu(Sb)2Sn2] 
[Zn(Sb)2Sn2] 
[Zn(Sb)2Sn2] 
[Zn(Sb)2Sn2] 
[Zn(Sb)2Sn2] 
S'-GMP 
(10^ M-') 
0.69 
0.33 
— 
0.13 
0.12 
— 
— 
5'-TMP 
(10^ M"') 
— 
— 
0.77 
— 
— 
1.32 
1.30 
Monitored at 
(nm) 
245 
708 
247 
328 
390 
255 
300 
Hyperchromism 
( % ) 
40 
04 
26 
05 
37 
22 
07 
Red Shift 
(nm) 
2 
1 
3 
2 
3 
4 
2 
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Figure 32. Absorption spectral traces of (a) Sb, (b) complex [Cu(Sb)2] , (c) complex 
[Zn(Sb)2j, (d) heterobimetallic complex [Cu(Sb)2Sn2] and (e) heterobimetallic complex 
[Zn(Sb)2Sn2] in 5% DMSO/ 5 mM Tris HCl/ 50 mMNaCl buffer upon addition ofCT DNA 
at 25 °C. Inset: Plots of [DNA]/ Sa-s/vs [DNA] for the titration ofCT DNA with complexes 
u, experimental data points; full lines, linear fitting of the data, [complex] 0.16 x 10"^ M, 
[DNA]0-}xlO-^M. 
Hyperchromism is indicative of electrostatic mode of binding while the hypochromism 
could be attributed to the partial intercalation which is also evidenced by a sharp decrease in 
the fluorescence intensity of complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] in EB replacement 
assay. The Ki, values further revealed that the magnitude of binding of [Cu(Sb)2Sn2] was 
higher than [Zn(Sb)2Sn2] in case of 5'-GMP, while it was reverse in case of 5'-TMP (Table 
3). When thymine binds to [Zn(Sb)2Sn2], hydrogen bonds are favoured between nitrogen of 
ligand with carbonyl oxygen of thymine. Secondly, the presence of electron withdrawing 
two 0X0 groups at the C2 and C3 position of the thymine lowers the energy of the lone pair 
orbital at N3 of thymine base which results in stronger molecular orbital interaction in 
comparison 1;o guanine. These results can be corroborated with the observation of UV-
visible titration with CT DNA and demonstrate the specific recognition of heterobimetallic 
complex [Zn(Sb)2Sn2] for thymine. Our results are consistent with the earlier reports on 
preferential binding to N3 position of thymine in the Zn(II) complexes [152]. 
To validate our hypothesis the binding of [Zn(Sb)2Sn2] to 5'-GMP and 5'-TMP was 
examined by 'H and ^'P NMR techniques. The 5'-GMP exhibited H8 signal at 8.07 ppm and 
Hr-H5' ribose proton signals of 3.85-5.80 ppm, respectively. In presence of the complex 
[Zn(Sb)2Sn2|, there was no significant shift in H8 signal of guanine. At different time 
intervals, the spectra remains unaltered after 24 hours, which was attributed to non-
participation of guanine on binding with [Zn(Sb)2Sn2] through coordination mode. However, 
the ribose proton Hr-H5' signals have shifted downfield -0.06 ppm, which indicate the 
preference for ribose sugar due to the presence of Sn(IV) hard Lewis acid center (Figure 35). 
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Figure 33. Absorption spectral traces of (a) heterobimetallic complex [Cu(Sb)2Sn2j and (b) 
heterobimetallic complex [Zn(Sb)2Sn2j in 5% DMSO/ 5 mM Tris HCU 50 mMNaCl buffer 
upon addition ofS'^MP at 25 °C. [Complex] 0.16xl(r''M, [5'-GMP] 0-1 x lO'"M. 
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Figure 34. Absorption spectral traces of (a) heterobimetallic complex [Cu(Sb)2Sn2] and (b) 
heterobimetallic complex [Zn(Sb)2Sn2] in 5% DMSO/ 5 mM Tris HCl/ 50 mMNaCl buffer 
upon addition of5'-TMP at 25 °C. [Complex] 0.16x W*M, [5'-TMP] 0-1 x la^M. 
31 The P NMR signal appeared in free 5'-GMP at 3.59 ppm which shifted upfield to 1.67 ppm 
indicating clearly that Sn(IV) was bound to phosphate group (Figure 36). 
On interaction of [Zn(Sb)2Sn2] with 5' -TMP, the signal ofN3 atom of 5'-TMP observed at 
7.64 ppm disappeared due to deprotonation of the N3 proton. The signal due to C6 atom of 
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5'-TMP at 6.2 ppm shifted to 6.9 ppm with increased intensity. The T-CH3 peaks at 1.95 
shifted to slightly higher frequency relative to that of free TMP. The rest of the signals 
associated whh free 5'-TMP merged with the signals of complex [Zn(Sb)2Sn2]. 
This has resulted in the enhancement of the intensity of signals of the metal bound 5 '-TMP. 
At different time intervals, the spectra remain unaltered and even after 24 hours no changes 
were observed in the spectral pattern (Figure 37). The P NMR signal appeared in free 5'-
TMP at 3.59 ppm which was shifted upfield to 1.70 ppm indicating clearly that Sn(IV) was 
bound to phosphate group. 
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Figure 35. ''HNMR spectra of (a) [Zn(Sb)2Sn2] (2.5 mmol) with 5'-GMP (5 mmol) at 25 °C. 
(b)5'-GMP alone. 
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311 Figure 36. "P NMR spectrum of (a) [Zn(Sb)2Sn2] (2.5 mmol) with 5'-GMF (5 mmol) (b) 5'-
GMP alone at at 25 °C. 
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Figure 37. 'HNMR spectra of (a) [Zn(Sb)2Sn2] (2.5 mmol) with 5'-TMP (5 mmol). (b) 5' 
TMP alone at at 25 °C. 
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The ' '^ Sn NMR spectrum of the complex [Zn(Sb)2Sn2] displayed one sharp signal at -
622.33 ppm attributed to hexacoordinate environment around the tin atoms. On interaction 
with 5'-TMP, the signal observed at -622.33 ppm shifts to -868.61 ppm (Figure 38). 
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Figure 38. "^Sn NMR spectra of (a) [Zn(Sb)2Sn2] (2.5 mmol) with 5'TMP (5 mmol) in 
DMSO (b) Complex [Zn(Sb)2Sn2] in DMSO at 25 °C. 
Fluorescence spectroscopic studies 
The ligand Sb, monometallic complexes [Cu(Sb)2] , [Zn(Sb)2] and their heterobimetallic 
complexes [Cu(Sb)2Sn2], [Zn(Sb)2Sn2] exhibited luminescence either in DMSO or in 
presence of CT DNA. Hence, binding studies of Sb and all metal complexes to CT DNA 
were carried out by fluorescence spectral titration in absence of any fluorophore [153]. Upon 
addition of CT DNA to the Sb and complexes there is enhancement in the fluorescence-
emission intensity as depicted in Figure 39. Since it is found that complexes with increased 
ligand hydrophobicity shows greater increase in emission intensities upon binding to 
polyelectrolytes viz. DNA, thus, we conclude that there is some interaction between the CT 
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DNA and complexes that occurs due to the hydrophobicity of both molecules. The binding 
constant (K) estimated for Sb, monometallic complexes [Cu(Sb)2], [Zn(Sb)2] and their 
heterobimetallic complexes [Cu(Sb)2Sn2], [Zn(Sb)2Sn2] by Scatchard equation were 8.3 x 
10^  M"', 1.3 x 10^  M-', 1.5 X 10^  M"', 3.5 x lO'' M'' and 4.8 x 10'* M"',respectively. 
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Figure 39. Emission spectra of (a) free Sb, (b) complex [Cu(Sb)2j, (c) complex [Zn(Sb)2], 
(d) heterobimetallic complex [Cu(Sb)2Sn2] and (e) heterobimetallic complex [Zn(Sb)2Sn2] in 
presence of DNA in Tris HCl/NaCl buffer at at 25 °C. Inset: Plots ofF/Fo versus 1/[DNAJ. 
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The binding consteint K values were of the order [Zn(Sb)2Sn2] > [Cu(Sb)2Sn2] > [Zn(Sb)2] = 
[Cu(Sb)2] > Sb. These results are consistent with the findings obtained from UV-vis spectral 
studies. 
Ethidium Bromide Displacement Assay 
To further investigate the mode of binding of the heterobimetallic complexes [Cu(Sb)2Sn2] 
and [Zn(Sb)2Sn2] the ethidium bromide displacement assay was carried out [154]. The 
extent of quenching of the fluorescence of EthBr bound to DNA would reflect the extent of 
DNA binding of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2]. EB is an intercalator that gives a 
significant increase in fluorescence emission when bound to DNA and its displacement from 
DNA results in a decrease in fluorescence intensity [155]. On addition of complexes 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] to CT DNA pretreated with EthBr ([DNA]/ [EthBr] = 1) 
there was a sharp decrease in emission intensity (Figure 40). Addition to the EB-DNA 
system induces notable fluorescence changes, which indicate that EB molecule, has been 
replaced by the complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2]. 
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Figure 40. Emission quenching spectra of heterobimetallic complex (a) [Cu(Sb)2Sn2j and 
(b) [Zn(Sb)2Sn2], with increasing concentration of quencher ethidium bromide, in the 
absence and presence ofCT DNA in buffer 5mM Tris -HCl/ 50 mMNaCl, pH= 7.2 at 25 
°C 
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Further, the quenching extents qualitatively K^r evaluated for [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] 
were found to be 0.98 x 10^  M''and 1.56 x 10^  M"\ respectively. Since EB was not 
completely displaced, partial intercalation in addition to the electrostatic mode of binding 
cannot be ruled out. 
DNA cleavage activity 
DNA cleavage without added reductant 
The DNA cleavage ability of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] were studied by agarose gel 
electrophoresis using supercoiled pBR322 plasmid DNA as a substrate. The activity of 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] was assessed by the conversion of DNA from Form I 
(Supercoiled Form) to Form II (Nicked Circular Form) or Form III (Linear Form). A 
concentration-dependent DNA cleavage by [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] were first 
performed. Briefly, pBR322 DNA was mixed with different concentration of [Cu(Sb)2Sn2] 
and [Zn(Sb)2Sn2] and mixture was incubated at 25 ^C for 45 minutes (Figure 41). 
(a) 
-• Formll 
•* Form in 
•*• Form I 
(b) 
i:.««#«lK 
Jit t^ 
4 5 
Figure 41. IJie cleavage patterns of the agarose gel electrophoresis diagram showing 
cleavage ofpBR322 supercoiled DNA (300 ng) by [Cu(Sb)2Sn2] (a) and [Zn(Sb)2Sn2] (b) at 
25 °C after 45 minutes of incubation. Lane 1, DNA control; lane 2, DMSO control; Lane 3, 
20 fiM of complex + DNA; Lane 4, 40 nM of complex + DNA; Lane 5, 60 juM of complex + 
DNA; Lane 6, 80 /uM of complex + DNA; Lane 7, 100 fiM of complex + DNA; Lane 8. 120 
IxM of complex +DNA. 
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With the inc;rease of concentration of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2], DNA was converted 
from Form I (Supercoiled Form) to Form II (Nicked Circular Form) and then to Form III 
(Linear Form). 
DNA cleavage in presence of activators 
Since the nuclease efficiency of complexes is usually dependent on activators [156]. 
Therefore, DNA cleavage activity of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] in presence of H2O2, 
ascorbate, 3-mercaptopropionic acid and glutathione was evaluated ( Figure 42). The 
cleavage activity of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] was significantly enhanced by these 
activators md follows the order: MPA> H202> AsO GSH for [Cu(Sb)2Sn2] while 
[Zn(Sb)2Sn2] follows the order MPA> AsO GSH> H2O2. 
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Figure 42. Agarose gel electrophoresis pattern for the cleavage of pBR322 supercoiled 
DNA (300 ng) by [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2j (120 fiM) in presence of different 
activating agents at 25 °C after incubation for 45 minutes. Lane 1, DNA Control; Lane 2, 
[Cu(Sb)2Sn2]+ H2O2 (0.4 mM) + DNA; Lane 3, [Cu(Sb)2Sn2j + Ascorbic acid (0.4 mM) + 
DNA; Lane 4, [Cu(Sb)2Sn2] + MP A (0.4 mM) + DNA; Lane 5, [Cu(Sb)2Sn2] + GSH (0.4 
mM) + DNA; Lane 6, [Zn(Sb)2Sn2] + H2O2 (0.4 mM) + DNA; Lane 7, [Zn(Sb)2Sn2] + 
Ascorbic acid (0.4 mM) + DNA; Lane 8, [Zn(Sb)2Sn2] + MP A (0.4 mM) + DNA; Lane 9, 
[Zn(Sb)2Sn2]+ GSH (0.4 mM) + DNA. 
DNA cleavage in presence of minor and major groove binding agent 
Minor groove binding agent DAPI [157] and major groove binding agent methyl green [158] 
were used to probe the potential interacting site of complex [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] 
with plasmid pBR322 DNA. The DNA was treated with DAPI or methyl green prior to the 
addition of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2]. The patterns presented in the Figure 43, 
demonstrated that [Cu(Sb)2Sn2] prefers both major and minor groove, whereas [Zn(Sb)2Sn2] 
prefers minor groove binding. 
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Figure 43. Agarose gel electrophoresis pattern for the cleavage of pBR322 super coiled 
DNA (300 ng) by [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] (120 fiM) in presence of DNA minor 
groove binding agent DAPI and major groove binding agent methyl green at 25 °C after 
incubation for 45 minutes. Lane 1, DNA control; Lane 2, [Cu(Sb)2Sn2] + DNA + DAPI (8 
fiM); Lane 3, [Cu(Sb)2Sn2] + DNA+ methyl green (2.5 juL of a O.Olmg/mL solution); Lane 
4, fZn(Sb)2Sn2]+ DNA + DAPI (8 juM); Lane 5, [Zn(Sb)2Sn2j + DNA+ methyl green (2.5 
fiL of a O.Olmg/mL solution). 
Reactive oxygen species responsible for DNA cleavage 
The interaction between metal complexes and dioxygen or redox reagents are believed to be 
a major cause of DNA damage [159]. To probe the potential mechanism of DNA cleavage 
mediated by complex [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2], some standard radical scavengers 
were used prior to the addition of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] to DNA solution. 
The involvement of ROS was investigated using terf-butyl alcohol and DMSO [160] as 
hydroxy! radical scavenger, sodium azide [161] as singlet oxygen scavenger and SOD as 
superoxide oxygen scavenger under identical conditions (Figure 44). On adding DMSO and 
tert-butyl alcohol (Lane 2,3 for [Cu(Sb)2Sn2] and Lane 6,7 for [Zn(Sb)2Sn2]) inhibit the 
DNA cleavage suggestive of involvement of diffusible (-OH) hydroxyl radicals as one of the 
ROS responsible for DNA breakage. On the other hand, addition of sodium azide (singlet 
oxygen scavenger) decreases the cleavage efficiencies, this reveals that 'O2 is also the 
activated oxygen intermediate responsible for the cleavage (Lane 4 for [Cu(Sb)2Sn2] and 
Lane 8 for [Zn(Sb)2Sn2]). Addition of superoxide dismutase (superoxide scavenger) to the 
reaction mixture reveals no significant quenching of the cleavage reaction indicating that 
superoxide anion is not the active species responsible for the cleavage (Lane 5 for 
[Cu(Sb)2Sn2] and Lane 9 for [Zn(Sb)2Sn2]) [162]. Thus, freely diffusible oxygen 
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intermediate or hydroxy! radical may be involved in the strand scission and hence a simple 
diffusible radical mechanism is applicable. 
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Figure 44. Agarose gel electrophoresis pattern for the cleavage of pBR322 supercoiled 
DMA (300 ng) by [Cu(Sb)2Sn2]( 120 ^M) and [Zn(Sb)2Sn2] ( 120 nM) in presence of 
reactive ox)'gen species at 25 °C after incubation for 45 minutes. Lane 1, DNA Control; 
Lane 2, [Cu(Sb)2Sn2j+ tert- butyl alcohol(0.4 mM)+DNA; Lnae 3, [Cu(Sb)2Sn2j+DMSO 
(0.4 mM)+DNA; Lane 4, [Cu(Sb)2Sn2j+sodium azide (0.4 mM)+DNA; Lane 5, 
[Cu(Sb)2Sn2]+SOD (15 units)+DNA; Lane 6, [Zn(Sb)2Sn2] + tert- butyl alcohol (0.4 mM) + 
DNA; Lane 7, [Zn(Sb)2Sn2] + DMSO (0.4 mM) + DNA; Lane 8, [Zn(Sb)2Sn2j + sodium 
azide (0.4 mM) + DNA; Lane 9, [Zn(Sb)2Sn2] + SOD (15 units) + DNA. 
Topoisomerase inhibition 
Topoisomerase I 
The mechaitiism of human Topo I (topoisomerase I) has been well-established [163,164]. 
The results of Topo I inhibition assay by different concentrations of [Cu(Sb)2Sn2] and 
[Zn(Sb)2Sn;2] are shown in Figure 45. Both complexes inhibited the ability of Topo I to relax 
negatively supercoiled plasmid DNA (IC50 is >12 ixM for [Cu(Sb)2Sn2] and 2.5 [iM for 
[Zn(Sb)2Sn2]). These findings imply that both complexes may block the DNA strand 
passage event of the enzyme, and serve as a catalytic inhibitor of Topo I. Since Topo I 
remove only the unconstrained positive supercoils, the negatively supercoiled DNA product 
would be identical to the topological state of the original plasmid substrate. In this case, the 
complexes will also appear to inhibit enzyme catalysis. The DNA topoisomerase inhibitory 
activity of the complexes under study was found to be concentration-dependent. 
Surprisingly, complex [Zn(Sb)2Sn2] displays a significant inhibitory action on Topo I rather 
than complex [Cu(Sb)2Sn2] (which displays a significant concentration dependent DNA 
cleavage and further exhibited strong cleavage in presence of different activators). 
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Figure 45. The cleavage patterns of the agrose gel electrophoresis diagram showing effect 
of different concentration of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] on the activity of DNA 
topoisomerase I (Topo I) at 25 °C. Lane 1, Topo I control; lane 2, DNA control; Lane 3, 2.5 
fiM of [Cu(Sb)2Sn2] + DNA + Topo I; Lane 4, 5.0 fiM of [Cu(Sb)2Sn2] + DNA + Topo I; 
Lane 5, 7.5 piM of [Cu(Sb)2Sn2] + DNA + Topo I; Lane 6, 10 fiMof[Cu(Sb)2Sn2] + DNA + 
Topo I; Lane 7, 12.5 nM of [Cu(Sb)2Sn2j + DNA + Topo L; Lane 8, 2.5 fiMof [Zn(Sb)2Sn2] 
+ DNA + Topo I; Lane 9, 5.0 fxM of [Zn(Sb)2Sn2] + DNA + Topo I; Lane 10, 7.5 fiM of 
[Zn(Sb)2Sn2j + DNA + Topo I; Lane 11, 10 nM of [Zn(Sb)2Sn2] + DNA + Topo I; Lane 12, 
12.5nMof'[Zn(Sb)2Sn2] + DNA + Topo I. 
Topoisomerase II 
The enzyme-mediated supercoiled pBR322 relaxation assay was performed to examine the 
influence of the complexes on the Topo II DNA activity. Interaction studies exhibited an 
inhibitory effect of the metal complexes on the Topo II DNA activity. Gel mobility assays of 
the complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] were examined at various concentration 
levels. The results of the concentration-dependent Topo II inhibition assay of [Cu(Sb)2Sn2] 
and [Zn(Sb)2Sn2] are shown in Figure 46. As the concentration increases complexes 
[Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] successively inhibited the activity of Topo II, and finally 
inhibited the activity of Topo 11 at a concentration of 12.5 fiM revealing a very promising 
effect on Topo 11 comparable to some classical topoisomerase inhibitors such as 
Camptothecin, Doxorubicin, Novobiocin [48], Etoposide, Hoechst 33258 [165], Topostatin 
[166], A-[Ru(bpy)2(uip)]^^ A-[Ru(bpy)2(uip)]^^ where ligand uip = (2-(5-uracil)-IH-
imidazole[4,5-fl [167], [Ru(bpy)2(dppz)]^\ [Ru(bpy)2(appo)]^^ where appo = 11-
aminopteridino[6,7-f][l,10]phenanthrolin-13(12H)-one [168].These findings implicate that 
complexes [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] are catalytic inhibitors of human topoisomerses 
II. 
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Figure 46. The cleavage patterns of the agrose gel electrophoresis diagram showing effect 
of different concentration of [Cu(Sb)2Sn2] and [Zn(Sb)2Sn2] on the activity of DNA 
topoisomerase II a (Topo II) at 25 °C. Lane I, Topo II control; lane 2, DNA control; Lane 3, 
2.5 fiM of [Cu(Sb)2Sn2] + DNA + Topo II; Lane 4, 5.0 fiM of [Cu(Sb)2Sn2] + DNA + Topo 
II; Lane 5, 7.5 fiM of [Cu(Sb)2Sn2j + DNA + Topo U; Lane 6, 10 fiM of [Cu(Sb)2Sn2j + 
DNA + Topo II; Lane 7, 12.5 fiM of [Cu(Sb)2Sn2] + DNA + Topo U; Lane 8, 2.5 fiM of 
[Zn(Sb)2Sn2j + DNA + Topo II; Lane 9, 5.0 fiMof[Zn(Sb)2Sn2j + DNA + Topo U; Lane 10, 
7.5 fiM of [Zn(Sb)2Sn2] + DNA + Topo II; Lane II, 10 fiMof [Zn(Sb)2Sn2] + DNA + Topo 
H; Lane 12, 12.5 fiMof [Zn(Sb)2Sn2] +DNA + Topo II 
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Conclusion 
The design of heterobimetallic trinuclear architecture utilizes a unique building block 
strategy which involves the combination of two different metal centres exhibiting 
differential behaviour towards the cellular target site on DNA A number of natural 
nucleases also require multinuclear metal centers to achieve a synergesitic effect in the 
process of substrate recognition and scission. The combination of a site-specific group and a 
scission moiety could enhance the regional selectivity and cleavage efficacy of such an 
artificial nuclease model. 
The in vitro DNA binding studies of novel class of heterobimetallic complexes [Cu(Sb)2Sn2] 
and [Zn(Sb)2Sn2] reveals an electrostatic mode of binding as well as major / minor groove 
binding, respectively. The heterobimetallic complex [Cu(Sb)2Sn2] exhibited an outstanding 
ability to affect DNA double strand scission in oxidative as well as fi-ee hydroxyl radical 
marmer. Our spectroscopic results demonstrate that heterobimetallic complex [Zn(Sb)2Sn2] 
is an avid and stronger DNA binder which is well corroborated with the literature reports. In 
addition, both the complexes exhibit high inhibitory effect on topoisomereses, in particular 
heterobimetallic complex [Zn(Sb)2Sn2] exhibits higher inhibition activity against Topo I at a 
very low concentration. Topoisomerases are crucial for cellular genetic processes such as 
DNA replication, transcription, recombination and chromosome segregation at mitosis, 
therefore studies on the interaction of small DNA binding molecules and topoisomerases are 
very important for exploring life processes, development of novel anticancer drugs and 
elucidating their underlying molecular mechanism. This work features novel design of 
potential metal-based chemotherapeutic topoisomerase inhibitors that additionally display 
specific groove binding. 
CHAPTER IV (a) 
Design, synthesis of new chiral metal-based cancer 
chemotherapeutic agents derived from L-, D- and DL-
tryptophan: Their enantioselective DNA binding, nuclease 
scission chemistry and antitumor activity. 
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Synthesis 
Synthesis of [Co(trp)(dabz)(H20)2]Cl 
The comple;xes were prepared by a general synthetic method in which corresponding 
tryptophan [L-tryptophan, D-tryptophan, DL-tryptophan (0.204 g, 1 mmol)] and NaOH 
(0.04 g, 1 immol) in 10 mL methanol was added to a methanolic solution (10 mL) of 
C0CI2.6H2O (0.238 g, 1 mmol) with stirring for ca. 0.5 hour followed by the addition of 1,2-
diaminobenzene (0.108 g, 1 mmol) taken in 5 mL of methanol. The reaction mixture was 
stirred for 3 hours with heating at 75 C. On completion of the reaction, the reaction mixture 
was kept at room temperature which yielded dark red product (in all 3 cases), which was 
washed with hexane and dried in vacuo. 
(L-form): Yield 75%. m.p. 240-242 °C. Anal. (%) Calc. for C17H23CIN4O4C0: C, 46.22; H, 
5.25; N, 12.68. Found: C, 46.30; H, 5.28; N, 12.73. [afo = -140. ESI (m/z^): 441 
[Ci7H23ClN404Co-H]^ 405 [Ci7H23ClN404Co-Cl+H]^ 369 [C17H23CIN4O4C0-CI-
2H20+H]^ 
(D-form): Yield 71%. m.p. 240-242 °C. Anal. (%) Calc. for C17H23CIN4O4C0: C, 46.22; H, 
5.25; N, 12.68, Found: C, 46.31; H, 5.29; N, 12.72. [afu = -34. ESI (mJz^. 441 
[Ci7H23ClN404Co-H]^ 402 [Ci7H23ClN404Co-Cl~2H]^ 369 [C17H23CIN4O4C0-CI-
2H20+H]^ 
(DL-form): Yield 65%. m.p. 242-245 °C. Anal. (%) Calc. For C17H23CIN4O4C0.CH3OH: C, 
45.63; H, 5.74; N, 11.82. Found: C, 45.78; H, 5.69; N, 11.82. [afu = +2. ESI (m/z'): 475 
[C17H23CIN4O4C0.CH3OH +2H]^ 
All enantiomers exhibited identical IR, UV-vis and EPR spectra. 
Selected IR data on KBr (v /cm''): 3420 v (H2O); 3364 v (NH2); 3232 v (N-H); 1635 (sym 
COO); 1375 (antisym.COO); 1508 (5(N-H); 1258 (imidazole N-H); 750 (Ar); 435 v (Co-
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N); 595 V (Co-0). UV-vis (1 x 10" 'M, D M S O ) [?J nm (E/dm^ mol'' cm"*)]: 270 (10680), 292 
(12512), 510 (670). 
Synthesis of [Cu(trp)(dabz)] CI 
These complexes were synthesized according to procedure described for 
[Co(trp)(dabz)(H20)2]Cl with CUCI2.2H2O (0.171 g, Immol). Blue colored products were 
isolated. 
(L-form): Yield 61%. m.p. 247-250 °C. Anal. (%) Calc. for C,7H,9N402ClCu: C, 49.76; H, 
4.67; N, 13.65. Found: C, 49.81; H, 4.72; N, 13.71. [af^ = -70. ESI (m/z^): 411 
[Ci7Hi9N402ClCu+H]^ 375 [Ci7Hi9N402CICu-Cl+H]^ 
(D-form): Yield 63%. m.p. 246-249 °C. Anal. (%) Calc. for C17H19N4O2CICU: C, 49.76; H, 
4.67; N, 13.65. Found: C, 49.82; H, 4.70; N, 13.70. [ a f D = +128. ESI (m/z^): 410 
[Ci7H,9N402ClCu]^ 373 [Ci7Hi9N402ClCu-Cl-H]^ 
(DL-form): Yield 59%. m.p. 248-252 °C. Anal. (%) Calc. for C17H19N4O2CICU.I.5CH3OH: 
C, 48.47; H, 5.46; N, 12.23. Found: C, 48.56; H, 5.42; N, 12.26. {a]\ = -10. ESI {mJz): 
458 [CnH,9N402ClCu.l.5CH30Hf. 
All enantiomers exhibited identical IR, UV-vis and EPR spectra. 
Selected IR data on KBr (v /cm"'): 3389 v (NH2); 3197 v (N-H); 1626 {sym COO); 1383 
{antisym. COO); 1571 <5(N-H); 1240 (imidazole N-H); 751 (Ar); 593 v (Cu-0); 429 v (Cu-
N). UV-vis (1 X 10"^  M, DMSO) [/!/ nm (e/dra^ mol"' cm-')]: 270 (23300), 363 (9140), 649 
(61). 
Synthesis of [Zn(trp)(dabz)]CI 
These complexes were synthesized by a similar procedure as described for 
[Co(trp)(dabz)(H20)2]Cl with ZnCb (0.136 g, Immol). White coloured products were 
isolated in all the three cases. 
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(L-form): Yield 66%. m.p. 275-278 °C. Anal. (%) Calc. for Ci7H,9N402ClZn: C, 49.54; H, 
4.65; N, 13.59. Found: C, 49.61; H, 4.69; N 13.66. H^ NMR (DMSO-i/g, ppm): 10.64 (s, IH, 
imidazole N-H); 7.61 (d, J = 7.84 Hz, IH, tryptophan H); 7.36 (d, J = 8.08 Hz, IH, 
tryptophan H); 7.23 (s, IH, tryptophan H); 7.08 (t, J= 7.2 Hz, IH, tryptophan H); 99 (t, J -
7.48 Hz, IH, tryptophan H); 6.61 (dd, J = 3.4, 3.4 Hz, 2H, Ar); 6.50 (dd, J = 3.44, 3.52 Hz, 
2H, Ar); 3.63 (s, 7H,amine H and chiral CH); 2.56 (t, J = 3 Hz, 2H, -CHj). '^ C NMR 
(DMS0-d6, ppm): 175 (0-C=0); 136 (Ar C-NH); 134 (Ar C-NH2); 126 (=CH-NH); 124 
(AT C); 121 (Ar C); 118 (Ar C); 115 (Ar C); 111 (Ar C); 109 (Ar C); 99.5 (Ar C); 52.5 
(NH2-CH); 29.7 (-CH2). [afo = -124. ESI (m/z^): 410 [C,7Hi9N402ClZn-2Hf, 375 
[Cl7H,9N402ClZn-Cl-H]^ 
(D-form): Yield 61%. m.p. 275-279 °C. Anal. (%) Calc. for Ci7H,9N402ClZn: C, 49.54; H, 
4.65; N, 13.59. Found: C, 49.63; H, 4.69; N, 13.65. ' H NMR (DMSO-de, ppm): 10.84 (s, 
IH, imidazole N-H); 7.55 (d, J = 7.52 Hz, IH, tryptophan H); 7.34 {d,J= 8.04 Hz, IH, 
tryptophan H); 7.26 (s, IH, tryptophan H); 7.03 (t, J= 7.32 Hz, IH, tryptophan H); 6.92 (t, J 
= 7.16 Hz, IH, tryptophan H); 6.67 (dd, J = 3, 3 Hz, 2H, Ar); 6.58 (dd, J = 3, 3 Hz, 2H, Ar); 
3.43 (s, 7H,amine H and chiral CH); 2.53 (t, J = 3 Hz, 2H, -CH2). '^ C NMR (DMSO-de, 
ppm): 174 (0-C=0); 137 (Ar C-NH); 134 (Ar C-NH2); 127 (=CH-NH); 124 (Ar C); 119 
(AT C) ; 116 (Ar C); 114 (Ar C); 111 (Ar C); 101 (Ar C); 53 (NH2-CH); 26 (-CH2). [af% -
+40. ESI (m/z^): 408 [Cl7Hl9N402ClZn-4H]^ 375 [Ci7Hi9N402ClZn-Cl-H]^ 
(DL-form): Yield 64%. m.p. 276-279 °C. Anal. (%) Calc. for Ci7Hi9N402ClZn: C, 49.54; 
H, 4.65; N, 13.59. Found: C, 49.58; H, 4.68; N, 13.63. ' H NMR (DMSO-de, ppm): 10.51 (s, 
IH, imidazole N-H); 7.58 (d, J = 7.62 Hz, IH, tryptophan H); 7.35 (d, J - 8 Hz, IH, 
tryptophan H); 7.22 (s, IH, tryptophan H); 7.07 (t, J= 8 Hz, IH, tryptophan H); 6.98 (t, J = 
8 Hz, IH, tr/ptophan H); 6.68 (d, J - 3 Hz, 2H, Ar); 6.60 (d, J = 3 Hz, 2H, Ar); 3.40 (s, 7H, 
amine H and chiral CH); 2.57 (s, 2H, -CH2). "C NMR (DMSO-de, Ppm): 174 (0-C=0); 
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137 (Ar C-NH); 134 (Ar C-NH2); 127 (=CH-NH); 125 (Ar C); 119 (Ar C); 116 (Ar C); 114 
(AT C); 112 (Ar C); 50 (NH2-CH); 28 (-CH2). [afu = -3. ESI (m/z^ ): 412 
[Ci7Hi9N402ClZn]^  
All enantiomers exhibited identical IR and UV-vis spectra. 
Selected IR data on KBr (v /cm''): 3402 v (NH2); 3297 v (N-H); 1622 {sym COO); 1356 
{antisym. COO); 1456 ^(N-H); 1277 (imidazole N-H); 738 (Ar); 580 v (Zn-0); 422 v (Zn-
N);. UV-vis (1 X 10"*M, DMSO) [AJ nm (e/dm^ mol"' cm'')]: 290 (24640). 
Results and discussion 
Synthesis of mononuclear complexes [Co(trp)(dabz)(H20)2]Cl , [Cu(trp)(dabz)]Cl and 
[Zn(trp)(dabz)]Cl were achieved by mixing stoichiometric amoimts of L-tryptophan, D-
tryptophan and DL-tryptophan with corresponding metal chloride followed by reaction with 
1,2-diaminobenzene (Scheme 5). The complexes are stable towards air and moisture and 
soluble in DMSO and DMF. Analytical data of compounds are consistent with their 
proposed molecular formulae. Molar conductance values of complexes in DMSO (1 x 10"^  
M) at 25 °C suggest their l.i electrolyte nature (37-43 Q'^cm^mol"'). Due to the presence of 
chiral auxiliary "L-tryptophan, D-tryptophan", complexes exhibited optical rotation [orjo 
values which indicate that all the complexes are optically active except with the complexes 
derived from racemic DL-tryptophan (an optically inactive component). In the complexes, 
the coordination geometry of central Co(II) ion is pseudo-octahedral whilst Cu(II) and 
Zn(II) complexes were found to possess square-planar and tetrahedral geometry, 
respectively. Comparative DNA binding studies were carried out with the complexes to 
evaluate their extent of binding in different conformations of chirality. The interaction 
studies of complexes with CT DNA indicate that complex [Cu(trp)(dabz)]Cl derived from 
L-tryptophcin binds to DNA with a strongest affinity. 
L, D or DL-tryptophan 
+ 
NaOH 
+ 
1,2-diaminobenzene 
CoCl2.6H20 ^ 
MCI2 
/ H2 H2 
I M 
H2 
^ 
.CI 
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Where M= Cu (U) and Zn (II) 
Scheme 5. Synthesis of metal complexes [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and 
[Zn(trp)(dabz)]Cl. 
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Figure 47. Cylindrical bonded three dimensional model of complexes (a) 
[Co(trp)(dabz)(H20)2]Cl, (b)[Cu(trp)(dabz)]Cl and (c) [Zn(trp)(dabz)]Cl. Color scheme: 
Co(II) dark gray; Cu(II) dark gray; Zn(II) dark gray; N dark blue; Ored; C gray. Chloride 
ion and other H atoms and are omitted for clarity. 
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IR spectra 
The IR spectra of the title complexes agree with the corresponding formulae and the 
proposed stracture (Scheme 5). In all cases the Av (Via(C02)- Vs(C02)) values were above 
230 cm'^  which clearly indicate unidentate carboxylate structure. The IR spectra of the 
complexes [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl exhibited a 
very broad Iband at -3220 cm' corresponding to the coordinated amino group of tryptophan 
and 1,2-diarainobenzene, which shifted from 3400 cm"^  suggesting that the coordination of 
-NH2 group of both amino acid and 1,2-diaminobenzene to the metal ions [169]. The 
coordination of water molecules to the Co(II) metal ion was supported by the appearance of 
non-ligand band in the region 840-851 cm" attributed to rocking mode of water [170] The 
coordination of tryptophan and complex formation were also revealed by the presence of 
medium intensity (Co/Cu/Zn-N), (Co/Cu/Zn-0) bands around (435, 429, 422) and (595, 
593, 580) cm"', respectively in far IR region. 
NMR specitral studies 
The complexes [Zn(trp)(dabz)]Cl (L, D and DL) were characterized by 'H , '^C and 2D 
COSY recorded in DMSO-de solution and showed signals for aliphatic and aromatic protons 
with chemical shift values in accordance with their proposed structure. There is a signal at 
10.46-10.84 ppm, which might be either the protonated carboxylic group of tryptophan or 
the imidazole -NH, because both give the NMR signal approximately in the same region. 
But the 21) COSY revealed that it is imidazole -NH and not the protonated carboxylic 
group, which further indicated that the carboxylic group of tryptophan is depratonated and 
binds to metal complex (Figure 48). 
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F/^wre ^«. 2D-C0SYNMR spectrum of [Zn(trp)(dabz)]Cl (L-form) 
Peaks with chemical shifts near 6.99-7.61 ppm were ascribed to "tryptophan" (aromatic 
ring) protons. Two distinct doublet of doublet at 6.61 and 6.50 ppm in the spectrum were 
attributed to the aromatic proton of 1,2-diaminobenzene shifted from 6.7 ppm of free 1,2-
diaminobenzene. Coupled with these observations, the characteristic signals at 3.42 (CH and 
NH2) and 31.46 (CH2), respectively fiirther confirmed the presence of tryptophan moiety in 
chiral mettJ complexes [171] (Figure 49). The obtained data of ' H N M R is in close 
agreement with the proposed structure. 
The C NMR spectra of complexes [Zn(trp)(dabz)]Cl were characterized by various 
resonances due to 0 -C=0, ArC-NH, ArC-NH2, =CH-NH, NH2-CH and -CH2 carbons at 
175, 136, 134, 126, 52.5 and 29 ppm, respectively of the coordinated L-tryptophan. In 
addition, '"'C NMR spectra of the complexes [Zn(trp)(dabz)]Cl revealed aromatic carbons at 
109-136 ppm, (Figure 50). 
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EPR studies 
The X-band EPR spectra of [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl (D, L and DL) 
respectively, have been measured to assess the oxidation state, geometry, and electronic 
configuration of the arche-types. For complex [Co(trp)(dabz)(H20)2]Cl (D, L and DL), in a 
pseudo-octahedral T>2h symmetry, the dxl y^  and dz^ orbitals transform as ag, whereas dxy, 
dxz, and dyz transform, respectively as big, b2o, and bjo. 
I \ m/ii 
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The bxg set has closely related energies and is separated from the ag set by a large energy 
gap (A lov^ -^spin electronic configuration given by [ag ,ag ,big ,b2g ,b3g ] is expected for a 
Co(III) ion and is thus associated with a lack of signal typical of diamagnetic species. 
Therefore, the fact that we observe a signal is indicative of the presence of Co(II) ions [172]. 
The EPR spectra of [Co(trp)(dabz)(H20)2]Cl (D, L and DL) interpreted in terms of g values 
display gn - 2.8850 and gi = 2.1869, characteristic of pseudo-octahedral cobalt complexes 
(Figure 51). No hyperfme splitting with the cobalt nucleus (1=7/2) was observed, which 
suggests that the exchange interaction between Co(II) ions is large enough to collapse this 
interaction into a single line [173]. 
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Figure 51. EPR spectra of complex [Co(trp)(dabz)(H20)2]Cl (L-form) a) at LNT b) at room 
temperature (at 25 °C). 
The complexes [Cu(trp)(dabz)] CI (D, L and DL) exhibit an anisotropic spectra with g\\ = 
2.194 and gi = 2.073 and gav = 2.11 computed from the expression gav^  = g|| ^ + 2gi^/3. 
These parameters are in good agreement with the values reported for other related square 
planar Cu(II) systems [174] and are typical of axially symmetrical d^  Cu(II) complexes. The 
trend g|| > gi> 2 reveals that the impaired electron is present in the dx -y orbital [169]. For a 
Cu(II) complex, g\\ is a parameter sensitive enough to indicate covalence. For a covalent 
complex, g|| < 2.3 and for an ionic environment, gy = 2.3 or more. In the present complexes 
gjl < 2.3 indicates an appreciable metal-ligand covalent character [175]. 
Electronic Spectra 
The UV-visible spectra of complexes at room temperature carried out in the region 190-
1100 nm in DMSO exhibits broad and intense absorption maxima. The UV-vis spectra of 
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[Co(trp)(dabz)(H20)2]Cl (D, L and DL) show a d-d transition band at 504-510 nm and two 
bands in U\^ region at 270-273 nm and 289-292 nm consistent with octahedral geometry of 
Co(II) ion [176]. The UV-vis spectra of [Cu(trp)(dabz)] CI (D, L and DL) revealed 
prominent bands at 639-650 nm, respectively attributed to dxz, dy^—>• dx'^ -y^  ligand field 
transitions [177], which were followed by a shoulder and strong bands in the UV region at 
270-272 and 359-363 nm assigned to the ligand to metal charge transfer (LMCT) and an 
intraligand charge transfer (IL) bands, respectively. These observations are typical of square 
planar geometry around Cu(II) metal ion. Square planar geometry of [Cu(trp)(dabz)] CI (D, 
L and DL) is in conformity with the observations deduced by EPR studies. 
Similarly, the electronic spectra of complexes [Zn(trp)(dabz)]Cl (D, L and DL) displayed 
transitions at 289-293 nm. 
Mass spectral analysis 
The formation of metal complexes and the speciation of various ionic forms in a DMSO 
solution were studied with ESI-MS. ESI-MS spectra of the complexes displayed prominent 
peaks corresponding to the molecular ion fragment. Three major peaks are observed at m/z 
441, 405, and 369 for complex [Co(trp)(dabz)(H20)2]Cl, which could be assigned to 
[Ci7H23ClN404Co-H]^ [Ci7H23ClN404Co-Cl+H]^ and [Ci7H23ClN404Co-Cl-2H20+H]^ 
respectively. The complex [Cu(trp)(dabz)]Cl presents two major peaks at m/z 411 and 375 
attributed to [Ci7Hi9N402ClCu+2H]^ and [Ci7Hi9N402ClCu-Cl+H]^ respectively. The 
complex [Zn(trp)(dabz)]Cl has also two major peaks at m/z 410 and 375 assigned to 
[Ci7H,9N402ClZn-2H]^ and [C,7H,9N402CIZn-Cl-H]^ respectively. The isotopic 
distribution patterns of the above peaks match well with the theoretical results. These 
observations indicate that the metal-ligated skeletons of these complexes are stable in 
solution. 
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X-ray diffraction analysis 
To obtain further evidence about the structure of the metal complexes, X-ray powder 
diffraction studies of the complexes (L-form) were performed as it was difficult to isolate 
single crystals suitable for single crystal X-ray crystallography. The diffractograms obtained 
for the metal complexes (L-form) are given in Figure 52. The XRPD patterns indicate 
crystalline nature for the complexes [Cu(trp)(dabz)]Cl & [Zn(trp)(dabz)]Cl, while 
amorphous nature for complex [Co(trp)(dabz)(H20)2]Cl was ascertained. 
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Figure 52 (a-c). X-ray powder diffraction patterns of L-form of metal complex 
[Co(trp)(dabz)(H20)2]Cl (a). [Cu(trp)(dabz)JCI (b) and [Zn(trp)(dabz)]Cl (c) 
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Interaction studies with DNA 
Absorption titrations 
The complexes [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl (L-, D-
and DL-fonn) displayed intense absorption bands at 270-293 nm in the UV region assigned 
to 71 - Ji* transitions of aromatic chromophore while [Cu(trp)(dabz)]Cl (L-, D- and DL-
form) shows another band at 359-363 nm assigned to MLCT transition, respectively. On the 
addition of CT DNA, complexes [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and 
[Zn(trp)(dabz)]Cl (L-, D- and DL-form) show an increase in molar absorptivity 
(hyperchromism; 15-30%, Table 4) with a blue shift of 3-7 nm at 270-293 nm. 
Table 4. The binding constant (Kb) values of complexes [Co(trp)(dabz)(H20)2]Cl, 
[Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl (L, D and DL) with the DNA (mean standard 
deviation). 
Complex Kb (M'') % Hyperchromism Blue Shift (nm) 
(L)-[Co(trp)(dabz)(H20)2]Cl 6.06 x 10'(± 0.04) 30 3 
(D)-[Co(trp)(dabz)(H20)2]Cl 2.79 x 10^  (± 0.03) 29 3 
(DL)-[Co(tirp)(dabz)(H20)2]Cl 4.18 x 10^  (±0.05) 28 4 
(L)-[Cu(trp)(dabz)]CI 3.94 x 10^  (±0.06) 28 3 
(D)-[Cu(trp)(dabz)]Cl 4.30 x 10^  (±0.03) 19 5 
(DL)-[Cu(trp)(dabz)]Cl 8.61 x 10^  (±0.04) 15 6 
(L)-[Zn(trp)(dabz)]Cl 7.54 x 10^  (±0.05) 28 4 
(D)-[Zn(trFO(dabz)]Cl 3.02 x 10^  (±0.06) 28 6 
(DL)-[Zn(t:rp)(dabz)]Cl 4.30 x 10\± 0.03) 19 3 
These changes are typical for complexes bound to DNA through non covalent interaction 
[178]. Hyi)Ochromism results from the contraction of DNA helix axes as well as the 
conformational changes on DNA, while hyperchromism results from the secondary damage 
of DNA double helix structure [179,180]. 
To quantify the extent of DNA binding, the intrinsic binding constant, Kb of the complexes 
were determined. The value of Kb obtained follows the order: [Cu(trp)(dabz)]Cl > 
[Zn(trp)(dabz)]Cl > [Co(trp)(dabz)(H20)2]Cl and for the different forms it follows L > DL > 
D trend (Figure 53, 54). 
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Figure 53. Absorption spectral traces of complex [Co(trp)(dabz)(H20)2]Cl in Tris HCl 
buffer upon addition ofCTDNA. Inset: Plots of [DMA]/ Sb vs [DMA] for the titration ofCT 
DNA with complexes at 25 °C. m, experimental data points; full lines, linear fitting of the 
-6 data, [complex] 6.67x W"M. [DNA] 0-33.3x IQ-'M. 
Figure 53(a-c) represents L-, D- andDL-form of complex [Co(trp)(dabz)(H20)2]Cl. 
Cu(II) complexes are known to cleave the double helix DNA efficiently to its nicked 
circular form and thereby show high nuclease activity. An explanation for higher Kb value of 
copper complexes is apparently that copper complexes are 'borderline' metals which show 
high affinity for both nucleobases and phosphate. In particular, Cu(II) complexes bind 
specifically to N7 of guanine nucleobase of DNA helix [181] 
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Figure 54. Absorption spectral traces of complex [Cu(trp)(dabz)]Cl, [Zn(trp)(dabz)]Cl in 
Tris HCl buffer upon addition of CT DNA. Inset: Plots of [DMA]/ st vs [DNA] for the 
titration ofCTDNA with complexes at 25 °C. m, experimental data points; full lines, linear 
fitting of the data, [complex] 6.67 x 10'^ M. [DNA] 0-33.3 x 10'^ M. 
Figure 54(af) represent L-, D- and DL-form for complexes [Cu(trp)(dabz)]Cl and 
[Zn(trp) (dabz)]Cl, respectively. 
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Additional!}', the introduction of chirality fine tunes the complexes for specific binding to 
different extent at the molecular target [182]. It further provides a rationale explanation for 
the high Kb value of L-form of [Cu(trp)(dabz)]Cl which implicates that the L-form of the 
Cu(II) complex possess greatest propensity for DNA than D- and DL-forms. Furthermore, it 
implicates that the different conformational features are processed differently by cellular 
machinery. L-form of the Cu(II) complex interacts with right handed B- DNA by two-pole 
complementary principle compatible to its molecular symmetry and therefore, exhibits 
strong electrostatic interactions ,additionally reinstated by hydrogen bonding [183]. 
Interaction with 5'-GMP and 5'-TMP 
To obtain concrete information and to determine the coordination of the metal ion to the 
specific site, interaction with low molecular building blocks of large DNA molecules viz; 
guanosine fi'-monophosphate and thymidine 5'-monophosphate becomes mandatory. Cu(II) 
and Zn(II) complexes, exhibit specificity towards guanine and thymidine nucleotides of 
DNA, respectively. Since the L-form of the complexes possess greatest propensity for DNA 
than D and DL-forms, therefore, complexes [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl (L-
form) were chosen for further interaction with nucleotides of DNA. On addition of 5'-GMP 
to the complexes [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl, there is a sharp increase 
"hyperchromic" effect in the absorption bands at 270-282 nm (Figure 55). This observation 
supports the multiple binding event of L-form of the Cu(II) complex as observed in case of 
CT DNA and also provides an authentic proof for binding to 5'-GMP through electrostatic 
interaction via phosphate backbone of the DNA helix. The intrinsic binding constant Kb 
values for [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl were compared to quantify the extent of 
binding of Cu(II) and Zn(II) and were of the order: 9.6 x lO"* and 1.2 x lO'* M'', respectively 
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which is indicative of higher preference of copper complex to the 5'-GMP in comparison to 
zinc complex. 
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Figure 55 (a and b). Absorption spectral traces of (a) complex [Cu(trp)(dabz)]Cl and (b) 
complex [Zn(trp)(dabz)]Cl (L-form) in DMSO upon addition of5'-GMP. [Complex] 6.67x 
la^M, [5'-GMPJ 0-33.3 x Iff^Mat 25 °C. 
Similarly, interaction studies of [Cu(trp)(dabz)]CI and [Zn(trp)(dabz)]Cl with 5'-TMP were 
carried under similar conditions (Figure 56). The Kb binding constant follows the order: 
[Cu(trp)(dabz)]Cl < [Zn(trp)(dabz)]Cl. The Kb value of zinc complex is four times greater in 
magnitude than Kb value of copper complex exhibiting preference of zinc for thymine in 
contrast to guanine. 
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Figure 56 (a and b). Absorption spectral traces of (a) complex [Cu(trp)(dabz)]Cl and (b) 
complex [Zn(trp)(dabz)JCl (L-form) in DMSO upon addition ofS'-TMP. [Complex] 6.67x 
ICf^M, [5'-GMP] 0-33.3 x Iff^Mat25 °C. 
The preference of Zn(II) for thymidine is attributed to two effects; first, when thymine 
binds, hydrogen bonds are formed between -NH2 groups of ligand; secondly a significant 
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stronger MO interaction was identified in thymine in comparison to guanine. Furthermore, 
the presence of electron withdrawing two oxo groups at the C2 and C3 position of thymine 
ring lower the energy of the lone pair orbital at N3 of thymine base [152]. 
The binding of [Zn(trp)(dabz)]Cl (L-form) to 5'-GMP and 5'-TMP was also validated by ' H 
and ^'P NMR techniques. The free 5'-GMP exhibited H8 signal at 8.07 ppm, on addition of 
complex [Zn(trp)(dabz)]Cl, there was a slight shift (-0.06 ppm) in H8 signal (Figure 57). On 
the other hand, on addition of 5'-TMP, the signal of N3 atom of free 5'-TMP at 7.64 ppm 
undergoes a substantial shift to 7.70 ppm (Figure 58). 
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Figure 57.'H NMR spectra of (a) complex fZn(trp)(dabz)J CI] (L-form) (2.5 mmol) with 5'-
GMP (5 mmol) (b) 5'-GMP at 25 °C in the aromatic region. 
Marzilli et al, have demonstrated that the phosphate group interaction dominates the 
formation constant of metal-nucleotide complexes and the base portion plays a secondary 
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role [184]. F^he ^'P NMR spectra of [Zn(trp)(dabz)]Cl in presence of 5'-GMP and 5'-TMP 
reveal a substantial downfield shift (3.59 ppm to 1.50 and 1.47 ppm) to that of free 
nucleotide (without the added complex). These results strongly support the electrostatic 
mode of interaction between phosphate groups (06 of phosphate group) with Zn(II) centre 
(Figure 59). 
<1 
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Figure 58. 'H NMR spectra of (a) complex [Zn(trp)(dabz)]Cl (L-form) (2.5 mmol) -with 5 -
TMP (5 mmol) (b) 5'-TMP at 25 °C in the aromatic region. 
a 
3h Figure 59. P NMR spectra of (a) complex [Zn(trp)(dabz)JClJ (L-form) (2.5 mmol) with 5'-
GMP (5 mmol) (b) 5'-GMP at 25 °C. 
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Fluorescence Studies 
The fluorescence emission titration of the complexes [Co(trp)(dabz)(H20)2]Cl, 
[Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl (L, D and DL) were carried out with CT DNA 
under identical experimental conditions. At room temperature, complexes exhibit emission 
bands around 258-500 nm when excited at 235-325 nm, respectively (Figure 60). 
To quantify the affinity of the complexes to DNA, Scatchard's equation was employed to 
evaluate binding constant K. Upon addition of CT DNA to the complexes 
[Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl (L, D and DL), there is 
enhancement in the fluorescence - emission intensity, which indicates that the complexes 
strongly interact with DNA. Since the hydrophobic environment inside the DNA helix 
reduces the accessibility of solvent DMSO to the complex and it restricts the complex 
mobility at the binding site which results in a decrease of the vibrational modes of relaxation 
and thus higher emission intensity [185]. The propensity to CT DNA of the complexes 
follows the order: [Cu(trp)(dabz)]Cl > [Zn(trp)(dabz)]Cl > [Co(trp)(dabz)(H20)2]Cl. The 
binding constant K values gave a similar trend of the DNA binding propensity as observed 
in case of absorption spectral studies (Table 5). 
Table 5. Emission properties of complexes [Co(trp)(dahz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and 
[Zn(trp)(dahz)]Cl (L, D and DL) bound to CT DM. 
Complex Emission (nm) Excitation (nm) Monitored at K(M'') 
(L)-[Co(trp)(dabz)(H20)2]Cl 
(D)-[Co(trp)(dabz)(H20)2]Cl 
(DL)-[Co(tip)(dabz)(H20)2]Cl 
(L)-[Cu(trp)(dabz)]Cl 
(D)-[Cu(trp)(dabz)]Cl 
(DL)-[Cu(tip)(dabz)]Cl 
(L)-[Zn(trp)(dabz)]Cl 
(D)-[Zn(trp)(dabz)]Cl 
(DL)-[Zn(tip)(dabz)]Cl 
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Figure 60. Emission spectra of complexes [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and 
[Zn(trp)(dahz)]Cl in Tris HCl buffer DNA in presence ofCTDNA at 25 °C. [DNA] 0-13 • 
10'^ M. Arrows show the intensity changes upon increasing concentration of the complexes. 
Figure 60 (a-i) represents L-,D- and DL-form for complex [Co(trp)(dabz)(H20)2]Cl, 
[Cu(trp)(dahz)]Cl and [Zn(trp)(dabz)]Cl, respectively. 
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Circular dichroism 
Circular dichoric studies are useful in diagnosing changes in the morphology of DNA during 
complex-DNA interactions [186]. 
The observed CD spectrum of CT DNA consists of a positive band at 275 nm (UV, Xmax, 
260 nm) due to base stacking and a negative band at 245 nm caused by helicity, which are 
characteristics of DNA in right-handed B form [187]. Simple groove binding and 
electrostatic interaction of the complexes with DNA shows less or no perturbation on the 
base stacking and helicity bands while intercalator enhances the intensities of both bands. 
The CD spectra of [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl (L 
and D). On addition of CT DNA exhibit a significant perturbation both in the negative and 
positive bands. These alterations in the CD spectra of DNA indicate strong conformational 
changes by the complexes. The negative DNA helicity band has disappeared which reveals 
that there ii5 unwinding of DNA helix upon interaction of complexes and possibility of 
transformation of B form of DNA into an A-like conformation of DNA [188,189]. A large 
red shift in positive ellipicity band supports this type of transformation. The CD spectra of 
complexes in presence and in the absence of DNA are depicted in Figure 61. 
DNA cleavage properties 
Since L-form of complex [Cu(trp)(dabz)]Cl shows maximum binding propensity with CT 
DNA, therefore the cleavage activity has been evaluated for complex [Cu(trp)(dabz)]Cl (L-
form). The ability of Cu(II) complexes to mediate DNA cleavage is well established in 
literature [178,190] owing to the fact that these complexes show their own selectivity for a 
cleavage mechanism either through oxidative or hydrolytic pathway, it is therefore 
imperative to study the effect of Cu(II) complex on pBR322 DNA in presence of activators, 
DNA recognition elements (groove binding) and radical scavengers. 
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Figure 61. CD spectra of (a) CTDNA alone (b) CD spectrum of metal complex (c) CTDNA 
in presence of metal complex in Tris HCl buffer at 25 °C. [Complex] = 1 xW* M, 
[DNA]=1XI0'''M. Figure (61.1-6) represents L- and D~form for complex 
[Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and [Zn(trp)(dabz)]Cl, respectively. 
92 
The DNA cleavage ability of [Cu(trp)(dabz)]Cl was studied by agarose gel electrophoresis 
using supercoiled pBR322 plasmid DNA as a substrate. A concentration-dependent DNA 
cleavage by [Cu(trp)(dabz)]Cl (Figure 62) was first performed. 
Briefly, pBR322 DNA was mixed with different concentrations of [Cu(trp)(dabz)]Cl in 
aqueous buffer solution (5mMTris-HCl/40mMNaCl, pH 7.40) without addition of a 
reductant, and the mixture was incubated at 310 K for 45 minutes. With the increase in 
concentration of [Cu(trp)(dabz)]Cl, DNA was converted from Form I to Form II and then to 
Form III. The amounts of Form I DNA decreased whereas those of Form II increased on 
increasing the concentration. The most impressive cleavage feature observed for these 
complexes is the appearance of Form III DNA before the disappearance of Form I DNA 
(lanes 3,4, 5 and 6). 
This phenomenon indicates that the complex [Cu(trp)(dabz)]Cl is capable of performing direct 
double-strand scission, [191], as a consequence, this complex is better suited for therapeutic 
applications particularly, in cancer chemotherapeutics, while many Cu(II) complexes are only 
able to cleave single strand successively. 
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Figure 62. The cleavage patterns of the agarose gel electrophoresis for pBR322 plasmid 
DNA (300ng) by [Cu(trp)(dabz)]Cl (L-form) at 25 °G Lane 1, DNA; Lane 2, 0.05 mmol 
complex + DNA; Lane 3, 0.10 mmol complex + DNA; Lane 4, 0.15 mmol complex + DNA; 
Lane 5, 0. 20 mmol complex + DNA; Lane 6, 0. 25 mmol complex + DNA. 
Activators such as ascorbic acid, H2O2, 3-mercaptopropionic acid (MPA) and glutathione (GSH) 
were used to investigate the DNA cleavage activity of complex [Cu(trp)(dabz)]Cl as shown in 
(Figure 63), the cleavage activity of [Cu(trp)(dabz)]Cl was significantly enhanced by these 
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activators. Their activating efficacy follows the order: GSH =2 MPA > Asc > H2O2. Thus, 
complex [Cu(trp)(dabz)]Cl exhibited a significant DNA cleavage activity in presence of 
glutathione. 
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Figure 63. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 plasmid 
DNA (SOOng) by [Cu(trp)(dabz)]Cl (L-form) (0.25 mmol) in presence of different activating 
agent at 25 °C after incubation for 30 minutes. Lane 1, DNA control; Lane 2, DNA + 
[Cu(trp)(dabz)JCl + GSH (0.4 mM); Lane 3, DNA + [Cu(trp)(dabz)]Cl+Asc (0.4 mM); Lane 4, 
DNA + [Cu(trp)(dabz)]Cl + MPA (0.4 mM); Lane 5, DNA + [Cu(trp)(dabz)JCl + H2O2 (0.4 
mM) 
DNA recognition elements (grooves binding) minor groove binding agent, DAPI and major 
groove binding agent ,methyl green were used to probe the potential interacting site of complex 
[Cu(trp)(dabz)]Cl with supercoiled plasmid pBR322 DNA. The supercoiled DNA was treated 
with DAPI or methyl green prior to the addition of [Cu(trp)(dabz)]Cl. The patterns presented in 
the (Figure 64), demonstrated that neither major nor minor groove grooves are the preferred 
reacting sites for the complex. Z. Guo et al. have attributed such pattern of gel electrophoresis to 
the interaction of complexes directly with exterior phosphates of DNA via electrostatic 
attraction [99]. 
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Figure 64. Agarose gel electrophoresis pattern for the clevage of pBR322 plasmid DNA 
(300ng) by [Cu(trp)(dabz)]Cl (L-form) (0.25 mmol) in presence of DNA minor groove 
binding agent DAPI and major groove binding agent methyl green at 25 °C after incubation 
for 30 minutes. Lane 1, DNA control; Lane 2, DNA + [Cu(trp)(dabz)]Cl + DAPI (8 juM); 
Lane 3, DNA + [Cu(trp)(dabz)JCl + Methyl green (2.5 fiL of a O.Olmg/mL solution). 
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The hypothesis proposed by them is in accord with the observed cleavage pattern presented by 
complex [Cu(tip)(dabz)]CI. 
To postulate a mechanism responsible for DNA cleavage mediated by complex 
[Cu(trp)(dabz)]Cl, another electrophoretic study with some standard radical scavengers was 
carried out viz; DMSO, tert-butyl alcohol, sodium azide and SOD as superoxide oxygen 
scavenger under identical conditions (Figure 65). Hydroxyl radical scavenger such as 
DMSO and tert-butyl alcohol scarcely inhibit the DNA cleavage (Lane 2 and 3) suggestive 
of non-involvement of diffusible (-OH) hydroxyl radicals as one of the ROS responsible for 
DNA breakage. For singlet oxygen scavengers, (Lane 5) there was much enhanced 
inhibition effect. There is complete inhibition in case of SOD (superoxide dismutase) (Lane 
4) which demonstrates the involvement of superoxide radical in DNA scission suggestive of 
oxidative cleavage mechanism. 
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Figure 65. Agarose gel electrophoresis pattern for the cleavage of pBR322 plasmid DNA 
(SOOng) by [Cu(trp)(dabz)]Cl (L-form) (0.25 mmol) in presence of standard radical 
scavengers at 25 °C after incubation for 30 minutes. Lane 1, DNA control; Lane 2, DNA + 
[Cu(trp)(dabz)]Cl + DMSO (0.4 mM); Lane 3, DNA + [Cu(trp)(dabz)]Cl + tert-butyl 
alcohal (0.4 mM); Lane 4, DNA + [Cu(trp)(dabz)JCl + Superoxide Dismutase (15 Units); 
Lane 5, DNA + [Cu(trp)(dabz)]Cl + NaNs (0.4 mM). 
The mechanistic pathway proposed for the interaction of complex [Cu(trp)(dabz)]Cl with 
DNA is given below: The first step is the interaction of Cu(II) complex with DNA through 
outer sphere, and then in the second step, reduction of the Cu(II) to Cu(I) complex by the 
reaction with the reducing agent. Reaction of the cuprous state with dioxygen leads to the 
generation of O2 . 
Cu(I)+ O2 • Cu(II) + O2 (5) 
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In this system, it is thought that superoxide dismutates to H2O2, 
202' +2H^ •O2 + H2O2 ' (6) 
The ROS formed are responsible for initiating DNA strand scission chemistry [192]. 
ROS species + DNA • DNA cleavage. (7) 
Antitumor activity 
DNA is the primary pharmacological target of many antitumor compounds [193] Since L 
form of these metal complexes shows greater binding affinity with DNA, therefore 
antitumor activity has been evaluated with L- form of Co(II), Cu(II) and Zn(II) complexes. 
In vitro anticancer activity of complexes [Co(trp)(dabz)(H20)2]Cl, [Cu(trp)(dabz)]Cl and 
[Zn(trp)(dabz)]Cl were screened against 14 different human carcinoma cell lines of different 
histological origin MIAPaCa-2 (Pancreatic), MCF-7, ZR-75-1 (Breast), SiHa ( Uterine 
Cervix), Colo205 (Colon), HOP-62, A549 (Lung), DWD (Oral), K562 (Leukemia), DU145 
(Prostate), A498 (Renal Cell), A2780 (Ovary), T24 (Urinary Bladder) and PC-3 (Prostrate). 
The Sulforhodamine-B (SRB) assay was used to assess the cellular proliferation. Among 
these complexes, the most promising result was shown by complex [Cu"^trp)(dabz)]Cl, as 
expected from the resuhs of in vitro DNA binding studies. The complex [Cu(trp)(dabz)]Cl 
exhibited excellent cytotoxicity (Gl5o<10) against MCF-7. However, moderate results were 
obtained against DWD (Gl5o=l 1) and A2780 (Gl5o=l 1). The results are presented in terms 
of GI50 values in the Table 6. 
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CHAPTER IV (b) 
Design, synthesis of new chiral metal-based cancer 
chemotherapeutic agents derived from L-, D- and DL-
tryptophan: Effect of structure variation on enantioselective 
DNA binding, cleavage and antitumor activity. 
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Synthesis 
Synthesis of L- and D-ICo(trp)(dach)(H20)2]Cl 
The complexes were prepared by a general synthetic method in which corresponding 
tryptophan [L-tryptophan, D-tryptophan, ( 0.204g, Immol)] and NaOH (0.04g, Immol) in 
10 mL methanol was added to an methanolic solution (10 mL) of C0CI2.6H2O (0.238 g, 
Immol) with stirring for ca. 0.5 hour followed by the addition of (lR,2R)-(-)-l,2-
diaminocyclohexane) (0.114 g, Immol) taken in 5 mL of methanol. The solution was stirred 
for 2 hours with heating at 85 °C. On completion of the reaction, the reaction mixture was 
kept at room temperature which yielded a red product (in both cases), washed with hexane 
and diethylether and dried in vacuo. 
(L-form): Yield 70%. m.p. 211 °C. Anal. (%) Calc. for C17H29CIN4O4C0: C, 45.59; H, 6.53; 
N, 12.51. Found: C, 46.01; H, 6.47; N,12.59. [a]\ (DMSO) = -25. ESI (m/z^): 446 
[Ci7H29ClN404C0-2H] .^ 
(D-form): Yield 66%. m.p. 212 °C. Anal. (%) Calc. for C17H29CIN4O4C0: C, 45.59; H, 6.53; 
N, 12.51. Found: C, 45.94; H, 6.46; N,12.57. [afu (DMSO) = +17. ESI (m/z^): 449 
[C,7H29C1N404C0+H]^ 
Both enantiomeric metal complexes exhibited identical molar conductance, IR and UV-vis 
data. 
Selected IR data on KBr (v /cm"'): 3384 v (NH2); 3218 v (N-H); 2948 v (CH2Cv); 1627 (sym 
COO); 1384 {antisym COO); 1507 J (N-H); 1275 v (imidazole N-H); 752 (Ar); 432 v (Co-
N); 585 (Co-0). UV-vis (1 x 10"*M, DMSO) ^ax/nm 291; 510. 
Synthesis of L- and D-[Cu(trp)(dach)]Cl 
These complexes were synthesized according to procedure described for L- and D-
[Co(trp)(dach)(H20)2]CI with CUCI2.2H2O (0.171 g, Immol). Sky blue coloured products 
were isolated. 
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(L-form): Yield 74%. m.p. 255 °C. Anal. (%) Calc. for C17H25CIN4O2CU: C, 49.04; H, 
6.05; N, 13.45. Found: C, 50.02; H, 6.05; N, 13.55. [afo (DMSO) = -47. ESI (m/z) 414 
[Ci7H25ClN402Cu-2H]^ 
(D-form): Yield 70%. m.p. 252-254 °C. Anal. (%) Calc. for C17H25CIN4O2CU: C, 49.04; H, 
6.05; N, 13.45. Found: C, 49.88; H, 5.97; N,13.52. [afn (DMSO) = + 22. ESI (m/z) 418 
[Ci7H25ClCuN402+2H]^ 
Both enantiomeric metal complexes exhibited identical molar conductance, IR and UV-vis 
data. 
Selected IR data on KBr (v /cm"'): 3352 v (NH2); 3219 v (N-H); 2892 v (CH2Cv); 1634 (sym 
COO); 1371 (antisym COO); 1553 S(N-H), 1255 (imidazole N-H); 755 (Ar); 581 (Cu-0), 
431 V (Cu-N). UV-vis (1 x 10"^M, DMSO) A^^/nm 287, 641. 
Synthesis of L- & D- [Zn(trp)(dach)]CI 
These complexes were synthesized by a similar procedure as described for L- & D-
[Co(trp)(dach)(H20)2]Cl with ZnC]2 (0.136 g, Immol). White coloured products were 
isolated in both the cases. 
(L-form): Yield 62%. m.p. 289 °C. Anal. (%) Calc. for Ci7H25ClN402Zn: C, 48.82; H, 
6.02; N, 13.40. Found: C, 49.05; H, 6.08; N, 13.49. [afu (DMSO) = -21. ESI (m/z) 417 
[Ci7H25ClN402Zn-H]\ 
(D-form): Yield 64%. m.p. 288 °C. Anal. (%) Calc. for Ci7H25ClN402Zn: C, 48.82; H, 
6.02; N, 13.40. Found: C, 49.01; H, 6.07; N, 13.48. [afo (DMSO) = +22. ESI (m/z), 417 
[Ci7H25ClN402Zn-H]^ 
Both enantiomeric metal complexes exhibited identical molar conductance, IR UV-vis and 
NMRdata. 
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Selected IR data on KBr (v /cm''): 3400 v (NH2); 3191 v (N-H); 2857 v (CHjcy); 1592 (sym 
COO); 1353 {antisym COO); 1461 d(N-Uy, 1278 (imidazole N-H); 741 (Ar); 424 v (Zn-
N); 578 V (Zn-0). UV-vis (1 x 10"^  M, DMSO) ^ax / nm 290. 'H N M R (DMSO-de, ppm): 
10.80 (s, IH, imidazole N-H); 7.57 (d, J = 8 Hz, IH, tryptophan H); 7.36 (d, J = 8 Hz, IH, 
tryptophan H); 7.23 (s, IH, tryptophan H); 7.06 (t, J = 8 Hz, IH, tryptophan H); 6.96 (t, J = 
8 Hz, IH, tryptophan H); 3.63 (s, 7H, amine H and chiral CH); 2.56 (t, J = 3 Hz, 2H, -CH2); 
1.86 (s, 2H, cyclohexane H); 1.61 (s, 2H, cyclohexane H); 1.13 (s, 2H, cyclohexane H). '^ C 
NMR (DMS0-d6, ppm): 178 (0-C=0); 136 (Ar C-NH); 126 (=CH-NH); 124 (Ar C); 121 
(Ar C); 118 (Ar C); 111 (Ar C); 110 (Ar C); 54 (NH2-CH); 35 (cyclohexane C); 29 
(cyclohexane C); 25 (-CH2). 
Results and discussion 
A parallel series of new chiral complexes similar to complexes of IV (a) was designed from 
L-, D-tryptophan and ancillary ligand "dach" instead of "dabz" in order to evaluate the 
effect of structure variation. (1,2-DACH) is a planar, non-aromatic, chiral ligand and it 
provides two additional chiral stereogenic carbon centers in contrast to dabz, which is 
achiral, and aromatic. Syntheses of mononuclear complexes [Co(trp)(dach)(H20)2]CI, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl were achieved by mixing stoichiometric amounts of 
L-tryptophan: and D-tryptophan with corresponding metal chlorides followed by reaction 
with (lR,2R)-(-)-l,2-diaminocyclohexane (Scheme 6). The compositions of the complexes 
were confirmed by elemental analysis, infrared, nuclear magnetic resonance spectroscopy, 
EPR, mass spectrometry and optical rotation. The complexes are stable towards air and 
moisture and soluble in DMSO and DMF. Molar conductance values of complexes in 
DMSO (1 x 10'^  M) at 25 °C suggest their 1:1 electrolyte nature (38-45 D''cm^ mol"'). Due 
to the presence of chiral auxiliaries "L-tryptophan or D-tryptophan" and (lR,2R)-(-)-l,2-
diaminocyclohexane ligand (1,2-DACH), the complexes 
HN~ 
L, D or Dl.-Tryptophan 
NaOH 
+ 
(I R,2R)-(-)-l,2-diaminocyclohexane^ 
CoCl^.eH^O 
O 
Co 
MCI; 2' '" ' - , ^ ' ' ' " 
o o 
Where M= Cu(II) & Zn(II) 
Scheme 6. Synthesis of complexes. 
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.ci 
.ci 
k CI 
c^**n 
€ $^< C-"C 
[Co(trp)(dach)(H20)2]Cl 
t • 
|Cu(trp)(dach)|CI 
X 
[Zii(trp)(dach)]CI 
Figure 66. Cylindrical bonded three dimensional model of complexes 
[Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl. Color scheme: Co(II) 
dark gray; Cu(II) dark gray; Zn(II) dark gray; N dark blue; O red; C gray. Chloride ion and 
other H atoms are omitted for clarity. 
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[Co(trp)(dach)(H20)2]CI, [Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl exhibited optical rotation 
[af^o values which indicate that all the complexes are optically active. 
IR spectra 
The IR spectra of [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]CI and [Zn(trp)(dach)]Cl were 
recorded in the region 4000-250 cm"' and analyzed in comparison to the free ligand. The 
data gave evidence for the coordination of the ligand to the metal ion. Metal complexes 
[Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl exhibit characteristic 
broad envelope at 3292-3350 cm'' attributed to v (NH2) coordinated to the Co, Cu and Zn 
centers [169]. 
The A value (> 200 cm'') is larger than the corresponding value in bidentate carboxylic 
moiety (< 200 cm"'), indicating that the carboxyl groups in all these metal complexes behave 
as mono-dentate ligands [139]. Absorption bands due to v (CH2) vibrations of the 
cyclohexyl ring were observed at 2857 - 2948 cm'' [194]. 
Further supportive evidence for this coordination mode is provided by the presence of v (M-
N) and v (M-0) bands at 424-432 and 578-585 cm'', respectively. The IR spectra of these 
metal complexes displayed bands in the range of 1255-1278 cm'' due to presence of the 
imidazole ring -NH [195]. 
NMR spectral studies 
The sharp signal at 10.80 ppm, is indicative of imidazole -NH. Peaks with chemical shifts 
near 6.93-7.57 ppm were ascribed to "tryptophan" (aromatic ring) protons. Coupled with 
these obseirvations the characteristic signals at 3.42 (CH and NH2) and 3.46 (Ci-l2), 
respectively further confirmed the presence of tryptophan moiety in chiral metal complexes 
[171]. Additional peaks in the range 1.13, 1.64 and 1.86 ppm, in the spectrum were 
attributed to different cyclohexyl ring protons [196] (Figure 67). 
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13/ The ' T NMR spectra of Zn(II) complex were characterized by various resonances attributed 
to 0-C=0, CH, CH2 and NH-CH carbons of tryptophan at 173, 56, 28.0 and 114 ppm, 
respectively. In addition, C NMR spectra of the Zn(II) complex revealed aromatic carbon 
signals at 120-132 ppm. The *^ C NMR spectra feature various resonances due to the 
cyclohexyl ring carbons at 19.00,20.29,23.94,26.70, 39.13 ppm [197,198] (Figure 68). 
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Figure 67. 'HNMR spectrum of complex [Zn(trp)(dach)]Cl (L-form). 
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Electron paramagnetic resonance spectroscopy 
The EPR spectra of [Co(trp)(dach)(H20)2]CI (L- and D-) interpreted in terms of g values 
displays gn = 2.9431 and gi = 2.548, characteristic of pseudooctahedral cobalt complexes 
similar to the [Co(trp)(dabz)(H20)2]Cl. The complexes [Cu(trp)(dach)]CI (L- & D-) exhibit 
an anisotropic spectra with g|| = 2.203 and gi ==2.106 and gav = 2.14 computed from the 
expression gav^  = g|| ^ + 2giV3. 
ifi ^ O^ I 
1 J* tD r«* o* [sj 
^ *'W ^ ' J »'» » ' l I 'J «'? <-l 
)|/>r>p<||^|l^>P^>#«tMjl^|^i>fi^Wtftff»<W Til rtiiiUtit 
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Figure 68. CNMR spectrum of complex fZn(trp)(dach)J CI (L-form). 
" I • 
20 pptn 
104 
Interaction studies with DNA 
Absorption titrations 
Absorption titration studies of both the enantiomers of [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)lCl and [Zn(trp)(dach)]Cl complexes were carried out in DMSO as a flinction 
of added CT DNA by monitoring the spectral changes of metal to ligand charge transfer 
(MLCT) bands in the region of 286-295 nm. Upon addition of CT DNA (0-33.3 x 10"^ ) to 
the complexes (6.67 x 10'^ ), a 'hyperchromic effect' was observed with a concomitant blue 
shift of 3-5 nrji, however, there were pronounced difference in the extent of binding in case 
of both the enantiomers and also for the different metal complexes (Figure 69). In our 
complexes, there was a significant blue shift which can be associated with change in 
environment around the metal centre (by coordinating to base nitrogen or phosphate oxygen) 
as the transition metal centres (Lewis acid) are attracted to negatively charged phosphate 
backbone of double helix, while no shift is usually consistent with groove binding leading to 
small perturbations [199], (Table 7). 
Table 7. The binding constant (Kb) values of all complexes with the DNA (mean standard 
deviation). 
Complex Kb (M"') % Hyperchromism Blue Shift (nm) 
(L)-[Co(trp)(dach)(H20)2] CI 5.9xl0^(±0.06) 37 3 
(D)-[Co(trp)(dach)(H20)2]Cl 1.3xl0\±0.05) 23 4 
(L)-[Cu(trp)(dach)]Cl 6.9xl0\±0.04) 34 5 
(D)-[Cu(trp)(dach)]Cl 2.6xl0^(±0.06) 32 3 
(L)-[Zn(trp)(dach)]Cl l.lxl0\±0.02) 28 5 
(D)-[Zn(trp)(dach)]Cl 2.8xl0\±0.06) 24 4 
The 1,2-DACH moiety is planar and non aromatic, but side chain of tryptophan possess an 
aromatic moiety (indole portion) so there is a probability of binding of these complexes 
via partial intercalation; nonetheless, 'hyperchromic' spectral changes support electrostatic 
interactions. In our experiments, there is a concomitant shift in absorption intensity, which 
rules out groove binding. Table 7 indicates that L-form of [Co(trp)(dach)(H20)2]Cl, 
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Figure 69. Absorption spectral traces of complexes [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]CI & [Zn(trp)(dach)]Cl in Tris HCl buffer upon addition ofCTDNA. Inset: 
Plots of [DNAJ/sb vs [DMA] for the titration of CT DNA with complexes at 25 °C. u, 
experimental data points; full lines, linear fitting of the data, [complex] 6.67 x 10'^ M, 
[DNA] 0-33.3 X la^M. 
Figure 69 (a-f) represents L- and D-formfor complexes [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl, respectively. 
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[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl complexes possess higher propensity for DNA 
binding in comparison to their D-enantiomer analogs. Furthermore, copper complex 
[Cu(trp)(dach)]Cl (L-Form) has shown maximum propensity for DNA which is concomitant 
with similar resuhs in literature [200]. 
Interaction with 5'-GMP and 5'-TMP. 
To investigate the specific recognition of complexes [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]Cl in their L-form with the nucleobases/ phosphate sugar backbone of 
0.6-
: 0.34 
-< 
243.00 3 » 6 . 5 0 55O.O0 
O.OO 241.OO 3 9 5 . 5 0 
Wavrlei i iEtU ( inn) 550.00 
(a) (b) 
1.25r 
0.«3 
O.OO 
0.6' 
J 0.34 
243.00 396.?0 
W a v f l e i i g O i ( lun) 
5 5 0 . 0 0 O.OO 2 4 1 . 0 0 3 9 5 . 5 0 W r t v r l e n g t l i ( l a n ) 5 5 0 . 0 0 
(C) (d) 
Figure 70. Absorption spectral traces of L-form of (a) & (c) complex[Cu(trp)(dach)]Cl and 
(b) & (d) complex[Zn(trp)(dach)]Cl, respectively in DMSO upon addition of5'-GMP & 5'-
TMP, respectively at 25 °C. Inset: Plots of 5'-GMP & 5'-TMP / st vs 5'-GMP & 5'-TMFfor 
the titration of 5'-GMP & 5'-TMP with complexes u, experimental data points; full lines, 
linear fitting of the data. [Complex] 6.67 x 10'" M, [5'-GMP] & [5'-TMP] 0-33.3 x W'M. 
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DNA helix, we have carried out binding studies of L-form of [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]CI with 5'-GMP and 5'-TMP in DMSO by UV-vis absorption titrations. On 
addition of increasing amount of 5'-GMP and 5'-TMP to [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]Cl there was a sharp increase in absorption intensity 'hyperchromism' and 
small blue shift of 2-3 nm (Figure 70). 
Hyperchromic effect is the result of damage caused to the secondary structure of DNA 
through phosphate backbone interaction while small blue shift is attributed to the 
coordinative interaction to N7 of 5'-GMP and N3 of 5'-TMP. This is an inherent 
characteristic feature of transition metals (Cu displays a very strong interaction with N7 
while Zn^ ^ possess affinity towards N3 of nucleobases). 
The complex [Zn(trp)(dach)]Cl was studied by H and P NMR spectroscopic method, 
([Cu(trp)(dach)]Cl complex is paramagnetic in nature, therefore it exhibits broadening of the 
chemical shift adjacent to the metal centre). The ' H NMR of free 5'-GMP and 5'-TMP in de-
DMSO exhibits H8 resonance and N3 resonances at 8.05 and 7.64 ppm, respectively and the 
ribose peak signals at 3.82-5.77 ppm (Figure 71, 72). On addition of [Zn(trp)(dach)]Cl (L-
form), there was no significant shift in H8 signal of 5'-GMP while the ribose signals were 
affected (-0.003 ppm) which could be attributed to the preference of the complex to ribose 
sugar rather than H8 proton (neighbouring peak to N7 atom of guanine). This observation is 
indicative of negligible coordination to nucleobases and further implicates high propensity 
for phosphate binding (This is evident from the large upfield shift of [Zn(trp)(dach)]Cl (L-
form) in ^'P signal of the phosphate group with [Zn(trp)(dach)]Cl (L-form) in comparison to 
free 5'-GMP). 
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Figure 71. H NMR spectra of 5'-GMP (a) and the reaction of complex [Zn(trp)(dach)]Cl 
(L-form) (2.5 mmol) with 5'-GMP (5 mmol) (b) at 25 °C in the aromatic region. 
An identical reaction which was followed by P NMR, revealed corresponding changes in 
intensities of ^'P NMR peak, which were consistent with the results of ' H NMR. The ^'P 
NMR spectra of 5'-GMP and 5'-TMP exhibits a signal at 3.59 ppm, which shifted to 2.70 
and 2.67 ppm, respectively on interaction with [Zn(trp)(dach)]Cl. Our results are consistent 
with those obtained earlier [201]. 
The observations deduced from above studies demonstrate that complex [Zn(trp)(dach)]Cl 
(L-form) interacts directly with the anionic phosphate backbone of the DNA helix which is 
further authenticated from the results deduced by fluorescence studies with K2HPO4. 
Steady-state emission titration 
Both L and D- enantiomeric complexes of [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]Cl emit luminescence in Tris-HCl buffer with the maximum wavelength of 
530 rmi. Figure 73, depicts the emission spectra of complexes in the absence and in presence 
of CT DNA. Upon addition of increasing amount of CT DNA, the emission intensities of L-
and D-en<mtiomeric complexes [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
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[Zn(trp)(dach)]Cl increased in comparison to the intensity of free unbound complexes 
(Table 8). 
V 
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Figure 72. 'HNMR spectra of5'-TMP (a) and the reaction of complex [Zn(trp)(dach)]Cl 
(L-form) (2.5 mmol) with 5'-TMP (5 mmol) (b) at 25 °C. in the aromatic region. 
Table 8. Emission properties of complexes bound to CTDNA 
Complex Emission 
(nm) 
Excitation 
(nm) 
Monitored at 
(nm) 
Ratio' K 
5.33 X 10^  
1.41 X 10^  
6.76x10^ 
2.52x10^ 
1.28x10^ 
2.76x10^ 
(L)-[Co(trp)(dach)(H20)2]Cl 520 
(D)-[Co(trp)(dach)(H20)2]Cl 522 
(L)-[Cu(trp)(dach)]Cl 520 
(D)-[Cu(trp)(dach)]Cl 520 
(L)-[Zn(trp)(dach)]Cl 520 
(D)-[Zn(trp)(dach)]Cl 523 
289 
288 
287 
289 
291 
289 
508 
510 
508 
512 
511 
506 
1.72 
1.60 
3.33 
2.56 
1.84 
1.52 
a = (Unbound/Fully Bound) 
The relative emission intensity of L-form has shown large enhancement in magnitude for 
complexes with respect to D-form complexes. Hydrophobic interactions between the 
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enantiomeric complexes and polyelectrolyte may induce changes in the excited state 
properties either due to electrostatic association or intercalation [202]. Cationic complexes 
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Figure 73. Emission spectra of complexes [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]Cl in Tris HCl buffer DNA in presence ofCTDNA at 25 °C. [DNA] 0-13 x 
1(T^ M. Arrows shows the intensity changes upon increasing concentration of the complexes. 
Figure 73.(a-f) represents L- and D-form for complex [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl, respectively. 
usually bind to DNA non-covalently as the cationic core of the complexes exerts a strong 
electrostatic attraction to the anionic phosphate backbone of DNA thus precluding 
substantial overlap with the base pairs leading to higher emission intensity indicative of 
electrostatic binding to the DNA. It is interesting to note that an increase in emission 
intensity yields the electrostatic association. The intercalative mode of binding will be 
I l l 
sensitive to ligand characteristics such as planarity of ligand, extent of aromatic n system 
available for stacking and depth of ligand which can penetrate into the double helix. On the 
other hand, electrostatic interaction would be more sensitive to the charge of the metal ion, 
ligand hydrophobicity and size of the complex [203]. 
Ethidium Bromide Displacement Assay 
In the competitive binding studies, [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]Cl (L-Form) complexes were added to CT DNA pretreated with ethidium 
bromide and then the emission intensities of DNA-induced ethidium bromide were 
measured (Figure 74). The results reveal that, with the addition of a metal complex to DNA, 
there was an appreciable decrease in the emission intensity. The extent of reduction of 
emission intensity gave a measure of the binding propensity of the complex to DNA. 
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Figure 74. Emission quenching spectra of (a) [Co(trp)(dach)(H20)2]Cl, (b) 
[Cu(trp)(dach)]Cl and (c) [Zn(trp)(dach)JCl (L-Form) with increasing concentration of 
quencher ethidium bromide, in absence and presence ofCTDNA in Tris HCl buffer at pH= 
7.2 at 25 °C. Arrows show the intensity changes upon increasing concentration of the 
ethidium bromide. 
Similar result has also been obtained with other metal complexes of tryptophan [118, 204]. 
Furthermore, complex [Cu(trp)(dach)]CI displays a larger decrease in emission intensity 
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suggesting that stronger binding propensity to CT DNA than the complexes 
[Zn(trp)(dach)]Cl and [Co(trp)(dach)(H20)2]Cl. 
Effect of phosphate group on the binding of complexes with DNA 
Since it is evident from the absorption spectral studies and steady-state emission titration 
that L-enantiomer binds to DNA more avidly than D-enantiomer, therefore the effect of 
phosphate on L-enantiomeric complexes [Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and 
[Zn(trp)(dach)]Cl (L-form) was studied. 
To validate our observations of UV-vis and florescence studies for selective binding site of 
complexes within the DNA helix, fluorescence titrations were performed in presence of 
increasing amount of K2HPO4 at 25 °C. As it is evident from Figure 75, that fluorescence 
intensity of complexes increases when K2HPO4 is added to the system. 
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Figure 75. Emission spectra of L-form of complexes (a) [Co(trp)(dach)(H20)2]Cl, (b) 
[Cu(trp)(dach)]Cl and (c) [Zn(trp)(dach)]Cl with increasing concentration of K2HPO4, in 
the absence and presence ofCTDNA in Tris HCl buffer atpH=' 7.2 at 25 °C. Arrows show 
the intensity changes upon increasing concentration of the K2HPO4. 
These results demonstrate a competitive binding behavior between the phosphate group of 
K2HPO4 and the phosphate component of DNA. The competitive binding of phosphate 
group of K2HPO4 weakens the interaction between the complexes and DNA, thus supporting 
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our previous observations that the complexes bind selectively to the phosphate group of 
DNA double helix by electrostatic interaction [205]. 
Effect of ionic strength on the binding of complexes with DNA 
In order to ascertain the probable binding mode between the molecule and DNA, 
fluorescence titrations were carried out under the conditions of increasing ionic strength (0-1 
X 10"^  M) thiough added NaCl. The fluorescence intensity of the studied complexes was 
appreciably quenched with increasing ionic strength suggesting that a cation such as Na^ can 
bind to phosphate group of the DNA by electrostatic forces to form cationic atmosphere 
around DNA. 
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Figure 76. Emission spectra L-form of complexes (a) [Co(trp)(dach)(H20)2]Cl, (b) 
[Cu(trp)(dach)]Cl and (c) [Zn(trp)(dach)]Cl with increasing concentration of NaCl, in the 
absence and presence ofCTDNA in Tris HCl buffer atpH= 7, at 25 °C. Arrows shows the 
intensity changes upon increasing concentration of the NaCl. 
This cationic atm.osphere shields the DNA and inhibits the binding of the positively charged 
molecules to the DNA phosphate backbone. This invokes a competitive interaction for the 
phosphate anions and subsequent addition of the cation weakens the surface binding 
interactions and hydrogen bonding between DNA and molecule. Thus, the results show that 
the complexes preferably bind to the DNA phosphate backbone by electrostatic interactions 
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because the increase in the ionic strength weakens the binding of the complexes with DNA 
[206]. In addition, it could be seen from Figure 76, that the effect of salt concentration on 
the fluorescence intensity of L-form of [Cu(trp)(dach)]Cl -DNA system was far greater than 
the other coimplexes; complex [Cu(trp)(dach)]Cl in L-form exhibits greater potency for 
DNA binding via electrostatic interactions. 
Circular dichoric studies 
The observed CD spectrum of CT DNA consists of a positive band at 275 nm due to base 
stacking and a negative band at 245 nm due to helicity, which are characteristic of DNA in 
right handed canonical B-form. On incubation of the present complexes 
[Co(trp)(dach)(H20)2]Cl, [Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl (L & D-Form) with CT 
DNA, the CD spectrum of DNA undergoes changes in both positive and negative bands. 
The enantiopreferential selectivity of L-form of complexes is recognized by CD spectra of 
these complexes on incubating with CT DNA, both positive and negative (ellipticity & 
helicity bands) exhibit increase in intensity and maximum increase of ellipticity was 
observed in case of [Cu(trp)(dach)]Cl (Figure 77), attributed to an stabilizing interaction 
with DNA in a similar manner to cisplatin; such changes in transition are indicative of 
B—-•Z form like conformation of DNA [207]. 
The D-form of complexes presented a very different behavior, both positive and negative 
bands exhibit decrease in intensity in comparison to free CT DNA CD spectrum; decrease m 
ellipticity is due to destabilization of DNA form attributed to the opening of DNA structure 
by formation of intra-strand DNA cross-links in a similar way as observed in case of 
transplatin [trans-(diammine)dichloro platinum(II)], a pharmacologically inactive isomer of 
cisplatin [208]. The larger decrease in intensity of the DNA helicity bands with a red shift as 
observed for D-form indicates that complexes exhibits a mode of DNA binding different 
from L-form. 
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From these CD assays which reveal interesting but different behavior, we could virtually 
discriminate between enantioprefersntial binding of DNA to L- & D-forms. 
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Figure 77. CD spectra ofCTDNA alone and in presence of (a) [Co(trp)(dach)(H20)2]Cl, 
(b) [Cu(trp)(dach)]Cl and (c) [Zn(trp)(dach)]Cl, L & D-form, respectively in Tris-HCl 
buffer at 25 °C. [Complex] = 1 xlO"' M, [DNA] =1 xW^ M. 
DNA cleaving studies 
Since L-enantiomers complexes show a remarkable DNA binding activity, therefore DNA 
cleavage activity was carried out with the complexes [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl (L-form). 
A concentration-dependent DNA cleavage by complexes was performed. The complex 
[Co(trp)(dach)(H20)2]Cl shows discernible DNA cleavage with increase in concentration, 
intensified nicked (Form II, NC) and linear (Form III, LC) was observed. The mobility of 
each form decreased with increase in the concentration of [Co(trp)(dach)(H20)2]Cl. With the 
increase of concentration of [Cu(trp)(dach)]Cl, DNA was converted from Form I to Form II 
and then to Form III. The conversion into Form III is attributed to the linear form of the 
DNA which suggests that the frequent cleavage resulted in nicks on both DNA strands 
close to each other, and as a consequence, in the opening of circular DNA form. Complex 
[Zn(trp)(dach)]Cl displayed conversion of pBR322 DNA Form I to Form II. 
Electrophoretic experiments reveal that complex [Cu(trp)(dach)]Cl shows highest cleaving 
ability of pBR322 DNA in comparison to [Co(trp)(dach)(H20)2]Cl and [Zn(trp)(dach)]Cl 
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(Figure 78); therefore, further cleavage studies were carried out with L-form of 
[Cu(trp)(dach)]Cl. 
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Figure 78. Gel electrophoresis diagram showing cleavage of pBR322 supercoiled DNA 
(300 ng) by L-form of complex at 25 °C, (a) [Co(trp)(dach)(H20)2]Cl,(b) [Cu(trp)(dach)]Cl 
and (c) [Zn(trp)(dach)]Cl. Lane 1, DNA; Lane 2, 0.05 mmol metal complex+ DNA; Lane 3, 
0.10 mmol metal complex + DNA; Lane 4, 0.15 mmol metal complex + DNA; Lane 5, 0. 20 
mmol metal complex + DNA; Lane 6, 0. 25 mmol metal complex + DNA 
The cleavage activity of [Cu(trp)(dach)]Cl were significantly enhanced by the activators and 
follow the order: H2O2 > A s c » MPA =; GSH (Figure 79) which can be correlated to other 
previous studies on the nuclease activity of bis(o-phenanthroline)copper(II) complexes 
[156]. 
*-FormII 
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Figure 79. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 plasmid 
DNA (300 ng) by [Cu(trp)(dach)]Cl (0.25 mmol) in the presence of different activating 
agent at 25 °C. after incubation for 30 minutes. Lane 1, DNA control; Lane 2, DNA + 
[Cu(trp)(dach)]Cl + H2O2 (0.4 mM); Lane 3, DNA + [Cu(trp)(dach)]Cl + Asc (0.4 mM); 
Lane 4, DNA + [Cu(trp)(dach)]Cl + MPA (0.4 mM); Lane 5, DNA + [Cu(trp)(dach)]Cl + 
GSH (0.4 mM). 
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Minor groove binding agent DAPI and major groove binding agent methyl green were used 
to probe the potential interacting site of complex [Cu(trp)(dach)]Cl with plasmid pBRR322 
DNA. The patterns presented in the Figure 80, demonstrated that neither major nor minor 
grooves are the preferred reacting sites for the complex [Cu(trp)(dach)]Cl. In these 
circumstances, complex [Cu(trp)(dach)]Cl could interact directly with exterior phosphate 
group of DNA via electrostatic attraction. These results are in agreement with the 
conclusions drawn from the DNA binding studies. The assumption is in accord with the 
above proposed binding mode for complex [Cu(trp)(dach)]Cl. 
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Figure 80. Agarose gel electrophoresis pattern for the clevage of pBR322 plasmid DNA 
(300 ng) by [Cu(trp)(dach)]Cl (0.25 mmol) in the presence of DNA minor binding agent 
DAPI and major binding agent methyl green at 25 °C after incubation for 30 min. Lane I, 
DNA control; Lane 2, DNA + [Cu(trp)(dach)]Cl + DAPI (8 ftM); Lane 3, DNA + 
[Cu(trp)(dach)]Cl + Methyl green (2.5 juL of a O.Olmg/mL solution). 
The comparative cleavage reactions were carried out to predict the mechanism of pBR322 
plasmid DNA scission by [Cu(trp)(dach)]Cl in presence of various radical scavengers such 
as DMSO, tert-butyl alcohol, NaNs and SOD (Figure 81). When hydroxyl radical scavenger, 
DMSO (Lane 2) and tert-butyl alcohol (Lane 3) were added to the reaction mixture, they 
were found to diminish the nuclease activity which was indicative of the involvement of 
OH' radicals in the cleavage process. These OH' free radicals participate in the oxidation of 
the deoxyribose moiety, followed by hydrolytic cleavage of the sugar phosphate backbone 
[209]. The DNA cleavage of the plasmid was also inhibited in the presence of NaNs (lane 
4), suggesting that ^02 is likely to be the reactive species responsible for the nuclease 
activity. Similarly, in the presence of SOD (Lane 5), the cleavage was inhibited which 
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indicate that O2' might be an inhibitor in the cleavage process and reducing the amount of 
O2' can improve the cleavage effect [192]. 
rorrau 
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Figure 81. Agarose gel electrophoresis pattern for the cleavage ofpBR322 plasmid DNA 
(300 ng) by [Cu(trp)(dach)JCl (0.25 mmol) in the presence of standard radical scavengers 
at 25 °C after incubation for SO minutes. Lane 1, DNA control; Lane 2, DNA + 
[Cu(trp)(dach)]Cl + DMSO (0.4 mM); Lane 3, DNA + [Cu(trp)(dach)]Cl + tert-butyl 
alcohol (0.4 mM); Lane 4, DNA + [Cu(trp)(dach)]Cl + NaNs (04 mM); Lane 5, DNA + 
[Cu(trp)(dach)JCl + Superoxide Dismutase (15 Units). 
On the basis of above results, the mechanistic pathway mediated by complex 
[Cu(trp)(dach)]Cl involves Cu(II) centre which is initially reduce to Cu(I) species and 
subsequently it would reacts with a dioxygen to form a peroxo Cu(II) derivative, which 
could generate active oxygen species needed for cleavage evidently supporting an oxidative 
cleavage mechanism. Since the nuclease activity of the complexes is not completely 
diminished either in the presence of singlet oxygen quencher or hydroxyl radicals, some 
DNA is probably cleaved by other than oxidative mechanism, possibly by a discemable 
hydrolytic path. 
Antitumor activity 
Since L-form of these metal complexes shows greater binding affinity with DNA, therefore 
antitumor activity has been evaluated, with L-form of [Co(trp)(dach)(H20)2]Cl, 
[Cu(trp)(dach)]Cl and [Zn(trp)(dach)]Cl complexes. In vitro anticancer activity of 
complexes was screened against 14 different human carcinoma cell lines of different 
histological origin. A close inspection of all cell lines reveals that some complexes 
demonstrated better selectivity for certain human cancer cell lines. For example, complex 
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[Co(trp)(dach)(H20)2]Cl had GI50 = 38 in A549 (lung cancer cell line), whereas complex 
[Cu(trp)(dach)]CI had GI50 = 43. Similarly, complex [Cu(trp)(dach)]Cl had a GI50 = 21 in 
MlAPaCa-2 (Pancreatic) compared to 47 and >80 for complex [Co(trp)(dach)(H20)2]Cl and 
[Zn(trp)(dach)]Cl in the same cell line. The reason for this selectivity has not yet been 
determined. The complex [Cu(trp)(dach)]Cl displays a better antitumor activity in 
comparison to both [Co(trp)(dach)(H20)2]Cl and [Zn(tri3)(dach)]Cl (Table 9). 
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Conclusion 
An analogous parallel series of chiral complexes of late 3d transition metals {Co(II), Cu(II) 
and Zn(II)} derived from L-tryptophan, D-tryptophan and DL-tryptophan (in case of dabz 
only) and diamines viz; 1,2-diaminobenzene (dabz) and (lR,2R)-(-)-l,2-
diaminocyclohexane (dach), were designed and synthesized with a aim to develop new 
efficacious metal-based cancer chemotherapeutic drugs. A majority of metal-based 
antitumor drugs exert their antitumor activity by the interaction with chiral target DNA and 
therefore, binding of metal complexes to DNA and nucleotides is of paramount importance. 
The most crucial factors responsible for drug design optimization such as specialized 
ligand scaffold, incorporation of site specific chiral motifs, biocompatible metal ions were 
incorporated in these complexes; and comparison of compound structures, conformations 
and metal ions was made to explore the effect of structure-activity and chirality on their 
DNA binding and cleavage activities. In vitro DNA binding studies viz; absorption 
titrations, fluorescence and circular dichorism in free complexes and in presence of DNA 
supported that both the enantiomers bind to DNA by noncovalent mode of binding by 
electrostatic interaction via phosphate backbone of the helix, however, L-form proved to be 
more potent and exhibited enhanced binding propensity for DNA as compared to D- or DL-
enantiomeric analogs. The complex [Cu(trp)(dach)]Cl (L-form) exhibited highest DNA 
binding afliinity and Cu(II) complex [Cu(trp)(dabz)]Cl (L-form) binds DNA more avidly 
than the other metal complexes Co(II) and Zn(II), respectively in their L-form which was 
quantified by their intrinsic binding constant Kb values. Interaction between complexes and 
pBR322 DNA has also been investigated by agarose gel electrophoresis, noticeably, the 
complexes exhibited effective DNA cleavage. To explore relationship between DNA-
binding and cytotoxicity, all complexes in L-form were screened for antitumor activity in a 
variety of human cancer cell lines .The [Cu(trp)(dabz)]Cl (L-form) exhibited a good 
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cytotoxicity against a series of cancer cell line tested in which it shows maximum 
cytotoxicity {Gl5o<10) against MCF-7 cell line (human breast carcinoma). The complex 
[Cu(trp)(dach )]C1 is however selective antitumor agent against MIA PaCa-2 (Pancreatic) 
with GI50 = 21 compared to 47 and >80 for complex [Co(trp)(dach)(H20)2]Cl (L-form) and 
[Zn(trp)(dach)]Cl (L-form) in the same cell line. Indeed, complex [Cu(trp)(dabz)]Cl (L-
form) is one of the most effective chiral cancer chemotherapeutic agent designed in terms 
of its selective antitumor activity, and it warrants further vigorous in vivo investigation. 
CHAPTER V 
Comparative in vitro DNA binding profile and antitumor 
activity of chiral Cu(II) and diorganotin(IV) complexes: 
Mechanistic approach based on enantioselectivity and their 
influence on artificial nuclease activity. 
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Synthesis 
Synthesis of Ligands and metal complexes 
Synthesis of (S) - and (R)-2-(2-hydroxy-l-phenylethylaminomethyl)phenol (LI) 
(S)/(R)-2-phenylglycinol (1.37 g, 10 mmol) and salicylaldehyde (1.22 g, 10 mmol) were 
stirred together in methanol (25 mL) for 1 hour at room temperature. The resulting yellow 
colored solution was monitored by TLC for the completion of the reaction and formation of 
Schiff base as reported earlier [72]. To this solution, NaBH4 (0.46 g, 12 mmol) was added in 
portions and was refluxed for 2 hours, the color of solution changed slowly from yellow to 
colorless. The solvent was removed under vacuum and residue dissolved in water (40 mL) 
and was extracted with CHCI3 (3 x 40 mL). The CHCI3 layers were combined and dried 
under vacuum. A white precipitate formed upon introduction of dry HCl was collected and 
washed with ether, and dried. 
(S-enantiomer): Yield 75%. m.p. 150-152 °C. Anal. (%) Calc. for C15H17NO2: C, 74.04; H, 
7.04; N, 5.76. Found: C, 74.10; H, 6.99; N, 5.81. [afo = +113. ESI-MS (m/z) 244 
[CisHnNCb+H]^ 
(R-enantiomer): Yield 78%. m.p. 148-151 °C. Anal. (%) Calc. for C15H17NO2: C, 74.04; H, 
7.04; N, 5.76. Found: C, 73.99; H, 7.02; N, 5.75. [afo = -HI. ESl-MS (m/z) 245 
[Ci5H,7N02+2H]^ 
Both enantiomers exhibited identical IR, UV-vis and NMR spectra. 
Selected IR data on KBr pellet (v/cm"'): 3250 v (OH); 3185 v (N-H); 1528 S(N-E); 2372 v 
(CH2); 1448 V (C-N); 1362 v (C-C); 1043 v (C-0); 749 v (Ar). UV-vis in 15% CH3OH-
Tris-HCl buffer [Jimax / nm (e / M'' cm"')]: 217 (38200), 277 (33690). 'H NMR (DMSO-dg, 
ppm): 2.14 (-0H); 3.65 (-CH2); 3.78 (chiral -CH); 3.85 (-CH2); 3.71 (-NH); 6.67 (t, IH, Ar 
H); 6.76 (d, IH, Ar H); 6.9 (d, IH, Ar H); 7.10 (t, IH, Ar H); 7.34 (multiple!, 5H, Ar H); 
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7.44 (-0H). "C NMR (DMSO-d ,^ ppm): 157.26 (Phenol-OH); 139.30 (Ph-N); 128.11, 
128.00, 127.87, 127.16, 127.12, 123.12, 118.43, 115.50 (Ar-C); 65.69 (-CH2OH); 64.13 
(chiral C); 49.44 (-CH2NH). 
Synthesis of (S)- and (R)-2-(benzylaniino)-2-phenylethanoI (L2) 
This was prepared according to a procedure similar to that of L2 except that (S)-/(R)-2-
phenylglycinol (1.37 g, 10 mmol) was mixed with benzaldehyde (1.09 g, 10 mmol) in 
methanol (25 mL), followed by in-situ reduction by NaBlLt and extraction with CHCI3. 
(S-enantiomer): Yield 78%. m.p. 140-143 "C. Anal. (%) Calc. for CisHieNO: C, 79.61; H, 
7.13; N, 6.19. Found: C, 79.56; H, 7.09; N, 6.16. [af^ = +163. ESI-MS (m/z) 227 
[Ci5Hi6NO+H]^ 
(R-enantiomer): Yield 74%. m.p. 140-142 "C. Anal. (%) Calc. for C15H16NO: C, 79.61; H, 
7.13; N, 6.19. Found: C, 79.68; H, 7.10; N, 6.22. [afo = -160. ESI-MS (m/z) 229 
[C,5H,6NCHf3H]^  
Both enantiomers exhibited identical IR, UV-vis and NMR spectra. 
Selected IR data on KBr pellet (v/cm'^ ): 3213 v (N-H); 2300 v (CH2); 1548 S(N-U); 1468 
V (C-N); 1365 v (C-C); 1045 v (C-0); 751 (Ar). UV-vis in 15% CHjOH-Tris-HCl buffer 
[Imax I m:a (e / M"' cm"')]: 214 (38010), 251 (15210). 'H NMR (DMSO-de, ppm): 2.14 (-
OH); 3.44 (-CH2); 3.60 (-CH2); 3.62 (-NH); 3.81 (chiral CH); 7.17-7.70 (multiplet, 9H, Ar 
H). '^ C NIVIR (DMS0-d6, ppm): 141.80 (Ph-N); 140.83, 127.89, 127.78, 127.71, 127.17, 
126.94,126.76,126.42,126.27 (Ar C); 66.68 (-CH2OH); 64.07 (chiral C); 50.87 (-CH2NH). 
Synthesis of (S)- and (R)- [Cu2(Ll)2] 
To a methanolic solution (10 mL) of LI (0.486 g, 2 mmol) was added a solution of CUCI2. 
2H2O (0.342 g, 2 mmol) in methanol (10 mL). The solution was stirred for 4 hours with 
heating at 80 °C. On completion of the reaction, the reaction mixture was kept at room 
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temperature which yielded green colored product, washed with hexane and dried in vacuo. 
(S-enantiomer): Yield 54%. m.p. 240-242 °C. Anal. (%) Calc. for CjoHsgNzOgCuz: C, 
52.86; H, 5.62; N, 4.11. Found: C, 52.81; H, 5.63; N, 4.08. [afo = +45. ESI-MS (m/z): 682 
[C30H38N2O8CU2+H]* 
(R-enantiomer): Yield 51%. m.p. 242-244 °C. Anal. (%) Calc. for CsoHjgNzOgCuz: C, 
52.86; H, 5.62; N, 4.11. Found: C, 52.91; H, 5.59; N, 4.07. [afv = -44. ESI-MS (m/z): 683 
[C3oH38N208CU2+2H]^ 
Both enantiomeric metal complexes exhibited identical molar conductance, IR and UV-vis 
data. 
Molar Conductance, AM (1 x 10"^  M, DMSO): 15.0 O'cmVol"' (non-electrolyte). Selected 
IR data on KBr pellet (v/cm'): 3300 v (OH); 3185 v (N-H); 1528 S(N-H); 2372 v (CH2); 
1448 V (C-N); 1362 v (C-C); 1043 v (C-0); 749 v (Ar); 538 v (Cu-0); 433 v (Cu-N). UV-
vis in 15% DMSO-Tris-HCl buffer [>.max / nm (e / M"' cm"')]: 217 (34480), 279 (14540), 
388 (1010), 680 (1350). 
Synthesis of (S) - and (R)- [Sn2(Ll)2] 
These complexes were synthesized according to procedure described for [Cu2(Ll)2l with 
(CH3)2SnCl2 (0.440 g, 2 mmol). White colored products were isolated. 
(S-enantiomer): Yield 57%. m.p. 265-269 °C. Anal. (%) Calc. for C34H5oN208Sn2: C, 
47.92; H, 5.91; N, 3.29. Found: C, 47.87; H, 5.88; N, 3.25. [afi) = +55. ESI-MS (m/z): 
854 [C34H5oN208Sn2+2H]^  "^Sn NMR (DMS0-d6, ppm): -379. 
(R-enantiomer): Yield 55%. m.p. 265-268 °C. Anal. (%) Calc. for C34H5oN208Sn2: C, 
47.92; H, 5.91; N, 3.29. Found: C, 47.81; H, 5.87; N, 3.22. [afo = -58. 
ESI-MS (m/z): 850 [C34H5oN208Sn2-2H]^  ''^SnNMR (DMSO-d ,^ ppm): -375. 
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Both enantiomeric metal complexes exhibited identical molar conductance, IR, UV-vis and 
NMR ( 'H £tnd "C) data. 
Molar Conductance, AM (1 x 10"^  M, DMSO): 11.0 Q"'cm^mor' (non-electrolyte). Selected 
IR data on KBr pellet (v /cm-'): 3230 v (OH); 3185 v (T4-H); 2372 v (CH2); 1528 (J(N-H); 
1448 V (C-N); 1362 v (C-C); 1043 v (C-0); 749 (Ar); 493 v (Sn-0); 418 v (Sn-N). UV-vis 
in 15% DMSO-Tris-HCl buffer [Xmax / nm (e / M"' cm"*)]: 230 (30300), 272 (29700). 'H 
NMR (DMS0-d6, ppm): 0.61 (6H, -CH3); 3.42 (br s, 4H, H2O); 3.48 (-CH2); 3.64 (chiral 
CH); 3.72 (-NH); 3.88 (-CH2); 6.41 (t, 2H, Ar H); 6.46 (s, 2H, Ar H); 6.9 (d, 2H, Ar H); 
7.36-7.44 (multiplet, 12H, ArH). "C NMR: 158.26 (phenol-OH); 137.30 (Ph-N); 128.11, 
127.87, 127.16, 127.12, 123.12, 118.43, 115.50 (Ar C); 65.69 (-CH2O); 64.13 (chiral C); 
49.44 (-CH2NH). 
Synthesis of (S)- and (R)- [Cu2(L2)2] 
The synthesis of this compound was carried out by the same method as described above by 
employing L2 (0.454 g, 2 mmol) with CUCI2.2H2O (0.342 g, 2mmol) and refluxed for 4 
hours, which yielded sky blue colored product, washed with hexane and dried in vacuo. 
(S-enantiomer): Yield 51%. m.p. 219-222 "C. Anal. (%) Calc. for C30H32N2O2CI2CU2: C, 
55.38; H, 4.96; N, 4.31. Found; C, 55.41; H, 4.99; N, 4.27. [erf ^ D = +93. ESI-MS (m/z): 651 
[C30H32N2O2Cl2CU2+H]^ 
(R-enantiomer): Yield 55%. m.p. 220-224 °C. Anal. (%) Calc. for C30H32N2O2CI2CU2: C, 
55.38; H, 4.96; N, 4.31. Found: C, 55.28; H, 4.91; N, 4.29. [afu = -94. ESI-MS (m/z): 652 
[C3oH32N202Cl2CU2+2H]^  
Both enantiomeric metal complexes exhibited identical molar conductance, IR and UV-vis 
data. 
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Molar Conductance, AM (1 x 10"' M, DMSO): 13.0 D'cm^mol"' (non-electrolyte). Selected 
IR data on KBr pellet (v /cm"'): 3213 v (N-H); 2300 v (CH2); 1548 (J(N-H); 1468 v (C-N); 
1365 V (C-C); 1045 v (C-0); 751 v (Ar) 538 v (Cu-0); 433 v (Cu-N). UV-vis in 15% 
DMSO-Tris-HCl buffer [hnax / nm (e / M"' cm"')]: 220 (38400), 256 (26140), 600 (2250). 
Synthesis of (S)- and (R)- [Sn2(L2)2l 
These complexes were synthesized according to the procedure described above with 
(CH3)2SnCl2 (0.440 g, 2 mmol).White colored products were isolated. 
(S-enantiomer): Yield 55%. m.p. 242-244 "C. Anal. (%) Calc. for C32H38N202Cl2Sn2: C, 
48.59; H, 4.84; N, 3.54. Found: C, 48.53; H, 4.87; N, 3.57. [afu = +36. ESI-MS (m/z): 792 
[C32H38N202Cl2Sn2+2Hf. "'SnNMR (DMS0-d6, ppm): -281. 
(R-enantiomer): Yield 52%. m.p. 240-244 "C. Anal. (%) Calc. for C32H38N202Cl2Sn2: C, 
48.59; H, 4.84; N, 3.54. Found: C, 48.49; H, 4.82; N, 3.56. [afu = -38. ESI-MS (m/z): 788 
[C32H38N202Cl2Sn2-2H]^ . "^SnNMR (DMS0-d6, ppm): -305 ppm. 
Both enantiomeric metal complexes exhibited identical molar conductance, IR, UV-vis and 
NMR ('H and '^ C) data. 
Molar conductance, AM (1 X 10"' M, DMSO): 16.0 Q'cm^mol"' (non-electrolyte). Selected 
IR data on ICBr pellet (v /cm"'): 3213 v (N-H); 2300 v (CH2); 1548 SQi-U); 1468 v (C-
N); 1365 v (C-C); 1045 v (C-0); 751 (Ar); 493 v (Sn-0); 418 v (Sn-N). UV-vis in 15% 
DMSO-Tris-HCl buffer [Xmax / nm (s / M"' cm"')]: 215(37410), 257(12060). 'H NMR 
(DMS0-d6, ppm): 0.94 (6H, -CH3); 3.11 (-CH2); 3.64 (-NH); 3.79 (chiral CH); 3.92 (-CH2); 
7.08-7.55 (multiplet,16 H, Ar H); 7.57 (d, 2H, Ar H). '^ C NMR (DMSO-dg, ppm): 138.30 
(Ph-N); 137.19, 129.34128.38, 128.09, 127.89, 127.44, 127.38, 127.09 (Ar C); 65.36 (-
CH2O); 63.73 (chiral C); 50.04 (-CH2NH). 
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Results and discussion 
New chiral complexes (S)- and (R)- of LI, L2, metal complexes [Cu2(Ll)2], [Sn2(Ll)2], 
[Cu2(L2)2]and [Sn2(L2)2] were designed and synthesized with a aim to develop new chiral 
chemotherapeutic antitumor entities. The synthesis involves the in situ reduction (by 
NaBH4) of Schiff base of salicylaldehyde / benzaldehyde and (S)- / (R)-2-phenylglycinol to 
yield the ligand LI and L2 (Scheme 7). The complexation of LI and L2 with CUCI2.2H2O 
and (CH3)2SnCl2 were carried to obtain stable complexes, soluble in DMSO and DMF 
(Scheme 8). Molar conductance values of metal complexes reveal their non electrolytic 
nature. 
C. Marzano in a recent review article have highlighted the development of copper 
complexes as anticancer agents and it was concluded that copper drugs particularly, with 
five-coordinate environments have shown better selectivity and improved antitumor 
efficiency [200]. In vitro DNA binding studies of both enantiomers (S)- and (R)- of ligands 
(LI and L2) and complexes were carried out to evaluate tiieir enantioselective influence. 
Comparison of Cu(II) drug entities with Sn(IV) complexes - a notably important class of 
metallated antitumor agents can suggest the judicious choice of metal ions for metal-based 
chemotherapeutic efficacious drug regimes. 
IR spectroscopy 
The IR spectra of the title (S)-/(R)- of complexes corroborates well with the corresponding 
formulae in scheme 7 and 8 and the proposed structure. The fi-ee ligand LI and L2 exhibits 
a characteristic band at 3250-3300 cm'' attributed to v (OH) vibration and a diagnostic IR 
band at 3180, 3152 cm' and 1597, 1603 cm'' due to v (-NH) and 5 (-NH), respectively. 
However, a typical conjugated Schiff base HC=N stretching vibration usually present at 
1575-1650 cm"' range [72] was absent in the ligand supporting the reduction of the Schiff 
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CHO 
Here, R =0H for LI 
And R = H for L2 
MeOH 
R. T. 
NaBH4 
A Extract with CHCI3 
Ph, H 
Scheme 7. Synthetic scheme ofligands LI & L2 
2 (/ \N / \ ( / "V) + 2MCI2 
^ ^ = / HO ^ = / 
R=0H(L1), R= H(L2) 
.2H2O 
[Cu2(Ll)2l, [Sn2(Ll)2l [Cu2(L2)2l, [Sn2(L2)2 
Here M= Cu(II) & (CH3)2Sn(IV) 
Scheme 8. Proposed synthetic scheme ofchiral metal complexes. 
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Figure 82. Cylindrical bonded three dimensional model of ligands LI (a), L2 (b), metal 
complexes [Cu2(Ll)2] (c), [Sn2(Ll)2j (d), [Cu2(L2)2](e) and [Sn2(L2)2j (f). Color scheme: N 
dark blue; O red; C gray; CI dark green; Cu(II) dark gray; Sn(IV) light green. H atoms are 
omitted for clarity. 
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base by NaBH^. The metal complexes were characterized by the absence of hydroxo v(OH) 
bands in the 3250-3300 cm"* region which indicate the deprotonation of phenolic/alcoholic 
-OH group and the involvement of this group in complexation [210]. In the (S)-/(R)-
[Cu2(L2)2]and [Sn2(L2)2], a broad band around 3400 cm"' suggests the presence of lattice 
water [211]. 
Nevertheless, the presence of bound aqua ligand in case of [Cu2(Ll)2] and [Sn2(Ll)2] has 
been observed at 3550 cm'' [212]. Further, bands in the region of 1536-1557 cm'' in 
complexes (S)-/(R)- [Cu2(Ll)2] and [Sn2(Ll)2] suggest phenoxide bridging with the metal 
atoms [213, 214]. 
The far IR spectra of these complexes show the appearance of bands due to metal-ligand 
stretching vibrations. Far IR spectra of the complexes exhibited absorption at -454-460 cm"' 
and ~ 417-505 cm"' attributed to v (M-N) and v (M-0) bands, respectively which further 
confirm the p;articipation of imine- alcohol/ phenolate bridged metal centre [215]. The bands 
that appear at 205, 230 cm'' and at 198, 237 cm"' in case of complexes (S)-/(R)-
[Cu2(L2)2]and [Sn2(L2)2], respectively have been assigned to v (M-Cl) vibrations, in accord 
with the literature data for this type of bridged bond [216, 217]. 
NMR spectral studies 
'H NMR spectra of the ligands LI and L2 exhibit signals due to -NH at 3.71 and 3.62 ppm 
and the phenolic -OH protons of LI in 7.52 ppm region, respectively (Figure 83, 84). In the 
complexes (S)-/(R) - [Sn2(Ll)2] & [Sn2(L2)2], however, small downfield shift of -NH 
proton signd and absence of a signal for the phenolic and primary alcoholic proton, 
indicates coordination of the secondary amine, phenolate and alcoholic oxygen to tin atom. 
Signals related to the substituents on chiral carbon center to -CH2 and the aromatic protons 
appear almost in the same region as those of the free ligand. 
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The '^ C NMR spectra of complexes (S)-/(R)- [Sn2(Ll)2] & [Sn2(L2)2] were characterized 
by various resonances due to 158.26 (C-phenol) [Sn2(Ll)2]; 137.30-138.30 (Ph-N), 137.19-
115.50 (Ar-C), 65.36-65.69 (-CH2O); 63.73-64.13 (chiral C); 50.04-49.44 (-CH2NH), 
respectively. 
The '^'Sn NMli lvalues in diorganotin (IV) derivatives are very sensitive to complexation 
and are usually greatly shifted downfield or upfield upon binding to a Lewis base. The 
upfield chemical (lvalues of-379 ppm, -375 ppm for (S)-/(R)- [Sn2(Ll)2], and -281 ppm, -
305 ppm for (S)-/(R)- [Sn2(L2)2], respectively are indicative of different conformations of 
enantiomers v/ith considerable shielding of the Sn(IV) nucleus and a high coordination 
number, consistent with the literature data for seven and six coordinated diorganotin(IV) 
complexes, respectively [138, 218] (Figure 85). 
EPR spectra 
The EPR spec;tra of both the enantiomeric Cu(II) complexes (S)-/(R)- [Cu2(Ll)2] exhibited a 
pronounced peak (gi =: 2.065), a broad shallow peak (g|| = 2.21) and gov = 2.5 computed from 
the formula gav^ = g\\+lgil^ typical of a d' complex consistent with five- coordinate 
Cu(ll) complexes possessing axial symmetry and with the unpaired electron present in the 
d / / orbital [219]. Whereas, Cu(II) complexes (S)-/(R)- [Cu2(L2)2]at LNT consist of abroad 
axial symmeltrical signal with ^ n = 2.15 and g± = 2.053 and gav at 2.44. These parameters are 
consistent with the square planar geometry of the Cu(II) complexes (S)-/(R)- [Cu2(L2)2]and 
are quite similar to the values reported for other related square planar Cu(II) systems. The 
trend g|| > g± > ge (2.0023) ftirther confirmed that the ground state of the Cu(II) is 
predominantly dxV orbital [145] (Figure 86). 
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Figure 85. Sn spectra of (a) [SnjiLl)}] & (b) [Sn2(L2)2] (S-enantiomer). 
In axial symmetry the g values are related by the expression G = (gp -2)1 (gi-2), which 
measure the exchange interaction between Cu centre in the bimetallic solid; if G > 4 
exchange interaction is negligible, G < 4 indicates considerable exchange interaction [220]. 
Absorption spectroscopy 
The complexes (S)-/(R)-[Cu2(Ll)2] exhibited absorption bands in the range 388 nm which 
was assigned to a metal to ligand charge transfer (MLCT) transition. The sharp peaks of the 
ligands LI and L2 and (S)-/(R)- complexes in the 215-280 nm range of the electronic 
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Figure 86. EPR spectra of[Cu2(Ll)2] & [Cu2(L2)2](S-enantiomer). 
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spectrum are attributed to intraligand charge transfer (ILCT) transitions, judged from their 
molar extinction coefficient values. 
It is possible to predict the stereochemistry of the local Cu(II) ion environment in five 
coordinated complexes from the positions and intensities of the d-d transition bands. 
According to valence bond theory, if a Cu(ll) ion (d )^ is five coordinate, there will be two 
probable coordination geometries around the metal ion (viz; trigonal-bipyramidal and square 
pyramidal). In the former, the Cu(II) ion adopts dsp^ or sp^d hybridization and in the latter 
d^ sp^  or sp^d .^ These two configurations of a d^  ion possess approximately equal energy and 
they can interconvert. In general, trigonal-bipyramidal Cu(II) complexes with ^Ai ground 
states exhibit a single relatively intense band at 800 ± 67 nm; on the other hand, the 
electronic spectra of square-based pyramidal complexes consists of a single or two bands 
covering the range 667 ± 50 nm [221]. Accordingly, the broad band observed at 680 nm in 
the spectra of Cu complexes (S)-/(R)-[Cu2(Ll)2] has been assigned to dxz, dyi;>-d/./ 
transition for a square pyramidal environment. However, only one d-d transition is observed 
at 680 nm indicating that both the Cu(II) atoms are in the same environment. The UV-vis 
spectra of Cu(II)complexes (S)-/(R)-[Cu2(L2)2] exhibit a broad d-d band centered at 610 nm 
commonly observed for Cu(II) complexes consistent with square planar geometry [148]. 
In vitro DNAi binding Studies 
Absorption spectral studies 
Both the (S)~ and (R)- enantiomeric complexes were interacted with CT DNA to examine 
the mode of binding and the extent of their binding. The absorption titrations of complexes 
were carried out at intra-ligand transitions observed in the range of 256-271 nm at a constant 
concentration of complexes (0.16 x 10"^  M) at 25 °C (Figure 87, 88). Due correction was 
made for the absorbance of CT DNA itself. With increasing CT DNA (0-0.4 x 10"* M), the 
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absorption bands of complexes were affected exhibiting hyperchromism (17% - 24%) and 
blue / red shift, respectively in absorption intensities. "H)^erchromic effect" arises mainly 
due to the presence of positively charged cations (Cu(II) and Sn(IV)) which bind to DNA 
via non-covalent interaction [222]. Pronounced blue shift of 4-6 nm in case of (S)-/(R)-
[Cu2(Ll)2] & [Sn2(Ll)2] while moderate red shift of 1-3 nm were observed for (S)-/(R)-
[Cu2(L2)2] and no shift was recorded in case of (S)-/(R)- [Sn2(L2)2], respectively. The red 
shift in complex [Cu2(L2)2] is attributed to the partial intercalation in between the base 
pairs of DNA due to the presence of benzaldehyde which lack -OH fimctionality and is less 
hydrophobic in contrast to salicylaldehyde analogs (S)-/(R)- [Cu2(Ll)2] & [Sn2(Ll)2]; hinder 
the partial intercalation and possess a strong hydrophobic interaction with hydrophobic 
interior accessible in major groove of DNA. Greater extent of hyperchromism and 
substantial blue shift in molar absorptivity in comparison to its (R)- enantiomeric analog 
revealed that (S)- enantiomer binds to DNA more readily and avidly, thereby displaying 
pronounced (Enantiomeric selectivity. The right-handed chkal B-form of DNA displays 
conformational compatibility TPCP- two pole complementarity principle to the (S)-
enantiomer of complexes, thereby underlining enantiomeric discrimination [183]. On the 
other hand, Z-form of DNA would bind equally to both tlie (S)- and (R)-enantiomeric forms 
[203]. This also accounts for such chiral complexes to be used as structural probes to 
validate DNA conformations [33]. Furthermore, the comparative DNA binding studies of 
complexes (S)- / (R)- of Cu(II) a transition metal ion and Sn(IV)- a non-transition metal 
ion and enantiomeric ligands LI and L2 revealed that Cu(n) complexes [Cu2(Ll)2] & 
[Cu2(L2)2]e;diibit greater binding strength in contrast to Sn(rV) complexes [Sn2(Ll)2] & 
[Sn2(L2)2] as quantified by intrinsic binding constant Kb data (Table 10). 
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Table 10. The binding constant (Kb) values of all complexes including ligands with the DNA 
(mean standard deviation). 
Complex/Ligand 
(S)-[L1] 
(R)-[L1] 
(S)-[L2] 
(R)-[L2] 
(S)-[CU2(L1)2] 
(R)-[CU2(L1)2] 
(S)-[Sn2(Ll)2] 
(R)-[Sn2(Ll)2] 
(S)-[Cu2(L2)2] 
(R)-[Cu2(L2)2] 
(S)-[Sn2(L2)2] 
(R)-[Sn2(L2)2] 
Kb(M-') 
8.30 xlO'(± 0.04) 
1.11 xlO\± 0.03) 
6.03 xlO\± 0.05) 
1.03 xlO^(± 0.08) 
1.94 xlO^(± 0.03) 
4.57 xlO^Ci 0.04) 
2.92 x l 0 \ ± 0.05) 
1.16 xlO\± 0.06) 
6.13 xlO\± 0.05) 
3.24 xlO\± 0.07) 
2.28 xlO\± 0.03) 
8.85 xlO^(± 0.05) 
% Hyperchromism 
20 
26 
22 
27 
24 
22 
17 
17 
25 
21 
18 
20 
Shift"'*' 
3a 
4" 
1^  
r 
6" 
6' 
A' 
3" 
3" 
2'' 
1" 
No Shift 
a = Blue shift, b= Red Shift 
This can be explained on the basis of their binding mode; hydrophobic interactions play a 
profound role for the stabilization of DNA in case of [Cu2(Ll)2] which possess -OH 
fimctionality in the ligand scaffold while in case of [Cu2(L2)2], partial intercalation is 
interpreted. Additionally, it is well documented in literature that Cu(II) complexes 
specifically bind covalently to the N7 guanme residue of DNA, with higher affinity than 
any other divalent cation [223]. This accounts for higher binding affinity of Cu complexes to 
DNA and theu" preference for cancer inhibition. Thus, a number of Cu complexes have been 
screened for jjnticancer activity, and some of them were found to be active both in vitro and 
in vivo. On the other hand, Sn(IV) complexes bind non-specifically via electrostatic 
interactions preferentially to the phosphate backbone of tlie DNA helix eliminating N7 metal 
binding; Sn(rV) ions have a hard Lewis acid nature, neutralize the negative charge of 
phosphate suigar, and bring conformation changes in DNA [118, 224]. 
The surface interactions through exterior DNA c«m not be ruled out due to saturation of 
secondary v;alency (high coordination number) in case of [Sn2(Ll)2] as this complex possess 
labile water molecules which can be substituted easily by phosphate oxygen atoms of the 
DNA helix. 
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Figure 87. Absorption spectral traces of LI, L2 & Cu2(Ll)2) inTris HCl buffer upon 
addition ofCTDNA at 25 °C. Inset: Plots of [DMA]/ St, vs [DNA] for the titration of CT 
DNA with complexes m, experimental data points; full lines, linear fitting of the data. 
[complex] 6.67xia^M, [DNA] 0-33.3x 10^M. 
Figure 87 (a-J) represents S- and R-enantiomers for ligand LI, L2 & complex [Cu2(Ll)2], 
respectively. 
Luminescence Spectroscopy 
The emission spectra of (S)- and (R)- of complexes and ligand LI & L2 have been 
measured in the absence and in presence of CT DNA. The spectral profile and emission 
maxima for (S)-/(R)-metal complexes and ligand LI & L2 exhibit luminescence 
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enhancement indicating a binding of these complexes with CT DNA by non-covalent 
manner (Table 11). 
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Figure 88. Absorption spectral traces of [Sn2(11)2], [Cu2(12)2] & [8112(12)2] in Tris HCl 
buffer upon addition of CT DNA at 25 °C. Inset: Plots of [DNA]/ Sb vs [DNA] for the 
titration ofCTDNA with complexes m, experimental data points; full lines, linear fitting of 
the data, [complex] 6.67x la^M, [DNA] 0-33.3 x Iff^M. 
Figure 88 (a-f) represents (S)- and (R)-enantiomers [Sn2(Ll)2], [Cu2(L2)2] & [Sn2(L2)2] , 
respectively. 
Partial intercalation may be attributed to the stacking interaction of the planar aromatic 
ligand (S)-/(R)- L2 in the DNA base pairs, these observations are consistent with other 
spectroscopic studies (Figure 89). While the electrostatic interaction may be due to the (S)-
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/(R)- Sn(IV) complexes [Sn2(Ll)2] & [Sn2(L2)2] which specifically bind to the phosphate 
backbone of DNA (Figure 90) 
Table 11. Luminescence properties of complexes including ligands bound to CTDNA 
Complex Emission 
(nm) 
Excitation 
(nm) 
Monitored at 
(nm) 
K 
(M-') 
(S)-[L1] 
(R)-[L1] 
(S)-[L2] 
(R)-[L2] 
(S)-[CU2(L1)2] 
(R)-[CU2(L1)2] 
(S)-[Sn2(Ll)2] 
(R)-[Sn2(Ll)2] 
(S)-[CU2(L2)2] 
(R)-[CU2(L2)2] 
(S)- [Sn2(L2)2] 
(R)-[Sn2(L2)2] 
240 
240 
240 
240 
240 
240 
240 
240 
240 
240 
220 
220 
220 
220 
220 
220 
222 
222 
220 
280 
220 
220 
250 
242 
310 
310 
257 
258 
312 
313 
332 
310 
319 
300 
318 
260 
7.33 X 10' 
1.30x10^ 
6.16x10^ 
1.10x10^ 
1.41x10^ 
1.76 xlO'* 
3.11 xlO'^ 
1.45 xlO'* 
4.89x10'' 
2.16 xlO'' 
2.59 X 10^  
7.68 X 10^  
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Figure 89. Emission spectra of(S- & R- enantiomer) of LI (a,b) and S-enantiomer ofL2 (c) 
in Tris HCl buffer in the presence of DNA at 25 °C. [DNA] 0-33.3 x 10'^ M. Arrow show the 
intensity changes upon increasing concentration of the complexes. 
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Figure 90. Emission spectra of (a) (R- enantiomer) ofL2, (S- & R- enantiomer) [Cu2(Ll)2] 
(b,c) [Sn2(Ll)2] (d,e), [Cu2(L2)2](f,g) & [Sn2(L2)2] (h,i) in Tris HCl buffer in the presence 
of DNA at 25 °C. [DNAJ 0-33.3 x W^ M. Arrows shows the intensity changes upon 
increasing concentration of the complexes. 
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EB competition studies 
As shown in Figure 91, addition of the Cu(II) complexes [Cu2(Ll)2] & [Cu2(L2)2](S-
enantiomer) to the EB-DNA system resulted in the appreciable reduction in fluorescence 
intensity. The extent of reduction of emission intensity gives a measure of the binding 
propensity of the complex to the DNA. 
The addition of (S)-/(R)- Sn(IV) [Sn2(Ll)2] & [Sn2(L2)2] complexes to the EB-DNA system 
did not induce notable fluorescence changes, which indicated that EB molecules could not 
have been replaced by Sn(rV) complexes, and therefore, the intercalative binding mode has 
been ruled out in case of Sn(IV) complexes (Figure 91). 
Effect of phosphate group on the binding of complexes with DNA 
To validate our observation of UV-vis and fluorescence studies for (S)-/(R)- Sn(IV) 
complexes [Sn2(Ll)2] & [Sn2(L2)2] fluorescence titrations were performed in presence of 
increasing amount of K2HPO4, which demonstrate that fluorescence intensity of Sn(IV) 
complexes increases when K2HPO4 is added to the system. These results demonstrate a 
competitive binding behaviour between the phosphate group of K2HPO4 and the phosphate 
component of DNA [225]. The phosphate group of K2HPO4 slightly weakens the interaction 
between the complexes and DNA [226], indicating that phosphate of K2HPO4 inhibited 
slighfly the binding of [Sn2(Ll)2] & [Sn2(L2)2] to DNA and this observation provides 
supportive evidence for electrostatic interaction of the (S)-/(R)- Sn(IV) complexes which 
exhibit selective binding to the phosphate group of DNA double helix (Figure 92). 
Circular dichroism 
The addition of Cu(II) complex [Cu2(Ll)2] (S-enantiomer) to the solution of CT DNA 
induced an increase in intensity for positive and decrease in negative ellipticity bands. 
Inverted effect was observed in case of positive band of [Cu2(Ll)2] -R-enantiomer because 
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Figure 91. Fluorescence emission spectra of the EB-CT DNA system in the absence and 
presence of complexes at 25 "C. (S- & R- enantiomer) (CU2L2) (a,b) [Sn2(Ll)2] (c d) 
[Cu2(L2)2j(e,f) & [Sn2(L2)2] (g,h) [complex], [EBJ, [DMA] = IXIff'. 
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Figure 92. Emission spectra of [Sn2(Ll)2] (S- & R- enantiomer) & [Sn2(L2)2] (S- & R-
enantiomer), with increasing concentration ofK2HP04, in the absence and presence ofCT 
DMA in Tris HCl buffer at pH= 7.2 at 25 "C. Arrows shows the intensity changes upon 
increasing concentration of the K2HPO4. 
of chiral effect governing the orientation of base pairs in DNA. On the other hand, complex 
[Cu2(L2)2] (S-enantiomer) revealed mild perturbation of both positive and negative bands 
except in case of R-enantiomer which detects opposite effect in negative ellipticity band 
(Figure 93). On addition of (S)-/(R)- Sn(IV) complexes [Sn2(Ll)2] & [Sn2(L2)2] to the 
solution of CT DNA, an increase in intensity for both positive and negative ellipticity bands 
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resulted, suggesting that the stacking mode and the orientation of base pairs in DNA were 
disturbed [227]. 
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Figure 93. CD spectra of CT DNA alone and in presence of S- & R- enantiomer of 
[Cu2(Ll)2] (a) [Sn2(Ll)2] (b), [Cu2(L2)2](c) & [Sn2(L2)2] (d) in Tris-HCl buffer at 25 °C. 
[complex] = 1 xlO'^ M, [DNA] =1 xlO'^ M. 
Blue line represent DNA alone, pink line represent S-enantiomer interacting with DNA and 
black line represent R-enantiomer interacting with DNA. 
Since the disturbance is mild, therefore, the B-form conformation of DNA was still 
maintained. The hydrophobicity and polarizability of ligand LI, that are higher than that of 
L2, could promote spontaneous aggregation of the complexes derived from ligand LI on 
DNA biopolymer acting as a helical material [228]. 
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DNA Cleavage properties 
DNA Cleavage without added reductant 
Since S-enantiomer exhibits a higher DNA binding ability therefore, further cleavage 
activity was performed with S-enantiomer. Upon gel electrophoresis of the reaction mixture, 
a concentration dependent DNA cleavage was observed. A significant conversion of 
supercoiled pBR322 DNA to Form II and Form III was observed with increase in 
concentration of complex [Cu2(Ll)2] (S-enantiomer). The most impressive cleavage feature 
observed for these complexes is that Form III DNA appears before the disappearance of 
Form I DNA (lanes 2, 3, 4, 5 and 6). This phenomenon indicates that the complex 
[Cu2(Ll)2] (S-enantiomer) is capable of performing direct double-strand scission [124], 
while many copper complexes are only able to cleave single strand successively. The 
complex [Cu2(L2)2](S-enantiomer) shows discernible DNA cleavage with the increase in 
concentration, more intensified nicked (Form II) while no linear (Form III) was observed. 
Sn(IV) (S-enantiomer) complexes [Sn2(Ll)2] & [Sn2(L2)2] exhibited different form of 
pBR322 DNA cleavage with different intensities. On increasing the concentration of (S)-
[Sn2(Ll)2] & [Sn2(L2)2], more intensified Form II was observed. No linea'- fonn (Form III) 
was observed (Figure 94). 
DNA cleavage in presence of recognition elements (Groove binding) 
Figure 95, demonstrates that Cu(II) complex [Cu2(Ll)2] (S-enantiomer) inhibits the methyl 
green (Lane 2) as well as DAPI (Lane 3) of the DNA digestion, whereas Cu(II) complex 
[Cu2(L2)2] (S-enantiomer) shows slight inhibition on methyl green (Lane 4) and did not 
show any effect on DAPI (Lane 5). In these circumstances, complex [Cu2(Ll)2] may bind to 
both major as well as minor, whereas complex [Cu2(L2)2] binds only to the major groove. 
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Figure 94. The cleavage patterns of the agarose gel electrophoresis for pBR322 plasmid 
DNA (300 ng) by S-enantiomer (a) [Cu2(Ll)2], (b) [Cu2(Ll)2], (c) [Sn2(Ll)2] & (d) 
[8112(12)2] at 25 °C, after 45 minutes of incubation in buffer (5mM Tris -HCU 50 mMNaCl, 
pH= 7.2).Lane 1, DNA; Lane 2, 0.05 mmol metal complex+ DNA; Lane 3, 0.10 mmol metal 
complex + DNA; Lane 4, 0.15 mmol metal complex + DNA; Lane 5, 0. 20 mmol metal 
complex + DNA; Lane 6, 0. 25 mmol metal complex + DNA 
Sn(IV) complexes [Sn2(Ll)2] & [Sn2(L2)2] of S-enantiomer demonstrate that neither DAPI 
nor methyl green affect the DNA cleavage activity of [Sn2(Ll)2] & [Sn2(L2)2], suggesting 
that neither major nor minor grooves are the preferred reacting sites for the complexes. In 
these conditions, complexes [Sn2(Ll)2] & [Sn2(L2)2] may interact directly with exterior 
phosphate of DNA via electrostatic attraction. 
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Figure 95. Agarose gel electrophoresis pattern for the cleavage of pBR322 plasmid DNA 
(300 ng) by complex [Cu2(Ll)2], [Cu2(L2)2], (a) [Sn2(Ll)2], [Sn2(L2)2](b) (0.25 mmol) in 
the presence of DNA minor binding agent DAPI and major binding agent methyl green at 25 
°C after incubation for 30 minutes. Lane 1, DNA control; Lane 2, DNA + metal complex + 
methyl green (2.5 /uL of a O.Olmg/mL solution).Lane 3, DNA + metal complex + DAPI (8 
fiM); Lane 4, DNA + metal complex + methyl green (2.5 fiL of a O.Olmg/mL solution).Lane 
6, DNA + metal complex + DAPI (8 fiM). 
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DNA cleavage in presence of activators 
Further activity of metal complexes [Cu2(Ll)2] & [Cu2(L2)2] (S-enantiomer) was perfonned 
with different activators viz; H2O2, ascorbate (Asc), 3-mercaptopropionic acid (MPA) and 
glutathione (GSH). As shown in Figure 96, the cleavage activity of Cu(II) complexes 
[Cu2(Ll)2] was significantly enhanced in presence of these activators. However, in the 
presence of H2O2, the DNA bands of [Cu2(Ll)2] & [Cu2(L2)2] completely diminished. The 
activating efficacy of [Cu2(Ll)2] follows the order: H2O2 > MPA > Asc ~ GSH. Similarly, 
complex [Cu2(L2)2] also follows the same order. 
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Figure 96. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 plasmid 
DNA (300 ng) by [Cu2(Ll)2](a), [Cu2(L2)2](b) (S-enantiomer) (0.25 mmol) in the presence 
of different activating agent at 25 C after incubation for 30 minutes. Lane 1, DNA control; 
Lane 2, DNA + metal complex + H2O2 (0.4 mM); Lane 3, DNA + metal complex + Asc (0.4 
mM); Lane 4, DNA + metal complex + MPA (0.4 mM); Lane 5, DNA + metal complex + 
GSH (0.4 mM). Lane 6, DNA + metal complex + tert-butyl alcohol (0.4 mM); Lane 7. DNA 
+ metal complex + NaNs (0.4 mM); Lane 8, DNA + metal complex + Superoxide Dismutase 
(15 Units), respectively. 
DNA cleavage in presence of reactive oxygen species 
On adding tert-butyl alcohol to [Cu2(Ll)2] & [Cu2(Ll)2], DNA cleavage is inhibited 
suggesting the possibility of hydroxyl radical as one of the reactive species (Figure 96). 
Thus, free radicals participate in the oxidation of the deoxyribose moiety, followed by 
hydrolytic cleavage of the sugar phosphate back bone in the absence of the scavengers. On 
the other hand, addition of NaNs also reduced the same extent of cleavage as in case of tert-
butyl alcohol; reveal that 'O2 may also be activated oxygen intermediate responsible for the 
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cleavage. Addition of SOD, to the reaction mixture shows no significant quenching of the 
cleavage revealing that superoxide anion is not the active species. These results suggest that 
in the DNA strand scission reaction caused by these complexes various diffusible oxygen 
intermediate species (hydroxyl radical or singlet oxygen) are probably involved. 
Since these complexes are able to cleave DNA in the absence of any reducing agent, it may 
be assumed that DNA might be cleaved by a discernible hydrolytic path. The commonly 
accepted mechanism of hydrolysis of deoxynucleotide phosphates involves nucleophilic 
attack of hydroxyl oxygen on the phosphorus to give a five-coordinate phosphate 
intermediate [230,231], The present complex [Cu2(Ll)2] contain water in coordination but 
complex [Cu2(L2)2] lacks coordinated water molecule but has Cu-N groups, and it has been 
reported previously that a phosphate ester bond can be also hydrolytically cleaved by 
Cu(II)complexes with N-containing ligands [232], and this eventuality can not therefore, be 
ruled out. 
Antitumor activity 
Cytotoxicity of both enantiomers of LI, L2 and complexes were investigated by SRB assay 
to establish whether they demonstrate any enantioselectivity in their cyctotoxic action. Both 
enantiomer of LI, L2 and complexes were screened against 19 different human carcinoma 
cell lines of different histological origin in terms of GI50 values (Table 12), Complex 
[Cu2(Ll)2] (R-enantiomer) and [Cu2(L2)2] (S-enantiomer) showed potent in vitro 
cytotoxicity. Most promising and significant activity was found in case of R-enantiomer of 
complex [Cu2(Ll)2] exhibiting a GI50 value <10 for T24 (Urinary Bladder), Diri45 
(Prostate), HCT15, SW620 (Colon) and U373MG (Astrocytoma) human cancer cell lines. 
The similar trend was followed in complex [Cu2(L2)2] which exhibited good cytotoxicity in 
same cell line panels but with S-enantiomer. This could be attributed to increased 
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lipophilicity of the complexes [40] derived from benzaldehyde and thereby, better cellular 
uptake. Interestingly, DNA binding measurement studies of complexes have also 
demonstrated the greater propensity of S-enantiomers. The DNA binding and cytotoxicity 
activity data are well in conformity in case of copper complex [Cu2(L2)2] while its complex 
[Cu2(Ll)2] exhibits different enantioselectivity (DNA binding studies reveal greater 
propensity of S-enantiomer for DNA while cytotoxicity studied shows good activities with 
R-enantiomer). 
Both enantiomers of ligand LI, L2 and [Sn2(Ll)2], [Sn2(L2)2] revealed comparable 
cytotoxicity indicative of poor activity. Enantioselective differences in cytotoxicity might 
arise from differences in deactivation by intracellular components, interaction with DNA or 
repair of DNA adducts. Alternatively, the profile of adducts produced on DNA binding or 
the bending induced in the DNA by each enantiomer could be important. The reason for its 
selectivity needs ftirther investigations for each of these possible factors. It is not always 
necessary that complexes exhibiting maximum DNA binding studies should reveal 
pronounced cytotoxicity [233]. 
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Conclusion 
New (S)- and (R)-enantiomeric complexes derived from 2-(2-hydroxy-l-
phenylethylaminomethyl)phenol and 2-(benzylamino)-2-phenylethanol have been 
synthesized by de novo synthetic strategy and thoroughly characterized. In vitro DNA 
binding studies of (S)- and (R)- enantiomers of ligands (LI & L2) and complexes were 
carried out to establish whether they demonstrated any enantioselectivity in DNA binding 
profile. Since enantiomeric effects are quite subtle and sensitive to the environment, 
therefore, it was desirable to carry out the comparative DNA binding studies with copper -
a transition metal ion and tin-a non-transition metal ion in the presence of two different 
ligand scaffolds viz. substituted aldehydes. Our objective was to explore the effect of metal 
ions and ligand types to modulate the interaction between the complex and DNA and to 
accentuate any enantiomeric differences. Our findings reveal that S-enantiomer of 
[Cu2(Ll)2] derived from chiral salicylaldehye precursor LI exhibits highest DNA binding 
propensity and cleavage activity, possessing distinct chiral preference over its R-
enantiomeric analog in contrast to [Cu2(L2)2] or [Sn2(Ll)2], [Sn2(L2)2]. Binding affinity 
for DNA follows the order: (S)-[Cu2(Ll)2] > (S)-[Cu2(L2)2] > (R)-[Cu2(Ll)2]> (R)-
[Cu2(L2)2]> (S)-[Sn2(Ll)2] > (S)-[Sn2(L2)2] > (R)-[Sn2(Ll)2] > (R)-[Sn2(L2)2]. Complex 
(R)-[Cu2(Ll)2] and (S)-[Cu2(L2)2] showed potent in vitro cytotoxicity (GI50 value <10) 
against T24 (Urinary Bladder), DU145 (Prostate), HCT15, SW620 (Colon) and U373MG 
(Astrocytoma) human cancer cell lines. Since the differences in cytotoxicity do not 
correlate with simple measurements of DNA binding which reveals greater propensity of 
S-enantiomer for DNA while cytotoxicity activity demonstrates good activity in case of 
R-enantiomer only, therefore it is concluded that strong DNA binding of the complexes is 
not always necessarily the criteria for significant in vitro cytotoxicity. 
CHAPTER VI 
Synthesis, characterization of chiral binuclear reduced Schiff 
base copper(II) complexes of a-amino propanol. Crystal 
structure of the R- enantiomers of salicylaldehyde analog: 
Enantiomeric DNA binding and cleavage studies. 
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Synthesis 
Synthesis of (S)- and (R)-2-((l-hydoxypropan)-2-ylamino)methyl) phenol (L3). 
(S)-/(R)-2-amino-l-propanol (0.75 g, 10 mmol) and salicylaldehyde (1.22 g, 10 mmol) were 
stirred together in methanol (15 mL) for 1 hour at room temperature. The resulting yellow 
colored solution was monitored by TLC for the completion of the reaction and formation of 
Schiff base. To this solution, NaBH4 (0.46 g, 12 mmol) was added in portions and was 
refluxed for 2 hours, the solution changed color slowly from yellow to colorless. The solvent 
was removed under vacuum and residue dissolved in water (30 mL) and was extracted with 
CHCI3 (3 X 30 mL). The CHCI3 layers were combined and dried under vacuum. Colorless 
liquid was formed upon introduction of dry HCl. 
(S-enantiomer): [afu (MeOH) +72.. 
(R-enantiomer): [a\\ (MeOH) -65. 
Both enantiomers exhibited identical IR, Mass, UV-vis and NMR spectra. 
Selected IR data on KBr pellet (v /cm"'): 3217 v (N-H); 1565 <^(N-H); 2312 v (CH2); 1475 
v (C-N); 1390 v (C-C); 1067 v (C-Oa,cohai); 1250 v (C-Ophenoie); 751 (Ar). ESI-MS (m/z) 181 
[C10H15NO2]'. UV-vis [CH3OH; hnJnm] 308. 
' H NMR (400MHz, DMSO-de): ^1.08 (3H, -CH3); 2.29 (-0H, IH); 2.85 (chiral -CH, IH); 
3.29 (-CH2, 2H); 3.59 (-CH2, 2H) ; 4.64 (-NH); 7.22-7.33 (multiplet, 5H, Ar-H); 7.57 
(phenol -OH). '^C NMR (100 MHz, DMSO): S 157.26 (Phenol-OH); 
128.53,128.17,127.13,126.99, 126.17 (Ar C); 65.52 (-CH2OH); 53.78 (chiral C); 51.12 (-
CH2NH). 
Synthesis of (S)- and (R)- 2-(benzylamino)propan-l-ol. (L4) 
This was prepared according to a procedure similar to that of L3 except that (S)-/(R)-2-
amino-1-propanol (0.75g, 10 mmol) was mixed with benzaldehyde (1.09 g, 10 mmol) in 
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methanol (15 mL), followed by in-situ reduction by NaBH4 and extraction with CHCI3. A 
colorless liquid was formed upcm introduction of dry HCl. 
(S-enantiomer): [afi) (MeOH) +127. 
(R-enantiomer): [afu (MeOH) -120. 
Both enantiomers exhibited identical IR, Mass, UV-vis and NMR spectra. 
Selected IR data on KBr pellet (v /cm"'): 3219 v (N-H); 1557 J(N-H); 2855 v (CHza); 
2353 V (CH2); 1478 v (C-N); 1401 v(C-C); 1043 v (C-Oakohai); 755 v (Ar). ESI-MS(m/z) 
165 [C,oH,4N02H]^ UV-vis [CH3OH; X„ax/nm] 313. 
'H NMR (400MHz, DMSO-dg): ^1.10 (3H, -CH3); 2.26 (-0H, IH); 2.69 (chiral -CH, IH); 
3.27 (-CH2, 2H); 3.59 (-CH2, 2H) ; 4.81 (-NH); 7.23-7.34 (multiplet, 5H, Ar H). '^ C NMR 
(100 MHz, DMSO): 126.95,126.77,126.09, 125.83, 125.44 (Ar C); 67.92 (-CH2OH); 54.98 
(chiral C); 54.87 (-CH2NH). 
Synthesis of (R)- and (S)- [Cu"2(jt-L3)2(OAc)2].2H20 
To a methanolic solution (10 ml) of L3 (0.362 g, 2 mmol) was added a solution of 
Cu(CH3CCX))2.H20 (0.398 g, 2 mmol) in methanol (10 mL) under refluxing condition for 3 
hours. On completion of the reaction, the reaction mixture was kept at room temperature 
which yielded blue colored product, washed with hexane and dried in vaccuo. 
(S-enantiomer): Yield 49%. m.p. 218-221 "C. Anal. (%) Calc. for C24H38N20,oCu2: C, 
44.92; H, 5.97; N 4.37. Found: C, 45.03; H, 5.95; N, 4.41. [afu (DMSO) +63. ESI-MS 
(m/z): 641 [C24H38N20ioCu2]^  
(R-enantiomer): Yield 46%. m.p. 217-219 °C. Anal. (%) Calc. for C24H38N2O10CU2: C, 
44.92; H, 5.97; N 4.37. Found: C, 44.86; H, 5.94; N, 4.40. [afu (DMSO) -53. ESI-MS 
(m/z): 641 [C24H38N20,oCu2]". 
Both enantiomeric metal complexes exhibited identical IR, UV-vis and EPR specta. 
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Selected IR data on KBr pellet (v /cm"'): 3450 (Lattice Water); 3120 (-NH); 2365 (-CH2); 
1632 cm"' for Vasym(OCO); 1391 cm"' for Vsyn,(OCO); 1546 ^(N-H); 1438 v (C-N); 1354 v 
(C-C); 1038 V (C-Oaikoxide); 1252 v (C-Ophenoiate); 752 V (AT); 521 v (Cu-0); 426 v (Cu-N). 
UV-vis [CH3OH; Xmax/mn] 246 (26140), 389 (23890), 661 (90). 
Synthesis of (R)- and (S)- [CU"2(H-OAC)2 (L4.H20)2] 
To a methanolic solution (10 ml) of L4 (0.330 g, 2 mmol) was added a solution of 
Cu(CH3COO)2.H20 (0.398 g, 2 mmol) in methanol. (10 mL) The solution was stirred for 4 
hours with heating at 80 "C. On completion of the reaction, the reaction mixture was kept at 
room temperature which yielded sky blue colored product, washed with hexane and dried in 
vaccuo. 
(S-enantiomer): Yield 45%. m.p. 224-226 °C. Anal. (%) Calc. for C24H38N2O8CU2: C, 
47.28; H, 6.28; N 4.59. Found: C, 47.19; H, 6.25; N, 4.61. [af^D (DMSO) +68. ESI-MS 
(m/z): 609 [C24H38N208Cu2]^  
(R-enantiomer): Yield 44%. m.p. 222-224 °C. Anal. Calc. for C24H38N2O8CU2: C, 47.28; 
H, 6.28; N 4.59. Found: C, 47.27; H, 6.31; N, 4.62. [af^ (DMSO) -72. ESI-MS (m/z): 610 
[C24H38N208CU2+H]^ 
Both enantiomeric metal complexes exhibited identical IR, UV-vis and EPR spectra. 
Selected IR data on KBr pellet (v /cm"'): 3753 (coordinated Water); 3262 (-NH); 2364 (-
CH2); 1636 cm"' forVasym(OCO); 1479 cm"' for Vsym(OCO); 1543 «5(N-H); 1440 v (C-N); 
1397 V (C-C); 1040 v (C-Oaikoxide); 762 v (Ar); 545 v (Cu-0); 432 v (Cu-N). 
UV-vis [CH3OH; Xmax/nm] 251 (25240), 676 (80). 
Results and discussion 
New chiral Cu(II) complexes (S)- and (R)- were designed and synthesized with a aim to 
develop new chiral chemotherapeutic antitumor entities exhibiting fewer side effects, less 
toxicity and enhanced target selectivity . The synthesis involves the in situ reduction (by 
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Scheme 10. Synthesis scheme of [Cu 2(l^-L3)2(OAc)2] .2H2O and [Cu 2(1^-0Ac) 2 
(L4.H20)2j metal complexes. 
NaBH4) of Schiff base of salicylaldehyde/benzaldehyde and (S)- and (R)-2-amino-l-
propanol to yield the ligand L3 and L4. The complexes were stable toward air and moisture 
and soluble in H2O and other common solvaits. Molar conductance values of complexes 
reveal their non electrolytic nature. The R-enantiomer of complex [Cu^iC^-
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L3)2(OAc)2].2H20 in methanol crystallizes after several days, in block shaped dark blue 
crystals, suitable in size fcr single-crystal X-ray diffraction. 
The S- and R- enantiomeis of Cu(II) complexes in this study are chiral and therefore have 
the potential to demonstrate both enantioselectivity and stereoselectivity in their interactions 
with a inherently chiral target such as DNA. In vitro DNA binding studies and cleavage of 
both enantiomeric (S)- and (R)-complexes were carried out to evaluate their enantioselective 
influence. 
X-ray structure of (R)-[Cu"2(^-L3)2(OAc)2].2H20 
Single crystal of (R)-[Cu"2(|i-L3)2(OAc)2].2H20 suitable for X-ray structure determination 
was obtained. All calculations were performed using SHELXL-97 implemented in WINGX 
system of programs. ORTEP view of [Cu"2(|i-L3)2(OAc)2].2H20 with atom numbering 
scheme and thermal ellipsoids are drawn at 30% probability level are given in Figure 97, 98. 
Diamond view of the asymmetric unit in [Cu"2(^-L3)2(OAc)2].2H20 and the metal atom 
connectivity diagram is shown in Figure 99, 100. The crystallographic data are given in 
Table 13, and the selected bond lengths and angles for the asymmetric unit are given in 
Table 14,15. The asymmetric part of unit cell of [Cu"2(|i-L3)2(OAc)2].2H20 consists of two 
crystallographically independent and chemically identical [Cu"2(^-L3)2(OAc)2].2H20 units 
la and lb, respectively and four symmetrically H-bonded water molecules. The asymmetric 
part represents a [Cu2] complex bridged by phenolate oxygen (Oph) atoms. Two tridentate 
deprotonated [OphNamOiaH] ligands bind the Cu" ion in a facial mode. This also provides 
angular arrangement of the binding sites arises from the non-polar structure of the ligand in 
the metal complex. In the square-pyramidal coordination environment, depending on the 
axial or equatorial positions, the Cu-0 bond distances in Cu-|j-Oph unit vary within a wide 
range of 1.936-1.900 for la and 1.927-1.981 A for lb, respectively. 
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Figure 97. ORTEP view of the fR-Cu"2(fi-L3)2(^-OAc)2j»2H20 with atom numbering 
scheme. Hydrogen atom were omitted for clarity. 
Figure 98. One Unit of labeled ORTEP view of [R-Ci^'2(^-1-3) 2(fi-0Ac) 2] with atom 
numbering scheme. H atoms and water molecules are omitted for clarity. 
Combination of two short and two long bonds clearly indicate the presence of an 
asymmetric CU2O2 diamond motif 
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Table 13. Crystallographic data for complexes [Cu 2(l^-L3)2(OAc)2].2H20 
CCDC No 
Color 
Molecular formula 
Molecular weight 
Crystal system 
Space group 
a (A) 
b(A) 
c(A) 
U(A )^ 
Dc(gcm-') 
Z 
F(OOO) 
Crystal size/mm 
|i (mm'*) 
e Range (°) 
R], wR2 [I > 2CT(1)] 
Goodness-of-fit on F 
Final difference map 
max, min (e A ' ) 
CCDC 765605 
Blue 
C24H30N2O10CU2 
633.58 
P-1 
Orthorhombic 
12.104(3) 
16.437(4) 
27.634(7) 
5498(2) 
1.531 
8 
2608 
0.06x0.09x0.19 
1.603 
2.09 - 28.43 
0.0650, 0.0995 
1.064 
1.210,-0.838 
R, = I ( IIFol - IFcll )/E|Fo|; WR2 = [ Ew(|Fo| - |Fc|)'/Sw(Fo)Y''; 
W = 0.75/(CT\FO) + 0.0010FO^). 
Further coordination from amine nitrogen (Nam), terminal alkoxido oxygen (Oai) and acetato 
oxygen (Oac) atoms complete the distorted N2O3 square pyramidal environments around 
each Cu". Within the diamond core the Cul-0ph-Cu2 angles are 102.51°, 102.16° for la and 
101.08°, 103.48° for lb. The solid angle around the bridging Oph atoms range from 356.2° to 
359.84° for a trigonal planar arrangement compared to a trigonal pyramidal structure. The 
bridging phenolate (Oph) groups provide an intramolecular Cu"-"Cu" separation of 3.063 A, 
3.049 A for la and lb, respectively. The calculation of the least-squares planes defined by 
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the atoms of the square-planar coordination plane including the central metal atom shows 
the copper ions to be displaced from the basal planes toward the alkoxido oxygen atom by 
0.764 (Cul) and 0.253 A (Cu2) of la and 0.208 (Cu3) and 0.317 A (Cu4) of lb, 
respectively. Within [Cu"2(li-L3)2(OAc)2], the symmetry of the coordination spheres around 
two the Cu" ions measured by the Addison parameter (t) [234] are best described by 
distorted square pyramids with x values for Cul, Cu2, Cu3 and Cu4 as 0.22, 0.33, 0.17 and 
0.10 respectively. Thus, the Cu2 center is more distorted with a shorter Cu-Oph distance of 
1.936 A for greater bonding interaction with bridging phenolate oxygen atom. On the basis 
of the coordination sphere symmetry, it was proposed that in the square pyramid 
coordination limit (near T=0) the magnetic orbitals are mainly dx2-y2 and weak ferromagnetic 
interactions should result [235]. The Cu-Nam distances (av. 2.007 A for la and av. 2.005 A 
for lb) are in normal range. The av. apical Cu-OaiH distances (2.236 A in la and 2.298 A in 
lb) are longer than the av, Cu-Oac distances (2.006 A in la and 1.964 A in lb). The terminal 
monodentate acetate groups having pendant carboxyl oxygen atoms show extensive H-
bonding network with four lattice water molecules. A hexacopper net was generated around 
three (Olw, 02w and 03w) H-bonded guest water molecules (Figure 101). 
Table 14. Selected bond lengths [A] in [CU"2(M-L3)2(OAC)2].2H20 
Cu(4)-0(9) 
Cu(4)-0(11) 
Cu(4)-N(3) 
Cu(4)-O(10) 
Cu(4)-Cu(3) 
Cu(3)-0(9) 
Cu(3)-0(11) 
Cu(3)-N(4) 
1.956(5) 
1.967(5) 
2.018(5) 
2.282(5) 
3.0487(13) 
1.927(4) 
1.981(4) 
1.993(5) 
Cu(l)-0(2) 
Cu(l)-0(1) 
Cu(l)-0(3) 
Cu(2)-0(4) 
Cu(2)-N(2) 
Cu(2)-0(3) 
Cu(2)-0(1) 
Cu(3)-0(12) 
2.271(5) 
1.990(4) 
1.958(4) 
2.201(5) 
1.999(5) 
1.979(4) 
1.936(4) 
2.315(5) 
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Figure 99. Twin structure of labeled Diamond view of fCu"2(fi-L3)2(fi-OAc)2j with atom 
numbering scheme. H atoms are omitted for clarity. 
Figure 100. One Unit of labeled Diamond view of fCu''2(fi-L3)2(fi-OAc)2j»2H20 with atom 
numbering scheme. H atoms are omitted for clarity. 
Two [Cui] complexes trap four water molecules within, which show intricate H-bonding 
network with Cu" bound acetate oxygen atoms [01W---05 = 2.828 A; 01W---07 = 2.778 
A, 01W---03W = 2.828 A; 02W---03W = 2.778 A, 03W---08 = 2.828 A; 012---07 = 
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2.778 A, 02W---02 = 2.828 A; 02W---014 = 2.778 A, 014---04W = 2.828 A; 016---04 = 
2.577 A]. All these distances are comparable to the 0---0 distances in ice (about 2.74 A) 
[236]. The (H20)3 trapped supramolecular [Cu"2(|i-L3)2(OAc)2]---(H20)3---[Cu"2(|a-
L3)2(OAc)2] arrangement is shown in Figure 102. The nice packing of the complex along 
three crystallographic axes is shown in Figures 103. 
Table 15. Selected bond angles ["] in [Cu'2(n-L3)2(OAc)2].2H20 
0(13)-Cu(4)-0(9) 
0(9)-Cu(4)-0(ll) 
0(9)-Cu(4)-N(3) 
O(13)-Cu(4)-O(10) 
O(ll)-Cu(4)-O(10) 
0(13)-Cu(4)-Cu(3) 
0(11)-Cu(4)-Cu(3) 
O(10)-Cu(4)-Cu(3) 
0(9)-Cu(3)-N(4) 
0(9)-Cu(3)-0(15) 
N(4)-Cu(3)-0(15) 
0(11)-Cu(3)-0(12) 
0(15)-Cu(3)-0(12) 
0(11)-Cu(3)-Cu(4) 
0(15)-Cu(3)-Cu(4) 
0(l)-Cu(2)-0(3) 
0(3)-Cu(2)-N(2) 
0(3)-Cu(2)-0(8) 
0(l)-Cu(2)-0(4) 
N(2)-Cu(2)-0(4) 
0(3)-Cu(l)-0(l) 
0(l)-Cu(l)-0(5) 
0(1)-Cu(l)-N(l) 
0(3)-Cu(l)-0(2) 
0(5)-Cu(l)-0(2) 
C(ll)-0(3)-Cu(l) 
Cu(l)-0(3)-Cu(2) 
Cu(2)-0(1)-Cu(l) 
C(25)-0(9)-Cu(4) 
C(35)-0(11)-Cu(4) 
Cu(4)-0(11)-Cu(3) 
162.7(2) 
76.87(18) 
93.1(2) 
88.9(2) 
106.84(17) 
132.59(17) 
39.62(13) 
118.29(12) 
169.5(2) 
96.91(19) 
92.7(2) 
111.36(17) 
88.91(18) 
39.29(13) 
129.55(13) 
77.62(17) 
93.66(19) 
151.59(19) 
101.79(18) 
81.43(19) 
76.85(16) 
154.49(18) 
91.4(2) 
105.60(17) 
93.17(18) 
131.4(4) 
102.16(19) 
102.51(18) 
126.9(4) 
131.1(4) 
101.08(19) 
0(13)-Cu(4)-0(11) 
0(13)-Cu(4)-N(3) 
0(11)-Cu(4)-N(3) 
O(9)-Cu(4)-O(10) 
N(3)-Cu(4)-O(10) 
0(9)-Cu(4)-Cu(3) 
N(3)-Cu(4)-Cu(3) 
0(9)-Cu(3)-0(ll) 
0(11)-Cu(3)-N(4) 
0(11)-Cu(3)-0(15) 
0(9)-Cu(3)-0(12) 
N(4)-Cu(3)-0(12) 
0(9)-Cu(3)-Cu(4) 
N(4)-Cu(3)-Cu(4) 
0(12)-Cu(3)-Cu(4) 
0(1)-Cu(2)-N(2) 
0(l)-Cu(2)-0(8). 
N(2)-Cu(2)-0(8) 
0(3)-Cu(2)-0(4) 
0(8)-Cu(2)-0(4) 
0(3)-Cu(l)-0(5) 
0(3)-Cu(l)-N(l) 
0(5)-Cu(l)-N(l) 
0(l)-Cu(l)-0(2) 
N(l)-Cu(l)-0(2) 
C(n)-0(3)-Cu(2) 
C(l)-0(1)-Cu(l) 
C(25)-0(9)-Cu(3) 
Cu(3)-0(9)-Cu(4) 
C(35)-0(11)-Cu(3) 
98.0(2) 
90.3(2) 
169.0(2) 
108.36(19) 
80.3(2) 
37.92(13) 
129.74(16) 
77.21(19) 
92.4(2) 
159.64(19) 
103.18(18) 
81.2(2) 
38.60(13) 
130.98(17) 
117.79(12) 
171.24(19) 
97.24(18) 
90.81(19) 
117.4(2) 
91.0(2) 
95.43(18) 
168.2(2) 
95.0(2) 
112.30(18) 
79.2(2) 
122.7(4) 
126.9(4) 
129.0(4) 
103.5(2) 
127.7(4) 
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Figure 101. H-bonding network of complex [Ci/'2(n-L3)2(OAc)2].2H20 
5 
a-axis b-axis c-axis 
Figure 102. Packing of complex [Cu 2(f^-L3)2(OAc)2].2H20 along three crystallographic 
axes 
(3-aX/5 b-axis c-axis 
Figure 103. Packing of complex [Cu 2(M-L3)2(OAC)2].2H20 along three crystallographic 
axes lattice water are shown in spacefill model 
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Spectroscopic studies 
IR spectroscopy 
IR spectroscopy is one of the useful techniques used to assign the carboxylate coordination 
modes, and the following trend is generally accepted as a guideline to differentiate various 
carboxylate coordination modes [215,237,238] (Figure 104). 
A V = Vasyn,(OCO)-Vsym(OCO) 
Av chelating < Av bridging < Av ionic < Av monodentate. 
' ' ' K .0 ' 
I \ / I I / \ / \ 
M M M M M U M M' 
Monpdentele Chelating Bldsfttale brMging Monoatomic bridging Chelatiig bridging 
(Mi-n':ii'^) (Mi-Ti';ri') itirT>':Ti') (nz-Ti^ :T|'^  [Hz-n^:n') 
Figure 104. Various carboxylate coordination modes. 
More precisely, comparison of the Av value of the respective carboxylate complexes with 
the Av value of the sodium salt of the same carboxylate should be used as a guideline in 
assigning the carboxylate coordination modes. Accordingly, (i) the chelating coordination 
mode occurs when Av of the studied complex « Av of the sodium salt; (ii) the bidentate 
bridging coordination mode occurs when Av of the studied complex < Av of the sodium salt, 
and (iii) the monodentate coordination mode exists when Av of the studied complex » Av 
of the sodium salt. Further, complex [Cu"2(^-L3)2(OAc)2].2H20 revealed an intense band at 
1632 cm'' for Vasym (OCO) and an intense band at 1391 cm"' for Vsym (OCO). The Av = 241 
cm'' value of complex [Cu'^(|i-L3)2(OAc)2].2H20 is higher than that reported for sodium 
acetate (Av =164 cm'') [239], and thus indicates a monodentate acetate coordination mode. 
Complex [Cu"2(^-OAc)2 (L4.H20)2] revealed one band at 1636 cm'' assignable for v, asym 
1 (OCO) and one band at 1479 cm'' assignable for Vsym (OCO). Thus, the Av =157 cm 
correspond to syn-syn bidentate bridging [240]. 
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A strong conjugated Schiff base HC=N stretching vibration usually present at 1575-1630 
cm"' range is absent in the ligand supporting the reduction of the Schiff base by NaBH4. A 
broad band around 3450 cm"' suggests the presence of lattice water [211] for [Cu"2(fi-
L3)2(OAc)2].2H20. Further, diagnostic IR bands at 3120, 3262 cm"' and 1546, 1543 cm 
due to V (-NH) and 5 (-NH), respectively for complex [Cu"2(^-L3)2(OAc)2].2H20 and 
[Cu"2(^-OAc)2 (L4.H20)2] were also observed [241]. 
The presence of bound aqua ligand in case of [Cu"2(|i-OAc)2(L4.H20)2] has been observed 
at 3753 cm"' [212]. 
Mass spectral analysis 
From the copper acetate bridged solid-state structure of both complexes (R and S-
enantiomer), the question arises as to whether this dimeric moiety is also maintained in 
solution. To verify whether the complex dimer still exist in a methanolic solution and simply 
decompose under the experimental conditions, mass spectrometery was done. Molecular ion 
peak was observed at 641 and 609 which corresponds to [CU"2(M-L3)2(OAC)2.2H20]^ and 
[Cu"2(^-OAc)2(L4.H20)2]^. The isotopic distribution patterns of the above peaks matches 
well with the theoretical results. These results indicate that the complexes are stable in the 
solution phase, as evidenced from the mass spectral features. 
UV-vis spectra 
Both compounds show a very broad d-d transition band around, 661 nm and 676 nm for 
[CU"2(M-L3)2(OAC)2].2H20 and [CU"2(|LI-OAC)2(L4.H20)2], respectively consistent with 
five-coordinate Cu(II) centers having square-pyramidal geometry [242] The stronger 
absorption bands at 393 nm of complex [Cu 2(|i-L3)2(OAc)2].2H20 can be ascribed to a 
charge trariisfer transition from the phenolate moieties to the terminal copper ions which is 
absent in complex [Cu"2(^-OAc)2(L4.H20)2], because of presence of benzaldehyde moiety. 
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The band ajound 247 nm and 251 nm may be ascribed to n-n* transition for [Cu^aCl^-
L3)2(OAc)2].2H20 and [Cu"2()i-OAc)2(L4.H20)2], respectively. 
EPR spectra 
EPR spectroscopy has proven to be a valuable tool for the elucidation of the molecular 
structure of the binuclear copper complexes [243,244]. Information regarding the immediate 
environment about the metal centre in complex [CU"2(M-L3)2(OAC)2].2H20 and [CU"2(M-
OAc)2(L4.H20)2] was obtained from ESR specfral studies. The X-band EPR spectra of 
[CU"2(^-L3)2(OAC)2].2H20 and [Cu"2(|i-OAc)2(L4.H20)2] were recorded at room and 
different temperatures in solid as well as in liquid state (Figure 105). The spectra (solid) at 
room temperature shows no hyperfine splitting of [Cu"2(n-L3)2(OAc)2].2H20 and [Cu°2(|i-
OAc)2(L4.H20)2] irrespective of temperature variation. The g values were given in Table 16. 
In solution state (methanol) four hyperfine lines in the spectra of [Cu"2(|i-L3)2(OAc)2].2H20 
and [Cu"2( i^-OAc)2(L4.H20)2] were observed reflecting the coupling with the Cu(n) 
nucleus (I = 3/2), indicative of the existence of Cu(II)- Cu(n) interactions [245] (Figure 
106). 
Table 16. EPR parameters of complexes fCu' 2(ju-L3)2(OAc)2j.2H20 and 
[Cu"2([iOAc)2(L4.H20)2] (R-enantiomer) 
Complex g|l gi giso gav G 
[Cu"2(^i-L3)2(OAc)2].2H20 (Solid) 2.0950 2.0379 2.0569 2.6754 2.5066 
[Cu"2(n-L3)2(OAc)2].2H20 (Liquid) 2.0700 2.0579 2.0610 2.6660 1.2089 
[Cu"2(^-OAc)2(L4.H20)2] (Solid) 2.0780 2.0470 2.0570 2.6670 1.6595 
[Cu"2(M-OAc)2(L4.H20)2] (Liquid) 2.0700 2.0480 2.0550 2.6610 1.4583 
No effect of temperature was observed in the liquid state as it remains the same with same 
hyperfine splitting. The trend g|| > gi > 2.02 reveals that the unpaired electron is present in 
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the dx^ .y^  orbital [219]. For a Cu(II) complex, g|| is a parameter sensitive enough to indicate 
covalence. 
+ 20"C 
Figure 105. EPR spectra of complex [€1/^2(^-13) 2(0Ac) 2]. 2 H2O and [Cu"2(/^-
OAc)2(14.1120)2] (R-enantiomer) at variables temperature in solid state. 
For a covalent complex, gy < 2.3 and for an ionic environment, g|| = 2.3 or more. In the 
present complexes g)| < 2.3 which indicates an appreciable metal-ligand covalent character. 
The parameter G = (g||-2)/ (gi-2), which measure the exchange interaction between the metal 
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center in a polycrystalline solid. According to Hathaway and Billing [220] G >4 indicate 
negligible exchange interaction in the solid complex. For the Cu(II) complex G <4 indicates 
considerable exchange interaction in the complex. However in solution state, extensive 
exchange interaction occurs (Table 16 ). 
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Figure 106. EPR spectra of complex [Cu"2{p-L3)2(OAc)2].2H20 and [CU"2(M-OAC)2 (L4. 
^20)2] at variables temperature in liquid state (methanol). 
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In vitro DNA binding Studies 
Absorption spectral studies 
The absorption spectra of the complexes in the absence and presence of CT DNA at constant 
concentration of complexes (66.6 x 10"^  M) are depicted in Figure 107. With increasing CT 
DNA (0-33.3 X 10"^  M), the absorption bands are affected exhibiting "hyperchromism" 26-
39 % which reflects higher binding propensity of the complexes for DNA. The labile acetate 
ion (or also water molecule for [Cu"2(|J-OAc)2(L4.H20)2]) of the complexes can be 
replaced by a nucleophile in DNA, usually a nitrogeneous base such as guanine (N7) leading 
to a strong DNA binding of the complexes [246,181]. In some cases, binding to the adenine 
N7 nitrogen has been also observed but to a lesser extent. Complex [Cu^ad^-
L3)2(OAc)2].2H20 (R- and S-enantiomer) possess blue shift of 5 and 3 nm in K-TZ*, with a 
concomitant increase of molar absorptivity, suggestive of strong structural and 
conformational changes involving coordination sphere binding with DNA, while complex 
[Cu"2(^i-OAc)2(L4.H20)2] (R- and S-enantiomer) shows a slight increase in molar 
absorptivity with no appreciable shift. Nevertheless, in both complexes (R- and S-
enantiomer), an aromatic moiety is present so the binding of these complexes could also 
involve partial intercalation of an aromatic ring between the base pairs of DNA (Figure 
107). 
To further illustrate the enantioselective approach of the complexes, the quantitative 
comparison of the DNA binding affinities of [Cu"2(|a-L3)2(OAc)2].2H20 and [Cu"2(|J-
OAc)2(L4.H20)2] (R- and S-enantiomer) with CT DNA, the intrinsic bmding constant Kb 
values of the complexes were determined by monitoring the change in the absorbance of the 
71-71* bands with increasing concentration of CT DNA. Furthermore, the Kb values (Table 
17) clearly indicate the enantioselective approach of the complexes emphasizing the stronger 
binding affinity of R-enantiomer for DNA in comparison to S-enantiomer. 
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Table 17. The binding constant (Kb) values of complexes with the DNA (mean standard 
deviation). 
Complex Kb(M-*) % Hyperchromism Blue Shift 
5.56x10'(±0.04) 
1.11 x l O \ ± 0.03) 
(R)-[Cu"2(^-OAc)2(L4.H20)2] 1.30 xlO\± 0.03) 
(R)-[CU"2(M-L3)2(OAC)2].2H20 
(S)-[Cu"2(^-L3)2(OAc)2].2H20 
(S)-[CU"2(^-OAC)2(L4.H20)2] 0.32x10" (±0.04) 
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Figure 107. Absorption spectral traces of (R- & S- enantiomer) of [Cu'\(^-
L3)2(OAc)2].2H20 (a,b) and [Cu'^2(ju-OAc)2(L4.H20)2j (c,d) in Tris HCl buffer upon 
addition ofCT DNA at 25 °C. Inset: Plots of [DNA]/ Sb vs [DNA] for the titration ofCT 
DNA with complexes m, experimental data points; full lines, linear fitting of the data, 
[complex] 6.67x 10'^M, [DNA] 0-33.3x lO'^M. 
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Interaction with nucleotides 
To obtain concrete information and to determine the coordination of the metal ion to the 
specific site, interaction with low molecular building blocks of large DNA molecules viz; 
guanosine 5'-monophosphate, adenosine 5'-monophosphate, cytidine 5'-monophosphate and 
thymine 5'-monophosphate using electronic absorption techniques becomes mandatory. On 
interaction of the [Cu"2(^-L3)2(OAc)2].2H20 (R-enantiomer) with 5'-GMP, there is a 
significant red shift (13 nm) in the LF band accompanied by change in intensity of the bands 
clearly indicating coordinate covalent binding mode while with other nucleotides viz; 5'-
AMP, 5'-CMP and 5'-TMP there is a relatively small blue shift of 6, 6 and 8 nm, 
respectively. Interestingly, with CT DNA a red shift of 5 nm was observed (Figure 108). 
This reveal that Cu complexes show preferential interaction toward guanosine residue and 
are coordinated presumably to DNA base such as guanine N7 forming a CUN3O3 
chromophore. Our results are well corroborated by other interaction studies of Cu(II) 
complexes with DNA components 5'-GMP, 5'-AMP, 5'-CMP and 5'-TMP using electronic 
absorption and EPR measurement [181]. 
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Figure 108. Absorption spectra of (R- enantiomer) of [Cu"2(f^-L3)2(OAc)2].2H20 and 
[Cu"2(n-OAc)2(L4.H20)2] (1 x 10'^ M) (a) in Tris HCl buffer, on interacting with guanosine 
5'-monophosphate (b), adenosine 5'-monophosphate (c), cytidine 5'-monophosphate (d), 
thymine 5'-monophosphate (e) and CT DNA (f) at 1 x 10''' Mat 25 °C. 
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Nonetheless, in case of complex [Cu"2(|i-OAc)2(L4.H20)2] (R-enantiomer), there is 
relatively small shitlt on interaction with the nucleotides as well as CT DNA .( 5'-GMP, 
CMP, TMP cause a red shift of 1-2 nm, while AMP and CT DNA blue shift of 2-3 nm 
(Figure 108). All theses parameters are consistent with groove binding in concord with 
observations of UV-vis absorption spectral studies of the complex with CT DNA [199]. 
Luminescence Spectroscopy 
Both the enantiomeric complexes [Cu"2(li-L3)2(OAc)2].2H20 and [Cu"2(^-OAc)2(L4.H20)2] 
(R and S) emit luminescence in Tris-HCl buffer at room temperature, when excited with 
light of 246nm wavelength. On addition of increasing concentration of CT DNA to the fixed 
amount of complexes, there is enhancement of the emission intensity indicative of strong 
interaction of the complexes with CT DNA as depicted in Figure 109. The enhancement of 
the emission intensity is largely due to the change in the enviromnent of the metal complex 
and related to extent to which the complex gets into a hydrophobic envirormient inside the 
DNA [185]. 
This effect arises because, in the presence of DNA, the metal complex is bound in a 
relatively non-polar environment compared to water. The binding constant K as quantified 
by Scatchard equation for the complexes (R)-[Cu"2(|i-L3)2(OAc)2].2H20, (S)-[Cu\^i~ 
L3)2(OAc)2].2H20, (R)-[Cu"2(li-OAc)2(L4.H20)2] and (S)-[Cu"2(^-OAc)2(L4.H20)2] was 
found to be 5.50 X 10^ 1.14 X 10 \ 1.34 X 10"* and 0.31 x 10^ respectively. 
£B competition assay 
EB emits intense fluorescence in presence of DNA due to its strong intercalation between 
the adjacent DNA base pairs. However, the enhanced fluorescence can be quenched 
evidently when there is a second molecule that can replace the bound EB or break the 
secondary structure of DNA. The addition of the complex [Cu"2(li-L3)2(0Ac)2].2H2O (R 
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and S) to DNA pretreated with EB causes an appreciable reduction in fluorescence intensity 
(Figure 110). 
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Figure 109. Emission spectra of(R- & S- enantiomer) of [Ci/^2(ju-L3)2(OAc)2j.2H20 (a,b) 
and [Cu"2(p-OAc)2(L4.H20)2j (c,d) in Tris HCl buffer DNA in the presence of DNA at 25 
°C. [DNA] 0-33.3 x 10' M. Arrow shows the intensity changes upon increasing 
concentration of the complexes. 
This suggests that the complex [Cu"2(li-L3)2(OAc)2].2H20 competes with EthBr in binding 
to DNA [181]. In contrast to complex [Cu"2(p-L3)2(OAc)2].2H20 (R and S), emission 
intensity of complex [Cu"2(n-OAc)2(L4.H20)2] (R and S) decreases to a smaller extent. But 
in both complexes R-enantiomer decreases to a larger extent in comparison to S-enantiomer. 
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Figure 110. Fluorescence emission spectra of the EB-CT DNA system in the absence and 
presence of complexes. (R- & S- enantiomer) [CU"2(M-L3)2(OAC)2J.2H20 (a,b) andfCu"2(M-
OAc)2(L4.H20)2] (c,d) at 25 °C. [complex], [EB], [DNA] = 1X10'^. 
Circular dichroism 
Circular dichroism (CD) is a powerful and sophisticated tool for identifying conformational 
changes of DNA. The secondary structure of DNA is greatly influenced by interaction of R 
and S-enantiomers and changes in conformation of DNA from B —• Z or B —• A. DNA 
form reveal influence of each enantiomer of given complex on DNA binding strength. The 
observed CD spectrum of CT DNA consists of a positive band at 275 nm due to base 
stacking arid a negative band at 245 nm due to helicity, which are characteristic of DNA. in 
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right handed canonical B-forai. Simple groove binding and electrostatic interaction of the 
complexes with DNA shows less or no perturbations on the base stacking and helicity bands 
while intercalator enhances the intensities of both the bands. On incubation of present 
complexes [Cu"2(^ -L3)2(OAc)2].2H20 and [Cu"2(^ -OAc)2(L4.H20)2] (R and S) with CT 
DNA, the CD spectrum of DNA undergoes changes in both positive and negative bands. 
iw ;•] ;;3 ;9j 300 
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Figure 111. CD spectra of CT DNA alone and in presence of S- & R- enantiomer of 
[Cu"2(ju-L3)2(OAc)2].2H20 (a) and [Cu"2(fi-OAc)2(L4.H20)2j (b) in Tris HCl buffer at 25 
°C. [Complex] = 1 xIO'^ M, [DNA] =1 xlO'^ M. Sky blue line represent DNA alone, dark 
blue line represent S-enantiomer interacting with DNA and red line represent R-enantiomer 
interacting with DNA. 
In complex [Cu"2(li-L3)2(OAc)2].2H20 (S-enantiomer), after addition of CT DNA the CD 
spectrum shows an increase in positive and negative ellipticity bands with a small red shift 
(~2 nm), while in case of R-enantiomer both positive base stacking and negative helicity 
bands showed a sharp decrease in comparison to CTDNA alone clearly underlining the 
enantioselective approach (Figure I l i a ) 
Similarly, in complex [Cu"2(|Li-OAc)2(L4.H20)2] (S-enantiomer), after addition of CT DNA 
the CD spectrum shows an increase in positive and in negative bands without shift in the 
band position, while in case of R-enantiomer reverse effect was observed as observed in 
case of [Cu"2(M-L3)2(OAc)2].2H20 (R-enantiomer) (Figure 111b). 
Such resuhs suggest that the CD spectra are closely correlated with DNA binding affinity. 
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Viscosity measurements 
To further explore the interaction properties between the complexes and the DNA, the 
specific relative viscosity of DNA was examined by varying the concentrations of added 
complexes and results are presented in Figure 112. 
0.00 0.02 0.04 0.06 0.08 O.'lO 0.12 
l / R = [Complexl/[DNA] 
Figure 112. Effects of increasing amount of complex [Cu"2(}i-L3)2(OAc)2].2H2O (R-
enantiomer) (u), [Cu"2(lJ--L3)2(OAc)2].2H2O (S-enantiomer) (•), [Cu'2(fi-OAc)2(L4.H20)2] 
(R-enantiomer) (f) and [Cu"2(fi-OAc)2(L4.H20)2] (S-enantiomer) (k)on the relative 
viscosity ofCTDNA at 25 ±0.1 °C. 
Hydrody:amic methods that are sensitive to length are regarded as o:ie of the least 
ambiguous and most critical tests of binding in solution in the absence of crystallographic 
structure data. On the other hand, photophysical experiments provide necessary but not 
sufficient clues to support a binding mode. Figure 112, shows the relative changes in 
viscosity upon addition of complexes [Cu"2(n-L3)2(OAc)2].2H20 and [Cu"2(pi-
OAc)2(L4.H20)2] (R and S). The interesting decrease in viscosity observ'.^ d for the 
complexes suggest that the hydrophobic interaction of the ligand with DNA surface, 
enhanced further by stronger hydrogen bonding interactions in case of salicylaldehyde 
analog which leads to bending (kinking) of the DNA chain. Similar bending of Cu(II) 
complexes of certain tridentate 3N ligands is previously reported in literature [189]. 
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DNA Cleavage properties 
DNA Cleavage without added reductant 
DNA cleavage was controlled by relaxation of supercoiled circular form of pBR322 DNA 
into the nicked and linear form. When a circular plasmid DNA is subjected to agarose gel 
electrophoresis, the fastest migration will be observed for supercoiled form (Form I). If one 
strand is cleaved, the supercoils will relax to produce a slower moving open circular form 
(Form II). If both strands are cleaved, a linear form (Form III) will be generated that 
migrates in between. All complexes could convert Form I DNA into Form II. Linear DNA 
(Form III) appears at 0.10 mM for [Cu"2(^-L3)2(OAc)2].2H20 (R-enantiomer) (lanes 3); 
however, at the same concentration, other complexes cleave Form I DNA into Forms II but 
linearized DNA was not observed suggesting that the cleavage may occur randomly over 
DNA since a significant portion of the plasmid already appears to be transformed into Form 
II without concurrent formation of Form III [247] (Figure 113). 
The most impressive cleavage feature observed for [Cu"2(n-L3)2(OAc)2].2H20 (R-enantiomer) 
is that Form III DNA appears before the disappearance of form I DNA (lanes 3 and 6) (Figure 
113 a). This phenomenon indicates that this complex is capable of performing direct double-
strand scission, while many other copper complexes are only able to cleave single strand 
successively [124]. The results demonstrate that all of the complexes designed in this study have 
remarkable cleavage activity, particularly complex [Cu"2(|i-L3)2(OAc)2].2H20 (R-enantiomer), 
which show higher activity than rest of the metal complexes. Enhancement in hydrophobicity 
conferred by salicylaldehyde would increase the mobility of the reactive Cu(II) species on 
DNA, which would also contribute to the higher cleavage activity [178].The behavior observed 
for the electrophoretic mobility of these complexes indicate that some conformational changes 
have occurred. This means that the degree of superhelicity of the DNA molecules has been 
altered. 
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Figure 113. The cleavage patterns of the agarose gel electrophoresis for pBR322 plasmid 
DNA (300 ng) by [Cu"2(^-13)2(OAc)2j.2H20 and [CU"2(M-OAC)2(L4.H20)2] (R- and S-
enantiomer) at 25 °C after 45 minutes of incubation in buffer (5mM Tris HCl/ 50 mMNaCl, 
pH= 7.2). Lane 1, DNA; Lane 2, 0.05 mmol metal complex-^ DNA; Lane 3, O.JO mmol metal 
complex + DNA; Lane 4, 0.15 mmol metal complex + DNA; Lane 5, 0. 20 mmol metal 
complex + DNA; Lane 6, ft 25 mmol metal complex + DNA 
DNA cleavage in presence of recognition elements (Groove binding) and reactive 
oxygen species 
In order to identify recognition elements (groove binding) and ROS that are responsible for 
the DNA cleavage reaction, experiments in the presence of methyl green, DAPI and 
different common scavengers such as tert-butyl alcohol and DMSO (hydroxyl radical 
scavengers), NaNs (singlet oxygen scavenger), D2O (which is known to increase the lifetime 
of the O2) and SOD were carried out, respectively with R-enantiomer. As shown in Figure 
114 (a,b), the complex [Cu"2(^-L3)2(OAc)2].2H20 inhibits the methyl green (Lane 2) as 
well as DAPI (Lane 3) (Figure 114a) of the DNA digestion, whereas [Cu"2(^-
OAc)2(L4.H20)2] shows inhibhion on methyl green and did not show any effect on DAPI 
(Figure 114b). In these conditions, complex [Cu"2(^-L3)2(OAc)2].2H20 may bind to both 
major as well as minor, whereas complex [Cu"2(^-OAc)2(L4.H20)2] binds only to the major 
groove. 
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The cleavage activity of [Cu"2(n-L3)2(OAc)2].2H20 is reduced dramatically by the presence 
of hydroxyl radical scavengers tert-butyl alcohol and DMSO (lanes a4, a5), indicating that 
the freely diffusible hydroxyl radical is one of the intermediates involved in the DNA 
scission process, while complex [Cu"2(|i-OAc)2(L4.H20)2] has a very slight effect on 
hydroxyl radical scavengers (lanes b4, b5). 
Singlet oxygen scavenger NaNs significantly diminishes the cleavage activity of both the 
complexes (lanes a6, b6), suggesting that 'O2 also takes part in the cleavage mechanism. The 
involvement of 'O2 is also demonstrated by the remarkable enhancement of the cleavage 
activity in D2O (lanes a7, b7), where the lifetime of 'O2 is significantly longer than that in 
water [124]. Addition of SOD, to the reaction mixture shows significant quenching of the 
cleavage revealing that superoxide anion is also the active species (lanes a8, b8). 
In summary, these complexes seem to follow some similar pathways in the cleavage 
process, in which hydroxyl radicals, singlet oxygen and superoxide anion are crucial ROS 
responsible for the cleavage reactions. 
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Figure 114. Agarose gel electrophoresis pattern for the cleavage of pBR322 plasmid DNA 
(300 ng) by complex [Cu"2(f^-L3)2(OAc)2].2H20 (a) and [Cj'2(ii-OAc)2(L4.H20)2](b) (R-
enantiomer) (0.20 mmol) in the presence of DNA minor groove binding agent DAPI, major 
groove binding agent methyl green and different ROS at 25 °C after incubation for 30 
minutes. Lane 1, DNA control; Lane 2, DNA + metal complex + Methyl green (2.5 nL of a 
O.OImg/mL solution); Lane 3, DNA + metal complex + DAPI (8 nM); Lane 4, DNA + metal 
complex + tert-butyl alcohol (0.4 mM); Lane 5, DNA + metal complex + DMSO (0.4 mM); 
Lane 6, DNA + metal complex + NaNj (0.4 mM); lane 7, DNA + metal complex + D2O (70 
%); Lane 8, DNA + metal complex + Superoxide Dismutase (15 Units), respectively. 
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Conclusion 
Another novel series of chiral potential metal-based chemotherapeutic complexes was 
designed and synthesized to ascertain structure-activity relationship of these complexes 
towards cellular target DNA. The synthesis involves the in situ reduction (by NaBH4) of 
Schiff base of salicylaldehyde / benzaldehyde derived from chiral a-amino alcohol to yield 
the ligands L3 and L4. These ligands were allowed to react stereoselectively with 
Cu(CH3COO)2.H20 to yield binuclear asymmetric complexes in the solid state as confirmed 
by X-ray structure determination in case of R-enantiomer. These binuclear Cu(Il) complexes 
show unusual acetate bridging structure and novel diamond core topology. 
The asymmetric part of the unit cell of R-enantiomer of [Cu"2(^-Ll)2(OAc)2].2H20 consists 
of two crystallographically independent and chemically identical [Cu^\([i-
Ll)2(OAc)2].2H20 units la and lb, respectively and four synraietrically H-bonded lattice 
water molecules. The asymmetric part represents a [Cu2] complex bridged by phenolate 
oxygen (Oph) atoms. Two tridentate deprotonated [OphNamOiaH] ligands bind the Cu" ion in 
a. facial mode. Combination of two short and two long bonds clearly indicate the presence of 
an asymmetric CU2O2 diamond motif The complexes exhibit square pyramidal geometr>^ 
around both the Cu(II) centers as ascertained by X-ray data in case of R-enantiomer, EPR 
studies at different temperatures (solid and liquid) and by UV-vis spectroscopic studies. In 
vitro complex-DNA interaction studies (UV-vis., Fluorescence, Circular Dichroism, 
Viscosity) reveal that both the complexes [Cu"2(|i-L3)2(OAc)2].2H20 and [CU'VH--
OAc)2(L4.H20)2] bind to DNA by coordinate covalent and groove binding, respectively. 
However, (R)-enantiomers bind more strongly in comparison to (S)-enantiomeric analogues. 
The R- and S-enantiomers of [Cu"2(^-L3)2(OAc)2].2H20 and [Cu"2(^-OAc)2(L4.H20)2] 
exhibit a remarkable degree of enantioselectivity in their interaction with DNA. 
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The present study demonstrates that studying the enantiomeric forms of biologically active 
copper complexes can provide a rationale for potent, safe, efficacious drug design therapy. 
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